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Abstract 
 
The vertebrate immune system contains a diverse inventory of genetic, epigenetic, 
molecular and cellular mechanisms dedicated to distinguishing and to determining appropriate 
responsiveness to “self” and “non-self.” Autoimmune diseases such as type 1 diabetes (T1D), 
caused by immune destruction of insulin-producing β cells in the pancreas, are the result of 
breakdowns in these mechanisms. Recent T1D research efforts have uncovered the opposing 
functions of pancreatic Foxp3+ regulatory T (Treg) cells and natural killer (NK) cells as critical 
determinants of tolerance versus autoimmunity. Here, we examine the extrinsic adaptive 
regulation of NK cells by Treg cells, and profile the tissue-specific heterogeneity of NK cells for 
intrinsic mediators of NK cell tolerance. 
Depletion of Treg cells in the BDC2.5/NOD model resulted in destruction of pancreatic 
islets and a high penetrance of T1D. Prior to the activation of T cells, there was a rapid and 
localized  activation of pancreatic NK cells,  including their proliferation and production of 
diabetogenic IFN-γ. How Treg cells exerted their dominant tolerance on NK cells in this setting 
was unclear.  We explored the molecular mechanisms underlying this NK/Treg  cell axis, 
following leads from a kinetic exploration of gene-expression changes early after punctual 
perturbation of Treg cells. Our data supported a scenario in which Treg cells controlled NK cell 
functions by limiting the bioavailability of T cell-derived IL-2 in the islets, representing a novel 
intertwining of innate and adaptive immunity.  
iv 
 
Cell intrinsic regulatory mechanisms, such as the expression of the Ly49 receptor family 
during NK cell education, tune NK cells to be  functionally self-tolerant.  However,  the 
transcriptional  repertoire of Ly49 receptors had never been comprehensively explored.  We 
performed RNAseq-based profiling of the Ly49 receptors, and uncovered a subtle difference in 
the expression of Ly49E and Ly49H on pancreatic NK cells compared to spleen. We also 
expanded the phenotypic  profiling of pancreatic NK cells using high-dimensional  mass 
cytometry and uncovered greater diversity than had previously been described. 
Taken together, these studies highlighted a new degree of heterogeneity in pancreatic NK 
cells and uncovered  a  novel  regulatory mechanism, originating from the adaptive immune 
system, responsible for maintaining NK cell tolerance. 
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Chapter 1: Adaptive and Innate Contributions to Autoimmunity 
 
1.1 Immune tolerance and autoimmunity 
 
  The vertebrate immune system contains a diverse inventory of genetic, epigenetic, 
molecular and cellular mechanisms dedicated to distinguishing and to determining appropriate 
responsiveness to “self” and “non-self”.  The evolutionary necessity for such a system is a direct 
manifestation of our best model of adaptive immunity termed “clonal selection theory.” This 
model was first postulated by Burnett and Jerne in the 1950s and has since been supported by 
decades of evidence (Hodgkin et al., 2007).  In an effort to explain the immune system’s ability 
to generate lymphocytes capable of combating a diverse repertoire of pathogens, the authors 
hypothesized that a “spontaneous production of random specificities must take place” (Jerne, 
1955).  In brief, their model proposed  an  immune system which generated  a  relatively low 
frequency of each “random specificity,” but that this low frequency expanded upon recognition 
of its target antigen.  The “randomness” that Burnett and Jerne first described was later 
confirmed to occur during the generation of B and T cell receptors (BCR and TCR, respectively) 
on developing lymphocytes.  The evolutionary fitness of such a system is clear in that it grants 
organisms with recognition capabilities against novel foreign pathogens.  The theory, however, 
also implies an obvious fitness consequence in that randomness within the immune response 
creates  the  potential for collateral or direct targeting of self  antigens.  The elimination  or 
disablement of these self-reactive lymphocytes following their genesis, designated as central 
tolerance, partially explains how such a system remains viable.  However, it is clear that central 
tolerance is an imperfect system that allows for auto-reactive lymphocytes to escape into the 2 
 
periphery.  Once in the periphery, these autoreactive lymphocytes are free to encounter their 
cognate self-antigen  and to cause autoimmunity (Mueller, 2010; Mathis and Benoist, 2010).  
Because of this imperfect system, mechanisms of peripheral tolerance are necessary to control 
aberrant immune responses.  
Although a formidable backup plan, peripheral tolerance can also breakdown.  The many 
consequences  of a collective  failure  in  central  or  peripheral tolerance  are exhibited by  the 
numerous clinical manifestations collectively termed “autoimmune disease.”  Experimental 
evidence supporting a complementary role for each system is best illustrated by the discovery 
that mice double deficient for Aire (a critical mediator of thymic central tolerance) and Foxp3 
(required for the development of Regulatory T (Treg) cells, further described in detail below as a 
dominant mediator of peripheral tolerance) develop significantly worse disease than either 
individual genetic perturbation (Chen et al., 2005a; Mathis and Benoist, 2010).  Interestingly, 
even in the double-deficient animals, not all organs are affected.  This heterogeneous disease 
pattern supports a model for peripheral tolerance in which a breakdown in multiple regulatory 
pathways, including anatomical barriers, are required for tissue-specific diseases.   
 
 
1.2  Foxp3: a dominant  mediator of peripheral tolerance required for Treg cells 
 
  Treg cells are now widely accepted as primary controllers of immune-responsiveness and 
peripheral immunological tolerance (Rudensky, 2011).  Initially, the existence of an auto-
regulatory “suppressor” population was wrought with controversy, prior to the identification of a 
rare (5-10%) population of CD25-expressing CD4+ T cells capable of preventing neonatal-3 
 
thymectomy-induced multi-organ autoimmunity (Sakaguchi et al., 1995)  and gastritis (Suri-
Payer et al., 1998).  Due to its controversial past, it was not until follow-up studies were 
published identifying specific Treg  cell  functional immuno-modulatory cytokines such as 
interleukin (IL)-10  (Papiernik et al., 1997), and receptors such as CTLA-4,  that the general 
consensus shifted towards acceptance (Sakaguchi, 2000).  A landmark finding came in a series of 
genetic studies identifying mutant Foxp3/FOXP3 as the cause of the scurfy disease in mice and 
IPEX (immune dysfunction, polyendocrinopathy, enteropathy, X-linked inheritance) disorder in 
humans – each characterized by X-linked inheritance, systemic lymphoproliferation as well as 
autoimmune-mediated wasting.  (Chatila et al., 2000; Brunkow et al., 2001; Bennett et al., 2001; 
Wildin et al., 2001).  Multiple follow-up studies confirmed that Foxp3 uniquely identified and 
was required for the development of the CD4+CD25+ suppressive cells,  and was partially 
sufficient to promote regulatory function in otherwise non-suppressive cells (Fontenot et al., 
2003; Hori et al., 2003; Khattri et al., 2003). The specific depletion of Treg cells using transgenic 
animals, generated by expressing diphtheria toxin receptor (DTR) under the promoter elements 
of Foxp3, confirmed the absolute requirement for Treg cells throughout the lifespan of mice to 
control systemic peripheral tolerance (Kim et al., 2007; Lahl et al., 2007). Notably, Kim and 
colleagues also described the expansion of multiple populations of immune cells downstream of 
Treg  cell  ablation  besides T cells,  including B cells, dendritic cells  (DCs), neutrophils, 
macrophages, and natural killer (NK)  cells.  These findings supported a broad suppression 
profile for Tregs  cells  that  play a critical role in the maintenance of peripheral tolerance,  by 
suppressing an otherwise autoreactivity-prone immune system.  
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1.3 Type 1 diabetes (T1D): the autoimmune manifestation of a break in tissue-tolerance for 
innate and adaptive immunity 
 
1.3.1 T1D overview: mouse models and the role of adaptive immunity 
 
  T1D is caused by destruction of insulin-producing β cells within the pancreatic islets of 
Langerhans.  As the biomass of β cells in the islets is diminished, lack of insulin production leads 
to impaired glucose homeostasis and hyperglycemia (Tisch and McDevitt, 1996).  T1D is a 
complex polygenic disease with the strongest genetic influence, like many autoimmune diseases, 
coming from the human leukocyte antigen (HLA) region, and contributions from over 50 other 
genomic loci (Xie et al., 2014).  However, genetic predisposition is not sufficient to cause T1D, 
illustrated by the fact that monozygotic twins have only 50% disease concordance rates (Barnett 
et al., 1981).  The remaining disease susceptibility presumably stems from epigenetic and 
environmental influences (although the potential contribution of stochasticity such as during the 
generation of the BCR and the TCR remains unclear).  Perhaps the most alarming evidence for 
an environmental influence on T1D is the dramatically increased prevalence of disease over the 
last several decades (Vehik and Dabelea, 2011) – significantly faster than could be accounted for 
by alterations in population-level genetics. 
Due to both the scarcity of human pancreatic tissue samples,  and tools capable of 
effectively predicting clinical disease, much of the mechanistic understanding of T1D etiology 
comes from animal models,  particularly  the nonobese diabetic  (NOD)  mouse.  In brief, 
autoreactive T cells to numerous T1D-related antigens escape selection in the thymus and 
migrate to the pancreatic lymph node (PLN), where they encounter and are activated by their 5 
 
cognate antigen beginning around 2-3 wks of age (Mathis and Benoist, 2012).  Upon activation, 
these autoreactive T (and B) cells invade the pancreatic tissue and establish residence near and 
within islets. B and T cells are both clear roleplayers in T1D  pathogenesis as experimental 
elimination of either cell type in mice ameliorate disease (Christianson et al., 1993; Yang et al., 
1997; Noorchashm et al., 1997).  This stage is often denoted as “checkpoint 1” in mice. Strong 
evidence supports the notion that the establishment of a robust insulitis does not necessitate the 
eventual progression to clinical diabetes (“checkpoint 2”).  
In any  given NOD colony, although 100% of mice  usually  develop insulitis, many 
animals will remain disease-free, including both males and females.  The lack of disease 
determinism following insulitis points to tissue-level peripheral tolerance mechanisms protecting 
the animals from local inflammation and islet destruction. Around this stage, NOD mice present 
with serum autoantibodies, which are considered clinical predictors of diabetes susceptibility.  
Interestingly, in humans, not all new-onset patients have serum autoantibodies (Bingley, 2010), 
and not all autoantibody-positive individuals present with T1D (Knip et al., 2010). Together, 
these  phenomenon  support a model in which multiple immuno-regulatory checkpoints exist 
downstream of the generation of autoreactive lymphocytes, especially in the local tissue 
environment. Whether or not the same checkpoints exist in humans as they do in mice, and more 
broadly, whether or not T1D is the same disease in humans and mice, is currently under debate. 
Human T1D could be a set of disease etiologies all leading to the eventual destruction of β cells 
and hyperglycemia. 
The strongest evidence for multiple checkpoints during disease came from transgenic 
derivatives of the NOD mouse model, such as transgene-encoded, cloned, islet-specific TCRs. 
These models were further useful in that they provided a  reductionist view of the role of 6 
 
individual autoreactive TCR specificities in disease.  One such example was the BDC2.5 model, 
derived from a CD4+ T cell clone restricted to the NOD major histocompatibility complex 
(MHC)-class-II Ag7 molecule (Haskins et al., 1988; Gonzalez et al., 1997b).  The BDC2.5 TCR 
clone is specific for the pancreatic antigen: chromagranin A (Stadinski et al., 2010). Supporting 
its utility as a mouse model in a more accurate representation of human disease, chromogranin A 
has also been confirmed as an autoantigen in human T1D (Gottlieb et al., 2014). The BDC2.5 
transgenic line has proven a rich resource for the discovery of genes molecules and cells 
responsible for pathogenicity of autoreactive T cells (Luhder et al., 1998; Kanagawa et al., 2002; 
Poirot et al., 2004).  When the BDC2.5 TCR transgenes are preferentially expressed on the NOD 
genetic background, a drastic increase in the rate of islet invasion occurs. Whereas in a normal 
NOD mouse, T cells stereotypically invade the islets at 15-18 days of age and progressively 
accumulate over the course of several months, the BDC2.5/NOD line has an immediate and 
massive infiltration – to the degree of invasion that a normal NOD islet, even in the later stages 
of disease, may never achieve. However, progression to diabetes occurs rarely (10-20%), and 
only months later, reflecting strong immunoregulation (Gonzalez et al., 1997a). 
 
 
1.3.2 An emerging role for innate immunity during T1D 
 
Conventional dogma implicates B and T cells, comprising adaptive immunity, as the 
primary cells responsible for autoimmunity. However, emerging research now supports a more 
complex cooperation of innate and adaptive immunity to mediate autoimmune disease. For 
example, canonical innate immune signaling was implicated in systemic autoimmune diseases 7 
 
such as lupus and rheumatoid arthritis upon the discovery that these patients contained elevated 
peripheral blood type 1 interferon (IFN) signatures compared to healthy controls. (Ronnblom and 
Eloranta, 2013). Innate immunity was also implicated during the pathogenesis of organ-specific 
autoimmune diseases such as T1D  through numerous immunological mechanisms. Antigen 
presenting cells (APCs), such as DCs, impacted disease through delivery (Turley et al., 2003) as 
well as presentation of islet antigens in the PLN (Hoglund et al., 1999).  Furthermore, early work 
indicated that macrophage-derived tumor necrosis factor (TNF)-α and type 1 IFN signaling were 
involved in disease by blocking macrophage invasion into the islets (Hutchings et al., 1990).  
However, more recent work implicated local pancreatic macrophage in T1D protection via their 
expression of the complement receptor of the immunoglobulin superfamily (CRIg) (Fu et al., 
2012).  The diversity of macrophage in the pancreas as well as the respective roles each subsets 
plays during diabetogensis is still under debate.  Innate-like natural killer T (NKT) cells are 
considered protective in T1D given that supplementation of NKT cells or transgenic expression 
of their TCR protected NOD mice from disease (Hammond et al., 1998; Lehuen et al., 1998). A 
recent  controversial  study  proposed that innate immunity (including neutrophils and 
plasmacytoid DCs [pDCs]) initiated T1D (Diana et al., 2013).  Finally, an emerging literature 
points to a pathogenic role for NK cells, traditionally considered innate immune cells.  In these 
studies, NK cells were correlated to the aggressivity of inflamed islet lesions in acute models of 
T1D (Alba et al., 2008; Tang et al., 2008; Feuerer et al., 2009b) and the onset of disease in NOD 
mice (Gur et al., 2010), discussed further, below. 
The exact role of innate immunity in T1D is still under investigation.  However, a 
common theme from these studies is that innate immune function often results in the modulation 
of adaptive immune responses.  Given these findings, a current model for T1D necessitates the 8 
 
inclusion of crosstalk between innate and adaptive immunity.  In this dissertation, we explore the 
role and regulation of NK cells during the pathogenesis of T1D – with a particular focus on NK 
cell crosstalk with the adaptive immune system. 
 
 
1. 4 NK cells and T1D 
   
1.4.1 NK cell biology 
 
  NK cells represent the third major arm of the lymphocyte lineage (along with B and T 
cells) and are historically described as having two primary effector functions: cytokine 
production  and cytotoxicity, encompassing a critical share of the body’s defense against 
microbial infection and cancer (Vivier et al., 2008). NK cells are traditionally described as 
members of “innate” immunity given their propensity for rapid immune responses and lack of 
randomized receptor rearrangement.  However, a growing body of evidence supports the notion 
that NK cells have immunological “memory” (Paust and von Andrian, 2011; Sun et al., 2014), 
placing NK cells as a bridge between innate and adaptive immunity (discussed further, below). 
Furthermore, often overlooked in the field of immune tolerance, NK cells are critical players in 
the recognition of self, non-self as well as “altered self.”  
The primary cell-intrinsic form of self-recognition by NK cells is mediated by a variety 
of activating and inhibitory receptors, collectively known as the NK cell receptors (NKCRs). The 
biological significance of the NKCR system is illustrated by the fact that the NKCR system 
evolved convergently in multiple species (mainly the Ly49 family in mice, the killer cell 9 
 
immunoglobulin-like receptor (KIR)  gene family in humans  and  the CD94/NKG2 family in 
both)  (Lanier, 2008).  These receptors recognize cellular  markers of stress as well as 
MHC:peptide molecules.  Depending on the context of an MHC molecule-NK cell interaction, 
NK cells can be activated or inhibited via these receptors.  Cell extrinsic regulation also guides 
the activation state of NK cells.  Like most immune cells, there is a significant amount of 
crosstalk that takes place between NK cells and the rest of the immune system.  This 
communication network includes DCs and macrophages as well as conventional T (Tconv) cells, 
Treg cells, and NKT cells (Lehuen et al., 2010). The combination of intrinsic and extrinsic stimuli 
leads to NK cell activation, including inflammatory cytokine production and cytotoxicity, or NK 
cell inhibition (a continuation of the tolerant state).  
 
 
1.4.2 NK cells in autoimmunity and T1D 
 
  Given their well-described inflammatory and immunomodulatory role, as well as their 
propensity to kill autologous cells in rare contexts (Hansson et al., 1981; King, 2000; Della 
Chiesa et al., 2003), NK cells have been hypothesized as mediators of autoimmunity (Johansson 
et al., 2005).  In reality, very few biological scenarios where NK cells kill healthy self-tissue 
have been discovered.  NK cells were first directly linked to T1D since early studies indicated 
that rat NK cells killed islet cells in culture (MacKay et al., 1986).  However, the earlier studies 
focusing on the role of NK cells in diabetes were full of confounding data.  For example, 
although depletion of NK cells in induced models of diabetes (streptozotocin and 
cyclophosphamide) indicated that they were required for the disease (Maruyama et al., 1991a; 10 
 
Maruyama et al., 1991b), the earliest results in rat genetic models did not agree (Ellerman et al., 
1993).  Further confusion came with findings in NOD mice showing that diabetes progression 
can be prevented with injection of Complete Freunds Adjuvant (CFA) (McInerney et al., 1991), 
the effects of which were shown to be mediated by NK cells (Lee et al., 2004).  It is important to 
note that many of the experimental tools (such as antibodies) used in these early studies were 
subsequently shown to not be NK cell-specific. 
  The strongest evidence supporting a role for NK cells in T1D came from more recent 
studies focusing on pancreatic NK cells.  Multiple studies have agreed that NK cells are readily 
found in the pancreas of NOD mice, some reporting evidence of NK cells even in the absence of 
autoreactive B and T cells (Brauner et al., 2010; Beilke et al., 2012). In both of these studies, the 
phenotype of pancreatic NK cells was explored. Compared to spleen and PLN, pancreatic NK 
cells had a distinct mature phenotype and were highly proliferative. Despite their activated 
phenotype (including increased CD25, CD69, and KLRG1 expression), pancreatic NK cells were 
hyporesponsive to activating stimuli – which paralleled an “exhausted” T cell phenotype. 
Poirot and colleagues explored the BDC2.5 T cell receptor transgenic mouse line in the 
NOD and C57BL/6.H-2
g7 (B6.H-2
g7) backgrounds, which displayed innocuous and destructive 
forms of autoimmunity, respectively. Their efforts were aimed at differentiating these insulitic 
lesions to determine what makes an aggressive lesion unique. They described that the more 
aggressive form of insulitis contained higher proportions of NK cells and NK cell specific 
transcripts (specifically the Ly49 family) compared with the control NOD background (Poirot et 
al., 2004). Because the MHC haplotypes between these strains were identical (each contained the 
NOD haplotype of MHC), the influence of MHC ligands was ruled out.  This finding has since 
been corroborated in numerous models of aggressive/acute T1D (Alba et al., 2008; Feuerer et al., 11 
 
2009b; Tang et al., 2008). Collectively, this correlation might support an immune-modulatory 
role for NK cells to impact the aggressiveness of the disease.  Importantly, depletion of NK cells 
using anti-asialo GM1 or anti-NK1.1  monoclonal antibody treatment protected from disease 
and/or dampened T cell activation in these studies, supporting a functional role for NK cells 
during acute forms of disease. Almost no evidence exists describing the mechanistic role of NK 
cells in the pancreas.  However, one study reported that depleting NK cells or neutralizing IFN-γ 
following  Treg  cell ablation  dampened pancreatic CD4
+  T cell activation and substantially 
delayed the onset of diabetes, respectively (Feuerer et al., 2009b). 
  The proposed functional role for NK cells recently came  under fire by Beilke and 
colleagues who showed little effect when NK cells were depleted in the NODNK1.1 mouse 
model (Beilke et al., 2012).  However, it is noteworthy that their treatment protocol lasted only 
from the 3-10 week age range and was cut off before the onset of disease (>12 weeks). The age 
range is noteworthy because the treatment protocol effectively missed two critical stages in T1D.  
First, the initial activation of autoreactive T cells which occur between day  14 through 18 
following birth.  Second, the treatment missed the later stages of insulitis maturation and disease 
onset. Because of these deficiencies, whether or not NK cells participate in activation of 
autoreactive T cells in the PLN or the onset of disease remains unclear. Importantly, given that 
NK cell frequency best correlates with the onset of disease in NOD mice (Gur et al., 2010), 
depleting NK cells during this timeframe is critical to drawing any conclusions about their 
function. 
  In contrast, Angstetra and colleagues studied the NOD4.1 model which preferentially 
expressed the transgene-encoded NOD4.1 TCR, restricted to the NOD MHC-class-II Ag7 
molecule (Verdaguer et al., 1997). They assessed whether or not NK cells acted as the functional 12 
 
killing arm in this model  using NK cell depletion  over 20wks, and discovered significant 
protection by doing so.  However, they also transferred BDC2.5 T cells into an NK cell-deficient 
NOD  host  and found that the absence of NK cells did not change the disease occurrence. 
Furthermore, in vitro studies indicated that NK cells were incapable of killing β cells from MHC 
sufficient or deficient animals.  Their data, (similar to  Fuerer  et.al.)  supported  an immuno-
modulating role for NK cells in T1D, rather than a direct killing of islet cells (Angstetra et al., 
2012). 
NK cells were reported to have a unique phenotype in human T1D patients. One study 
compared recent-onset and long-standing blood samples and found a small but distinct reduction 
in  peripheral blood NK  cell  numbers of patients with recent-onset disease. These cells also 
displayed the most wide-ranging expression of IFN-γ.  In contrast, the long-standing diabetic 
patients had the lowest levels of activating receptors NKG2D, NKp46 and NKp30 (Rodacki et 
al., 2007).  These data supported earlier work that indicated reduced NK cell cytotoxicity in 
patients with long-standing T1D (Lorini et al., 1994).  Whether or not the “altered” NK cell 
phenotype in human T1D is a result of the disease or a potential cause is still unknown. One 
explanation might be that NK cells in long-standing T1D patients have an “exhausted” 
phenotype due to an undocumented hyperactivation in the pancreas at the onset of insulitis or β 
cell destruction. Another hypothesis is that the phenotype of NK cells in T1D patients are an 
inconsequential result of a dysfunctional immune system in an autoimmune-prone individual. 
The preponderance of evidence points to NK cells playing a role in T1D.  Despite their 
name, NK cells likely do not  kill  β  cells.  Rather, NK cells might  support  or cause  an 
inflammatory environment in the pancreas  that  influences  disease onset.  The small line of 
evidence supporting a protective role for NK cells during CFA treatment is noteworthy, but 13 
 
represents a highly contrived setting not representative of the normal spontaneous disease in 
NOD mice.  However, this confounding data might support a context-dependent role for NK 
cells in T1D – subject to where and how NK cells are activated 
.   14 
 
Chapter 2: How Regulatory T Cells Control Pancreas-Infiltrating NK Cells to Prevent Islet 
Inflammation and Autoimmunity 
 
2.1 Publication Reference (see appendix A for a full original reprint) 
 
Jonathan Sitrin,  Aaron Ring, K. Christopher Garcia, Christophe Benoist
  and Diane Mathis 
(2013). Tregs Control NK Cells in an Insulitic Lesion by Depriving them of IL-2. The Journal of 
Experimental Medicine 93:2260. doi:10.1084/jem.20122248 
 
2.2 Additional Introduction 
 
  The immune system requires a complex set of central and peripheral tolerance 
mechanisms in order to appropriately respond to foreign pathogenic insult while simultaneously 
maintaining self tolerance. Treg cells are a critical player in the lifelong maintenance of that 
tolerance and utilize a variety of mechanisms in order to suppress inappropriate immune 
responses.  When Treg cells fail, autoimmune diseases such as T1D develop.  Many immune cells 
are subject to Treg cell control, including NK cells (Kim et al., 2007; Feuerer et al., 2009c), but 
the molecular basis for this regulation was unknown.  A  widely-accepted  paradigm in 
immunology is that innate immunity instructs adaptive immunity via inflammatory cytokine 
secretion, and activation of antigen presentation machinery.  The discovery that Treg cells control 
the innate immune compartment was one of the findings that altered  that  model.  A  more 
accurate  model for immune tolerance includes  innate and adaptive immune-cell  cross-talk.  
However, the exact mechanisms used by innate and adaptive immune cells to signal to one 15 
 
another were not well understood.  Specifically, how Treg cells control NK cells in the pancreas 
was unclear, and whether or not there were tertiary cells involved was unknown.  In this chapter, 
we explored this molecular interaction and uncovered a novel mechanism for innate and adaptive 
immune-cell cross-talk involved in diabetes protection. 
 
 
2.2.1 The protective role of Treg cells in T1D 
 
Diminished Treg  cell function has been implicated in numerous human  autoimmune 
diseases, including T1D  (Buckner, 2010). Supporting this concept, there is a drastic 
overrepresentation of T1D in patients with mutations in FOXP3 (Wildin et al., 2002; Torgerson 
and Ochs, 2007; Moraes-Vasconcelos et al., 2008). While the association of Treg  cells and 
autoimmune diseases is clear, the specific role Treg cells play in each autoimmune setting, and 
how Treg cell suppressive function is diminished remains unclear. 
The earliest line of evidence supporting a protective role for Treg cells in NOD mice was 
the discovery that the accelerated disease found in CD28-deficient NOD mice could be explained 
by the lack of CD4+CD25+ cells expressing CTLA-4 (Salomon et al., 2000). In this study, 
adoptive transfer of (what were later confirmed to be Foxp3-expressing) Treg cells delayed or 
completely protected these mice. This finding supported earlier studies implicating CTLA-4 in 
the pathogenesis of T1D using monoclonal antibody blockade (Luhder et al., 1998)– although at 
the time, the effect of anti-CTLA-4 treatment on Treg cells was unknown. 
While the protective effect of Treg cell adoptive transfer was confirmed in numerous 
studies, many of these studies also noted that transfer of Treg cells did not affect the formation of 16 
 
robust insulitic lesions (Tang et al., 2004; Tarbell et al., 2004; Herman et al., 2004). These 
findings implicated local pancreatic suppression as the primary mechanism supporting Treg cell-
mediated protection from T1D.  
Supporting this concept, efforts to locally expand or boost Treg cells have also proven 
fruitful in the prevention of T1D in NOD mice. Numerous signaling pathways and strategies 
involved in Treg cell function, activation and homeostasis were invoked to accomplish this task.  
These  pathways  included treatment with IL-2  (Rabinovitch et al., 2002; Tang et al., 2008; 
Grinberg-Bleyer et al., 2010), retrovirus-induced local production of IL-2 (Johnson et al., 2013), 
alternative expression of CTLA-4 splice variants (Vijayakrishnan et al., 2004), and islet-specific 
pulsed TGF-β (Peng et al., 2004).  In all of these studies, boosting Treg cell number, frequency or 
function protected T1D models from disease. 
 
 
2.2.2 Exploring where and how Treg cells protect from T1D 
 
Where and how Treg cells exert there protective effect during diabetogenisis has become 
clearer over the last several years. Two experimental strategies  were crucial for this 
determination.  First, the BDC2.5 TCR transgenic model was crossed to the Foxp3-deficient 
scurfy mutant mouse (Foxp
sf.BDC2.5/NOD) to generate Treg cell-deficient T1D-prone animals.  
In this model, the absence of Treg cells did not change the kinetics or phenotype of the initial T 
effecter (Teff)  cell priming phase and did not  alter the trafficking of Teff  cells to the islets.   
However, these animals developed a highly penetrant and aggressive form of T1D, indicating 
that the insulitis was immediately destructive compared with  the normally longstanding 17 
 
protection in a Foxp3-sufficent setting.  These data supported a model in which Treg  cells 
impinged on the local activation of T cells at the site of inflammation and had little effect on 
priming in the PLN  (Chen et al., 2005b). However, a major critique of this study was the 
constitutive absence of Treg cells. 
The second crucial study that uncovered  a functional role for Treg  cells during T1D 
protection  entailed a mouse expressing  the  DTR  under the promoter/enhancer  elements of 
Foxp3, in conjunction with the BDC2.5 TCR transgenic mouse line (BDC2.5/NOD.Foxp3
DTR 
mice). This model combined normal (Treg cell-sufficient) immune system hematopoiesis, T cell 
activation in the PLN and insulitis formation with the ability to perturb Treg cells in a punctual 
and specific manner. In doing so, this model also allowed for the careful molecular delineation of 
the downstream effects of Treg cell loss because genes that changed immediately following Treg 
cell ablation were  presumed to be indicative of the molecular programs that Treg cells were 
continually suppressing.  Treg cell ablation provoked nearly 100% penetrance of diabetes within 
days (Feuerer et al., 2009c), confirming the absolute and continual requirement for Treg cells to 
guard against T1D.  Analysis of the insulitic lesion revealed, surprisingly, that the earliest 
detectable responders to the loss of Treg cells were NK cells, which accumulated to a higher 
fraction of the infiltrate and produced IFN-γ within hours. Subsequently, there was increased 
activation of and IFN-γ  production by diabetogenic CD4
+  T cells.  Neutralizing IFN-γ  or 
depleting NK cells dampened pancreatic CD4
+ T cell activation and substantially delayed the 
onset of diabetes.  Thus, there seemed to be a direct and continual requirement for Treg cells to 
keep NK cells, and ultimately diabetes, in check. However, it remained unclear exactly how Treg 
cells controlled NK cell function. 
 18 
 
2.2.3 Mechanisms of Treg cell suppression and the control of NK cell functions in other 
contexts 
   
Treg cells utilize a wide variety of mechanisms to maintain peripheral tolerance. First and 
foremost, the very nature of commitment to the Treg  cell lineage is widely accepted as an 
immunosuppressive mechanism given the trend for autoreactive thymocytes to become Treg cells 
(Hsieh et al., 2006).  Foxp3  expression  inhibits the production of IL-2 while amplifying the 
production of CTLA-4 and CD25 in a cell-intrinsic fashion.  The former has potent 
immunosuppressive function and the latter is critical for the maintenance, stability and function 
of the cell.  Other basic mechanisms of suppression include inhibitory cytokine secretion, direct 
cytolysis, indirect targeting of antigen presentation, metabolic disruption and competition for IL-
2 (Vignali et al., 2008). Whether these described mechanisms, or new mechanisms were relevant 
for the control of NK cell functions in the BDC2.5/NOD.Foxp3
DTR model was unclear. 
Treg cells produce a number of inhibitory cytokines including IL-10, transforming growth 
factor (TGF)-β and IL-35 that are potent inhibitors of immune cell activation in vitro and in vivo. 
TGF-β is particularly relevant given its described role in the suppression of NK cells in the 
Foxp
sf  model  (Ghiringhelli et al., 2005).  This report also  described an inverse correlation 
between Treg cells and NK cell frequency and function in cancer patients. Similar correlations 
were  seen in numerous other clinical settings, especially during other  cancer treatments 
(Ghiringhelli et al., 2006)  and  during  blood cell transplantation (Trzonkowski et al., 2004). 
Furthermore, transfer of Treg  cells into tumor models prevented NK  cell anti-tumor activity 
(Shimizu et al., 1999; Smyth et al., 2006) and transplant rejection (Barao et al., 2006).  In these 
studies, when modeled in vitro, Treg cells were potent suppressors of NK cell cytotoxicity but Treg 19 
 
cell function was contact dependent, blocked using anti-TGF-β monoclonal antibodies and was 
insensitive to formaldehyde fixation (Ghiringhelli et al., 2005).  While these data supported a 
suppressive mechanism involving direct contact between Treg cells and NK cells, one further 
study showed that impairment of Treg cells resulted in the activation of NK cells through indirect 
activation of DCs and increased expression of IL15Rα (Terme et al., 2008).  Whether or not the 
control of NK cells by Treg cells was mediated through direct TGF-β signaling or indirectly 
through APCs was unclear, but explored further in our study. 
   20 
 
2.3 Additional Discussion 
 
  We described a model in which Treg cells, through expression of CD25 and sequestration 
of IL-2, act as gatekeepers of tolerance and immune function in the pancreas. From this model, 
we conclude that the level of IL-2, as well as its availability to certain IL-2R-expressing cells of 
different affinities, is paramount to the determination of autoimmunity versus tolerance. In our 
proposed scenario, an active competition for limiting cytokine acts as a buffer between local Treg 
cells and NK cells, but also likely for local CD4+ and CD8+ T cells, DCs and B cells.  Whether 
or not these cell types, or others, are active players in this competition should be explored in 
further detail. 
The expression of CD25, required for functional Treg cell generation, also enables Treg 
cells to bind IL-2 with high affinity and sequester IL-2 away from other cells (de la Rosa et al., 
2004; Barthlott et al., 2005; Scheffold et al., 2005; Pandiyan et al., 2007).  This suppression-via-
sequestration mechanism has been shown to dampen IL-2 production and proliferation, and to 
lead to apoptosis in Teff cells (Wing and Sakaguchi, 2012). Notably, this mechanism does not 
require the presence of an APC or costimulation, and thus has the capacity to act directly and 
broadly on immune cells in many contexts. 
The CD25-deficient mouse model develops a systemic lymphoproliferative syndrome 
similar to that of both the Foxp3-deficient and CTLA-4-deficient animals (Willerford et al., 
1995). Initially, this finding was thought to be due to the lack of Treg cells; however, follow-up 
studies using a Foxp3-GFP reporter highlighted a pool of Foxp3-expressing cells in these 
animals that could suppress effector cells in vitro (Fontenot et al., 2005). It remains unclear how 
much of the phenotype of CD25-deficiency can be explained by the lack of sequestration of IL-2 21 
 
versus the lack of overall fitness and protective functions of Treg cells. Our findings add a level of 
complexity to the growing body of work focused on Treg cell-expressed CD25.  As Fontenot and 
colleagues described, the lack of CD25 on Treg cells is associated with reduced Foxp3 expression 
and yields cells that are functionally “unfit” in the periphery (Fontenot et al., 2005). However, 
we and others  have shown that CD25 itself acts in a functional capacity to limit immune 
responses. Whether or not this mechanism acts in a broader set of organs and disease settings 
remains to be explored.  Also unclear is to what degree the wild-type  in vivo suppressive 
capacity of Treg  cells  is attributable  to their sequestration of IL-2 compared with  other 
suppressive mechanisms.  Given that CD25 is highly expressed by Treg cells in most settings, 
these cells likely act as IL-2 buffers wherever they reside, supporting the concept that CD25 acts 
as a  “core module” of Treg  cell function  as described by Wing and Sakaguchi  (Wing and 
Sakaguchi, 2012). 
In an effort to explain the systemic control of IL-2, one group proposed a “quorum 
sensing” model (Amado et al., 2013).  In their study, deficiency in IL-2, and therefore Treg cells, 
led to increased IL-2 production in T cells (as read out using IL-2 reporter mice).  However, 
administration of IL-2 decreased the number of IL-2-producing T cells, diminished the IL-2 
production in those cells and increased Treg  cell numbers.  These findings experimentally 
supported  a systemic auto-regulatory feedback loop controlling IL-2 availability.  In brief, 
decreased IL-2 eventually yielded more IL-2 and vice versa. However, it is clear from our work 
that many other cell types can participate in this feedback loop or be subject to its imbalances (as 
an “input” or “output”) – notably NK cells that are subject to IL-2 availability and produce IL-2-
promoting cytokines such as IFN-γ. 22 
 
  Our findings emphasize an intriguing cross-talk between innate and adaptive immunity 
with parallels to models of infection. NK cell production of IFN-γ was critical to the proper 
clearance of Leishmania major infection in one study (Bihl et al., 2010).  In this model, it was 
discovered that CD4-deficient animals showed improper NK cell activation that was not the case 
for CD8-depleted animals.  The origin of the NK cell-activating stimulus during infection was 
antigen-specific CD4+ Tconv  cells that produced IL-2.  An indirect role for APCs  was also 
described via the engagement of the CD40/CD40L pathway upstream of IL-12 production.  
Neutralization of IL-2, together with IL-12, was the strongest inhibitor of this response.  These 
findings offered support for a scenario similar to the one we proposed in that antigen-specific 
CD4+ Tconv cells created an IL-2-rich environment, with secondary extrinsic stimuli from DCs. 
There are two major differences between our findings and the findings in the Leishmania 
major infection model.  First, Bihl and colleagues found no change in the activation status of NK 
cells in their model when CD25+ Treg  cells were blocked and/or depleted (albeit  with anti-
CD25).  Although activating IL-2 is a molecular mechanism shared between the two studies, the 
primary limiting factor controlling IL-2 in their system was likely the production of IL-2 rather 
than the post-secreted competition for IL-2.  The second major difference involved the role of 
IL-12 produced by local myeloid cells.  In Feuerer et.al., preliminary data indicated  a 
requirement for IL-12 for the normal response of NK cells to Treg cell ablation. More precisely, 
anti-IL-12 treatment in conjunction with Treg cell ablation decreased the production of IFN-γ by 
NK cells but did not alter the levels of granzyme B transcript. However, the kinetics did not 
match as a primary regulatory mechanism, because IL-12 production by DCs was slower than 
IFN-γ production by NK cells.  Therefore, although an indirect role for IL-12 could have been 
partially responsible, it must have been secondary compared with control via competition for IL-23 
 
2. The difference in interpretation and conclusion might be due to the time points being analyzed 
in each study.  In our study, the very earliest transcriptional responses (7-8hrs) were examined in 
order to make an isolated determination of primary mechanism without confounding effects from 
other activated cells. In the infection system, 12hrs and further were analyzed.  This might seem 
like a small discrepancy but evidence from Feuerer et. al supported the notion that DCs did not 
produce IL-12 until after the 12hr timeframe.  Importantly, pancreatic NK cells did showed signs 
of transcriptional activation prior to Treg cell ablation in the BDC2.5/NOD model (unpublished 
observations).  This mild stimulatory state could have provided the priming needed for NK cell 
responsiveness, including the induction of CD25 on NK cells.  Supporting this concept, IL-12 
was required for the upregulation of CD25 on NK cells during mouse cytomegalovirus (MCMV) 
infection  (Lee et al., 2012).  Together,  Treg  cell  ablation, in an environment of prior local 
inflammation, might act as the brake-release on an already “primed” cell. 
Supporting a role for local inflammation for the full responsiveness of NK cells to the 
loss of Treg cells, Beaulieu and colleagues recently reported that the induction of Zbtb32 drives 
NK cell proliferation in an inflammatory cytokine-dependent manner (Beaulieu et al., 2014). In 
their study, IL-12, IL-18 and type 1 IFN induced Zbtb32 expression – rather than activating 
receptor engagement.  The combination of IL-12 and IL-18 was the most potent Zbtb32-inducing 
condition, which implied that a strong inflammatory setting was needed to drive maximal NK 
cell proliferation.  Their findings might explain the variable kinetics differentiating pancreatic 
and splenic NK cells responding to Treg cell ablation from our study or the differences between 
the BDC2.5/NOD.Foxp3
DTR and Foxp3
DTR models’ rates of NK cell expansion (hours versus 
days) (Kim et al., 2007; Feuerer et al., 2009c). Those differences may be due to differential 
expression of Zbtb32.  NK cells residing in an already-stimulated state, such as they are in the 24 
 
inflamed pancreas, would be much more proliferative following a secondary driving stimulus 
such as the loss of Treg cells, and newly available IL-2.  Supporting this hypothesis, although 
Zbtb32  was  not  significantly different in  pancreatic  versus splenic NK cells at baseline 
(unpublished observations), it was uniquely induced in the pancreas following the loss of Treg 
cells (Sitrin et al., 2013). 
Taken together, our studies and the study by Bihl and colleagues emphasized a tight 
molecular,  cellular, and tissue-level  control of IL-2, which may need to be kept within a 
tolerogenic balance to prevent systemic or tissue-specific autoimmunity.  Reminiscent of a sieve 
with dynamic inputs and outputs, as long as IL-2 remains in a balanced input-output state, the 
tissue remains tolerant.  However, a severe IL-2 decrease or increase pushes the system into an 
autoimmunity-prone state (the former due to an effect on Treg cells and the latter due to NK and 
Teff cells). These inputs/outputs could include transcriptional control of IL-2, the number of cells 
secreting IL-2, its secretion rate, the number of cells able to “experience” the IL-2 via IL-2R 
(including non-immune cells), the type of IL-2R complexes on those cells as well as the need for 
any co-activating cytokines or cell types.  Future research efforts must take careful consideration 
into studying the local IL-2 availability in a given tissue in order to gain a better understanding 
about how a tissue can mount an appropriate immune response versus developing autoimmunity.  
The pancreas served as an instructive example in which low- and high-dose IL-2 had opposing 
effects on T1D.  The former boosted Treg cells and protected from disease while the latter caused 
mouse and human T1D (Tang et al., 2008; Long et al., 2012; Sitrin et al., 2013).   To that point, 
T1D  clinical trials dedicated to appropriate dosing of IL-2  were very recently  undertaken 
(Waldron-Lynch et al., 2014). 25 
 
  Our study does not implicate a role for the Treg cell contact-dependent TGF-β suppressive 
mechanism previously described in numerous cancer models. Why specific Treg cell mechanisms 
are utilized under certain conditions (such as TGF-β in cancer) and not others (T1D) remains 
unclear.  Treg cells are now appreciated to be highly context-dependent immune suppressors. The 
mechanism explaining this contextualized function seems to be the co-opting of transcription 
factors previously identified to polarize Teff  cells based upon their stimulation  and local 
environment. For example, Treg cell conditional ablation of IRF4 (a transcription factor required 
for TH2 polarization), STAT3 (required for TH17 polarization) or  Tbet  (required for TH1 
polarization) led to aberrant  immune control centered around each transcription factor’s 
respective TH cell polarization profile (TH2, TH17 and TH1, respectively) (Zheng et al., 2009; 
Chaudhry et al., 2009; Koch et al., 2009).  It remains possible that tumor Treg cells and pancreatic 
Treg cells prior to T1D-onset have distinct transcriptional or functional identities. Further analysis 
of the transcriptional programs from each population would yield a better grasp on how each cell 
suppresses the local immune compartment in a unique fashion. 
  Gasteiger and colleagues confirmed Treg cell control of NK cells via an IL-2-dependent 
mechanism in two accompanying publications to our own (Gasteiger et al., 2013a; Gasteiger et 
al., 2013b). In their study, Treg  cells restrained the splenic  expansion of a phenotypically 
immature NK cell due to the NK cell’s preferential expression of CD25 – similar to what we 
described in the pancreas. With regards to NK cell tolerance, they presented compelling data 
showing that Treg cell ablation did not enhance NK cell responsiveness to general activating self- 
and non-self ligands. However, depletion of Treg cells did enhance NK cell targeting of “missing-
self” ligands such as MHC class 1-deficient target cells – paralleling the increased cytotoxicity 
against MHC class 1-deficient targets in our model. Importantly, they mechanistically explained 26 
 
these findings by showing that IL-2 enhanced NK cell conjugation with weaker target cells and 
increased Ca
2+ flux upon target cell engagement.  
The increased recognition of weaker target cells is particularly intriguing because it could 
explain the usefulness of IL-2-based cancer therapies.  Despite the more recent body of work 
outlining the tolerogenic function of IL-2, it was initially described as an immuno-stimulatory 
molecule and has been used in stimulatory immunotherapy for years. Recombinant IL-2 was first 
approved for renal cell carcinoma and metastatic melanoma in 1992 and 1998, respectively 
(Rosenberg, 2014). There are two important clinical implications for the effects of IL-2 on NK 
cells.  First, given that Treg cell ablation could not provoke direct NK cell autoreactivity, even in 
the presence of a strong activating ligand, NK cells may be poor responders to some cancers 
(especially if those cancerous cells contain features of self-tissue). However, given that IL-2 
enhanced NK cell killing of weaker (previously-tolerated) target cells, the opposite possibility 
could also be true: certain cancers might be great targets for IL-2-based NK cell therapies, even 
if NK cells are  naturally  non-responsive.  Understanding how to manipulate NK cell 
responsiveness to target cells will be critical for appropriately designing cancer therapies moving 
forward.  
One major difference between the findings from our study and that of Gasteiger and 
colleagues was the interpretation of whether or not the IL-2-based suppressive mechanism was 
direct or indirect. Rather than a semantic argument, these interpretations imply different, albeit 
not mutually exclusive findings.  In our direct model, the NK cell-activating IL-2 was already 
available in the tissue and did not need to be newly produced by T cells.  In the indirect model, 
Treg cell loss provoked new IL-2 expression from T cells, which implied that T cell help was the 
limiting factor in this regulatory axis.  Similar to Leishmania major infection with IL-12, the 27 
 
differences for IL-2 might come down to timing.  As previously discussed, the very immediate 
downstream effects of Treg cell depletion included an immediate burst of IL-2 availability that 
was responsible for NK cell activation in  the BDC2.5/NOD setting.  Evidence from 
transcriptional profiling supported the notion that T cells produced new IL-2 sometime between 
15 and 24 hrs (Feuerer et al., 2009c) but that the new protein was not yet apparent at 24hrs. The 
IL-2-induced NK cell activation in the Gasteiger model was likely due to new IL-2, produced 
after the 24hr timeframe (or the combination of the initial burst and secondary production). Both 
sources of IL-2 could contribute to the immune response following the loss or dysfunction of Treg 
cells. 
  The sequestration of tissue-available IL-2, as we report, represents a novel mechanism 
explaining Treg cell control of NK cell function.  More broadly, this regulatory mechanism also 
adds to the growing body of literature describing the complexity of innate and adaptive immune-
cell crosstalk. In the future, it would be advantageous to determine whether or not this regulatory 
axis functions in other contexts, as well as to determine if this mechanism is similarly utilized by 
the human immune system. 
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Chapter 3: Profiling of the Ly49 Receptors and NK Cell Heterogeneity in T1D 
 
3.1 Introduction 
 
  3.1.1 Historical definitions and heterogeneity of NK cells 
 
  Unlike T and B cells with randomly generated  receptors, NK cell heterogeneity is 
currently accepted as germline encoded, implying a theoretical “maximum” heterogeneity. The 
question of NK cell heterogeneity has been historically complex.  Part of the lack of 
understanding can be attributed to the variable historical definition of NK cells.  NK cells in 
mice have been defined by the lack of expression of CD3 combined with the expression of the 
Ly49 family, the NKG family (such as NKG2D), the NKR family (such as NK1.1) and most 
recently by the NKp46 receptor.  Human NK cells have  traditionally  been  defined by their 
expression of CD56 and CD16. NK cells have also been defined by their anatomical locations, 
including the bone marrow, thymus, spleen, liver, lung, lymph nodes, pancreas and placenta, as 
well as by  their dependency on  certain cytokines,  such as IL-15.  More recently, NK cell 
definitions have included dependency on certain transcription factors. For example, thymic NK 
cells depend on Gata-3  for  differentiation,  whereas blood and splenic  NK cells do not 
(Vosshenrich et al., 2006). Circulating liver and splenic NK cells depend on Nfil3, whereas 
resident liver, skin and uterine NK cells remain present in Nfil3-deficiency.  Resident liver and 
skin NK cells depended on Tbet whereas uterine NK cells remained present in the Tbet-knockout 
animals (Sojka et al., 2014a). A better understanding of the molecular cues required for NK cell 
subset differentiation is required for understanding the true heterogeneity of this population. 29 
 
  3.1.2 A modern view of NK cell heterogeneity using mass cytometry 
 
A recent technological advancement enabled a much clearer picture for the phenotypic 
diversity of NK cells. Horowitz and colleagues utilized the novel time-of-flight mass cytometry 
(CyTOF) technology on human peripheral blood, including 5 pairs of monozygotic twins.  Their 
analysis included 28 different receptors commonly expressed by NK cells (with a theoretical 
maximum of 2
28  possible combinations of markers).  Their  data indicated  a vastly greater 
phenotypic heterogeneity than had ever been described before.  No single NK cell phenotype 
could account for more than 7% of total NK cells. Furthermore, the top 50 phenotypes 
represented only ~15% of total NK cells.  The study also found a high concordance of inhibitory 
receptor expression between identical twins, not true of the activating receptors.  This finding 
invoked a proposed model in which genetics were strongly deterministic for inhibitory receptor 
patterns (and tolerance to self) whereas environmental cues impacted the expression of activating 
receptors (and recognition of non-self).  The total diversity was estimated to be between 6,000 
and 30,000 distinct human NK cell phenotypes within an individual and 108,000-125,000 at a 
population level (Horowitz et al., 2013).  These data vastly expand our  view of NK cell 
phenotypic diversity and emphasize an environmental responsiveness in NK cell phenotypes. 
 
 
3.1.3 NK cell education and tolerance through expression of Ly49 receptors 
   
  NK cells are sensitive to their environment, especially through interactions of the Ly49 
family of receptors and cells expressing MHC class I molecules.  The inhibitory Ly49 receptors, 30 
 
containing transmembrane immunoreceptor tyrosine-based inhibitory motifs  (ITIMs), are 
expressed in a variegated fashion on single NK cells and can show great variability between 
individual cells (Nash et al., 2014).  This variegated pattern is thought to arise during bone 
marrow differentiation when NK cells first engage MHC class I molecules – the point at which 
they become “educated.” This model, often called the “arming” model, postulates that the 
education process tunes NK cell reactivity in the periphery and prevents autologous cell killing.  
Once in the periphery, NK cells continually interact with local autologous cells in a cell-to-cell 
trans-fashion, at which point two major outcomes are possible. If the target cell has normal MHC 
class I expression, with a non-activating peptide, direct engagement of ITIM-bearing receptors 
leads to the intracellular recruitment of inhibitory tyrosine phosphatases and the prevention of 
immune synapse formation (Jaeger and Vivier, 2012). However, in a non-self (virus) or 
transformed self (cancer) setting, NK cells recognize either the altered MHC:peptide repertoire, 
the lack of MHC class I expression or an overexpression of activating ligands. The lack of 
inhibitory signal or the excess of activating signal through immunoreceptor tyrosine-based 
activating motif (ITAM)-containing receptors, such as CD3ξ or DAP10/12, leads to proliferation, 
cytotoxicity and often inflammatory cytokine production (Lanier, 2005). This balance  of 
activating and inhibitory receptors,  along with the ability of NK cells to respond to the 
inflammatory milieu in tissues, outlines the need for NK cells to be tuned in an effective way to 
remain tolerant to self.  
The NK cell education process is best illustrated by two major findings.  First was the 
discovery that NK cells from MHC-I-deficient mice were hyporesponsive in killing capacity 
(Bix et al., 1991).  This finding can be partially explained by follow-up studies showing that full 
activation of NK cells to target cells required  co-engagement  of their activating receptors 31 
 
(Cerwenka et al., 2001; Diefenbach et al., 2001; Arase et al., 2002; Smith et al., 2002; Sun, 
2010). The second discovery identified a small fraction (~15%) of B6 NK cells that lacked any 
inhibitory Ly49 expression. Although these NK cells maintained  a mature phenotype, they 
exhibited  hyporesponsiveness when engaged through activating receptors (Fernandez et al., 
2005). 
Unlike B and T cell differentiation which is appreciated to be clonotypically restricted 
following proper BCR and TCR rearrangement and expression, NK cell education is considered 
to be highly dynamic. The best evidence supporting a non-terminal NK cell education process 
came from a set of studies describing NK cells from MHC-deficient animals regaining function 
and normal responsiveness following their transfer into MHC-sufficient hosts.  Additionally, 
MHC-sufficient NK cells can be transferred into MHC-I-deficient hosts and eventually lose 
responsiveness (Joncker et al., 2010; Joncker et al., 2010; Sun, 2010).  Interestingly, this tolerant 
state can be broken by a highly proinflammatory stimulus such as MCMV infection, in which 
previously tolerant NK cells rapidly reject the MHC-deficient cells of chimeric mice (Sun and 
Lanier, 2008). Collectively, these findings support a highly complex, dynamic and environment-
dependent model for NK cell education and tolerance,  in an effort to keep NK cell-
responsiveness in check. 
   
 
3.1.4 NK cell receptors in T1D: NKG2D and NKp46 
   
NK cell receptors are critical cell intrinsic regulators of NK cell responsiveness that have 
been implicated in the control of viruses (Schenkel et al., 2013; Rahim et al., 2014), tumor 32 
 
surveillance (Tu et al., 2014), allergies (Kusnierczyk, 2013) and autoimmunity (Rogner et al., 
2001; Carnaud et al., 2001). Exactly where and how these receptors exert their disease influences 
is currently under investigation.  With regards to T1D, two groups have identified potential 
mechanistic functions for NK cell receptors, including NKG2D and NKp46. 
The discovery that NKG2D stress ligands are expressed by islet cells in the pancreas of 
prediabetic NOD mice opened up  the possibility that NK cells directly target and kill these 
stress-ligand-expressing cells.  In line with that hypothesis, blockade of NKG2D using non-
depleting monoclonal antibody treatment in NOD mice significantly delayed diabetes. However, 
the authors attributed that protection to the inhibition of autoreactive CD8+ T cell activation 
rather than through an effect on NK cells (Ogasawara et al., 2004).  In addition, the role of 
NKG2D in T1D recently came under fire from a study showing that anti-NKG2D treatment and 
NKG2D deficiency had no protective effect in either the BDC2.5/NOD or  NOD.NK1.1 T1D 
models (Guerra et al., 2013).  It remains unclear exactly how NKG2D participates in T1D. The 
discrepancy in NKG2D-focused research in T1D may point to environmental cues altering the 
levels of stress ligands (NKG2D targets) on β cells from different facilitates but more work is 
needed in this area. 
  A second line of research identified NKp46 ligands in the pancreas and showed that an 
NKp46 fusion protein “stained” β cells in the islets of prediabetic NOD mice. Furthermore, 
NKp46 deficiency was associated with protection from streptozotocin-mediated T1D (but keep 
in mind that the relevancy of this induced model to natural T1D is suspect).  This study also 
confirmed a defect in NK cell killing of β cells in vitro, and less degranulation of pancreatic NK 
cells in vivo due to NKp46 deficiency. To support the relevance of NK cells in the natural NOD 
disease course, they correlated NK cell frequency with hyperglycemia onset (Gur et al., 2010). 33 
 
The authors did not identify the ligand relevant to NKp46 binding, but did identify the specific 
regions (membrane proximal domain) and residues (Thr
125 and Asn
216) of NKp46 required for 
binding to β cells in a follow-up study (Gur et al., 2011). From a functional standpoint, injection 
of an NKp46-Fc fusion protein protected NOD mice from disease.  The investigators assigned 
this protection to the endogenous generation of anti-NKp46 blocking antibodies. Whether or not 
their assumption is true remains unclear. In disagreement with their proposed mechanism of 
action, anti-NKp46 monoclonal antibody treatment had no effect on T1D in BDC2.5/NOD or 
NOD mice in our hands (unpublished observations). 
 
 
3.1.5 NK cell receptors in T1D: Ly49 and KIR 
 
A key open question in the T1D field is how established genetic risk loci contribute to 
disease in the NOD mouse.  One locus, idd6, is situated at the NK cell gene complex on 
chromosome 6 near the Ly49 receptor family (Rogner et al., 2001). In support of this finding, 
NOD mice congenic for the B6 NK cell receptor gene complex (including the B6 allele of the 
idd6 region) showed increased NK cell functionality as well as protection from disease (Carnaud 
et al., 2001).  How, mechanistically, the B6 idd6 region and the Ly49 receptors confer protection 
from disease remains unclear.  Genomic sequencing of this region indicated that the NOD idd6 
region  contained the largest set of Ly49 receptors, especially the activating Ly49 receptors, 
compared with all other sequenced strains (Belanger et al., 2008). This study reported some 
strain-specific Ly49 expression differences between B6 and NOD mice, for Ly49D, G and H/I, 
as measured by flow cytometry, corroborating a prior  study  that  found differences in the 34 
 
expression of Ly49D, C/F/H and A/P (Poirot et al., 2004). Given that monoclonal antibodies are 
not available for many Ly49 receptors, and because the ones that do exist tend to be cross-
reactive  (between Ly49 receptors) or specific for B6 alleles,  little  was  known about their 
comprehensive expression patterns in NOD mice (especially in the pancreas). 
Studies on  multiple human populations implicated the KIR genes in susceptibility to 
diabetes.  One study found a significant overrepresentation in inhibitory KIR2DL2 and 2DL5 
and activating 2DS1, 2DS2 and 3DS1 in Latvian T1D patients compared with controls (Nikitina-
Zake et al., 2004). Furthermore, they stratified for the high risk HLA-DR3 and DR4 alleles and 
found that the DR3 or DR4 genotype combined with 2DL2 or 2DS2 were significantly more 
likely to be patients than controls.  Similar results were reported from our lab describing an 
overrepresentation of KIR2DS3 in connection with the HLA-DRB1*04 and DQB1*0302 HLA 
complexes in patient cases but not controls (Rodacki et al., 2007).  Conflicting data came from 
Park and colleagues who did similar work in Korean patients but found 2DL5 and 2DS2 to be 
underrepresented in T1D patients (Park et al., 2006). A Finnish study also showed an 
underrepresentation of 2DS5 in T1D patients (Middleton et al., 2006).  However, there is a great 
deal  of conflict in this field,  potentially due to altered KIR haplotypes in different global 
communities, as emphasized by another study that found no association of KIR to T1D in a 
Basque population (Santin et al., 2006).   
In subsequent years, more studies showed that polymorphisms of specific KIR genes 
were  better predictors of T1D than KIR genotype alone (e.g.  KIR2DL2 polymorphism 
rs2756923) (Ramos-Lopez et al., 2009).  Although the complexity of these data make it hard to 
distill, one current model asserts that human diabetes patients have, on average, more activating 
KIR than non-diabetic individuals (van der Slik et al., 2003).  This model notably matches the 35 
 
genomic data from NOD mice as previously discussed (Belanger et al., 2008).  Importantly, the 
connection of T1D to both activating and inhibitory receptors indicates a more  complex 
mechanism than hyperactive/hypersensitive NK  cells.  Given that HLA DR3/DR4  and 
DRB1*04/DQB1*0302 increased the risk for T1D in certain KIR genotypes, and stratifications 
that include KIR ligands are better predictors than KIR alone, it is evident that NK cell receptor 
genotypes are part of a complex set of autoimmunity risks.  Notably, some of the same KIR 
genes that predicted risk for T1D also did so for other diseases such as KIR2DS1 with psoriasis 
(Jobim et al., 2008). 
 
 
3.1.6 Tissue-specific profiling of Ly49 receptors  
 
Despite their long-standing connection to  T1D in mice and humans, a functional 
association between the KIR and Ly49 receptors and diabetogenesis has never been established. 
This lack of connection is perhaps unsurprising given that little effort has been expended to 
comprehensively assess the expressed repertoire of these receptors, especially in contrast to the 
wealth of strain-to-strain genomic comparisons (Rahim et al., 2014). 
In regards to tissue-specific NK cell expression differences, Sojka and colleagues profiled 
8 Ly49 receptors by flow cytometry on tissue-resident versus conventional NK cells and found 
significant differences between the two populations. However, these tissues included liver, 
thymus, uterus, skin and spleen, but pancreas data were lacking.  Only one study analyzed the 
differences between pancreas and spleen, but only for 2 Ly49 receptors (G2 and D).  This study 
found a slight underrepresentation for both in the pancreas of NOD mice (Brauner et al., 2010). 36 
 
Here, we describe our efforts to fill these many different knowledge gaps by profiling the 
diversity of NK cells and their receptors in multiple fashions: first, we assessed the collective 
Ly49  receptors  expressed by NOD mice in diabetes-relevant and control organs using 
monoclonal antibody staining and flow cytometry.  Second, we comprehensively assessed the 
Ly49 receptor expression profile using high-throughput RNA sequencing (RNAseq).  To our 
knowledge, this represents the first comprehensive transcriptional repertoire assessment in any 
strain – including a quantitative comparison between multiple organs. Finally, we used the novel 
CyTOF platform to assess high-dimensional NK cell heterogeneity at the single cell level.  
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3.2 Materials and Methods 
 
Mice 
NOD/ShiltJ and BDC2.5/NOD TCR transgenic (Katz et al., 1993) mice were bred in our 
colony at the Jackson Laboratory, and were genotyped and maintained at Harvard Medical 
School (under specific-pathogen-free conditions). Females between 7-10 (Ly49 profiling) and 
17-19 (CyTOF profiling) weeks  of age were generally used.  Protocols were approved by 
Harvard Medical School’s Institutional Animal Care and Use Committee. 
 
Cell Preparations and Monoclonal Ly49 Receptor Antibody Staining 
For the purpose of collecting a highly purified sample of NK cells, the following steps 
were taken. Postmortem intracardial perfusion was performed with 30ml PBS.  Following 
surgical removal of organs, cells were isolated from the pancreas, spleen and lung by 
mechanically  separating  with  scissors  before  passing  through  a  40μm  filter  into  DMEM 
supplemented with 2% fetal bovine serum (Omega Scientific).  Bloody samples were treated 
with ACK Lysing Buffer (Lonza) for 5min on ice.  Cells were Fc blocked (2G42, prepared in-
laboratory) before surface or intracellular stains were performed using mAbs against CD3 (145-
2C11 and 17A2, BioLegend), CD19 (6D5, BioLegend) and NKp46 (29A1.4, BioLegend). Flow 
cytometry was performed using an LSRII (BD), and data were analyzed using FlowJo (Tree 
Star) software. Fluorescent-coupled mAbs from Biolegend or Ebiosciences were used to identify 
Ly49 receptors (Ly49H clone 3D10; Ly49A clone YE1/48.10.6; Ly49E clone CM4; Ly49A-B6 
clone A1; Ly49A/D clone ebio12A8; Ly49G clone AT8; Ly49I clone YLI90; LY49D clone 4E5; 
Ly49G2W clone ebio4D11; Ly49CFHI clone 14B11). 38 
 
 
RNASeq  
Cells were double-sorted to high purity (>99%) on a Moflo Cell Sorter (Beckman 
Coulter) directly into Trizol (Invitrogen).  RNA was prepared as described by the Immunological 
Genome Project (www.immgen.org). Barcoded sequencing libraries were prepared using the 
Illumina TruSeq RNA Preparation v2 Low Sample protocol (Rev. D). Quality control for library 
read size was performed on the 2100 Bioanalyzer (Agilent Technologies) before normalizing and 
pooling. Sequencing was run on the Illumina HiSeq2500 with 100bp single-reads. The 
Makrigiannis lab (A Makrigiannis, S. Anderson) provided annotation of the idd6  region as 
described in (Belanger et al., 2008), which was used as a scaffold to align sequencing using 
TopHat (Trapnell et al., 2009). Aligned sequencing data were visualized using IGV Genome 
Browser (https://www.broadinstitute.org/igv/home). HTSeq-count was used for counting reads. 
Strict criteria were used for aligning and counting –  no basepair  mismatches and only 1 
alignment per read. Normalization was performed using the DESeq package in bioconductor. 
Normalized data were visualized and analyzed using Microsoft Excel. 
 
Organ and Cell Preparation for CyTOF 
Postmortem intracardial perfusion was performed with 30ml PBS.  Following surgical 
removal of organs, cells were isolated from the pancreas and spleen by mechanical separation 
with scissors. The pancreas was bathed in a shaking water bath at 37°C in digestion buffer (1 
mg/ml collagenase IV [Sigma-Aldrich], 10 U/ml DNaseI [Sigma-Aldrich], and 1% [Thermo 
Fischer Scientific] in DMEM [Invitrogen]) before passing through a  40μm  filter  into  Cell 
Staining Buffer [CSB] (500mL Ca
2+Mg
2+-free PBS [Gibco], 2.5g (0.5%) BSA, 100mg (.02%) 39 
 
Sodium Azide).  Bloody samples were treated with ACK Lysing Buffer (Lonza) for 5min on ice.  
Cells were Fc blocked (2G42, prepared in-laboratory) before staining 1-2million cells in 1uM 
103Rh viability dye intercalator (DVS Sciences) in CSB for 15min at 37°C. Cells were washed 
and then stained with surface metal-coupled monoclonal antibodies (provided by the Harvard 
Medical School CyTOF Consortium and Antibody Core: Joshua Keegan and Jim Lederer) in 
CSB for 30min at room temperature. Cells were then washed twice in CSB before diluted into 
fixation and permeabilization buffer (1.6% formaldehyde and 0.3% saponin in Ca
2+Mg
2+-free 
PBS) for 10min at room temperature. The cells were then washed in permeabilization buffer 
(0.3% saponin in CSB) before staining with intracellular metal-coupled antibodies for 30min at 
room temperature. Stained cells were washed twice in permeabilization buffer with the final 
dilution into fixation and permeabilization buffer overnight with DNA Intercalator (DVS 
Sciences). The samples were then washed three times in MilliQ water before dilution with 
EQTM four element calibration beads (DVS Sciences) and run on the CyTOF machine at the 
Dana Farber Cancer Institute Flow Cytometry Core. 
 
CyTOF Data Analysis  
.FCS files were generated for each sample during data acquisition on the CyTOF machine 
which were analyzed using Cytobank as previously described (Kotecha et al., 2010).  
Hierarchical, high-throughput, multi-dimensional analysis was performed using Spanning-tree 
Progression Analysis of Denisty-Normalized Events (SPADE) and visualized in Cytobank as 
previously described (Qiu et al., 2011). For SPADE analysis, settings included: 500 maximum 
nodes, 5% down-sampling with 3 biological replicates clustered in the same tree. 
 40 
 
Statistical analyses  
Data are presented as means ± S.D. Significance was assessed by the Student's t-test or 
Mann Whitney test using Prism 5 (GraphPad Software). A P value of <0.05 was deemed 
statistically significant.  
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3.3 Results 
 
  3.3.1 Identifying Ly49 receptor expression on splenic and pancreatic NK cells 
 
  The genomic region containing the Ly49 receptor family was recently sequenced in NOD 
mice.  However, whether or not NOD-derived NK cells express these receptors was less clear.  
To better understand the protein-level Ly49 receptor profile of NK cells from BDC2.5/NOD 
mice, we assessed splenocytes using a full set of monoclonal antibodies to the Ly49 receptors 
(Figure 3.1).  In brief, 8 of 9 Ly49 receptor antibodies from this panel had a clear positive signal 
on NK cells, with little to no background signal in non-NK cells.  Ly49I (clone YLI90), reactive 
in B6 animals, had no signal in either population. Ly49A and D antibodies stained the majority 
of NK cells.  Meanwhile, Ly49H antibodies identified about half of NK cells and the Ly49G2/W, 
A/P and E/F antibodies identified minority fractions of NK cells. 
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Figure 3.1: Ly49 Receptor Antibodies Identify Splenic  NK Cells from NOD Mice.  
Representative  overlayed  Ly49 receptor monoclonal antibody flow cytometry plots for 
splenocytes from BDC2.5/NOD mice. Ly49 receptor antibodies and clones are listed below each 
plot. Blue histograms indicate CD3
-NKp46
+ NK cells. Red histograms indicate NKp46- cells. 
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  A smaller set of Ly49 receptor antibodies (in the same staining panel as allowable by 
fluorescent signal overlap and compensation) was used to assess the expression of Ly49 on 
pancreatic NK cells (Figure 3.2A). As was the case for spleen, non-NK cells expressed very little 
or no Ly49 receptor antibody signal.  In contrast, pancreatic NK cells readily stained with all 3 
Ly49 receptors  examined.  Similar to what was seen in the  splenic NK cells, anti-Ly49D 
recognized the largest fraction of NK cells, followed by Ly49H, then Ly49G2W. 
  Due to the variegated expression pattern of Ly49 receptors, the combined expression of 
Ly49 receptors on pancreatic NK cells was assessed with the  smaller panel.  All possible 
combinations of Ly49 receptors (2
3=8) were represented in the pancreas, to varying degrees 
(Figure 3.2B). Surprisingly, the largest fraction (representing about half of all pancreatic NK 
cells) was a Ly49-triple-negative population. Whether or not this population is similar to the 
hyporesponsive, non-Ly49-expressing population in B6 animals remains unclear. Pancreatic NK 
cells were described as hyporesponsive in one study (Brauner et al., 2010) and the lack of Ly49 
expression might indicate an “uneducated” or “disarmed” NK cell phenotype.  
Notably,  all 4 combinations of Ly49D+ NK cells  were the next 4 most represented 
populations following the triple-negative population. 
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Figure 3.2: Variegated Expression Pattern of Ly49 Receptors on Pancreatic NK Cells.   
(A) (Left) Representative overlayed flow cytometry plots for pancreatic infiltrate from non-NK 
cells (NKp46-,  red histogram) and NK cells (CD19
-CD3
-NKp46
+,  blue histogram). (Right) 
Summary data for individual Ly49 receptor expression from 4 replicates of 2 independent 
experiments. (B) The same data as in A, separated into the 8 combinatorial expression patterns of 
3 different Ly49 receptors. Ranked in order from left to right of most expressed to least 
expressed. Mean ± SD presented for summary data. 
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3.3.2 Comprehensive, unbiased, and tissue-specific Ly49 receptor profiling 
 
Monoclonal antibody profiling of the Ly49 receptor expression on NK cells ultimately 
had three major issues.  First, many of the Ly49 receptors do not have antibodies available to 
identify them.  Second, the antibodies that are available are highly cross-reactive. Finally, almost 
no validation of accurate Ly49-reactivity has been performed in the NOD mouse.  Due to these 
issues, a more thorough and strain-specific analysis tool for Ly49 receptor identification is 
desirable. 
RNAseq-based gene expression profiling was utilized as an unbiased and comprehensive 
approach. For the organ-  and  strain-specific analysis, the sequenced and annotated Ly49-
receptor-containing region of NOD mice (idd6) was used to map reads.  A first-pass 
visualization of the mapped reads showed no obvious exon-level differences in gene expression 
between organs (Ly49D shown for example in Figure 3.3), arguing against pre-translational 
modification of RNA species for these genes (including differential-splicing events).  Of note, 
the “densest” read-pileups were consistently centered at exons but some intronic mapping was 
evident. Whether or not there is a functional consequence to intronic RNA expression at the 
Ly49 receptor loci remains unclear, but it could indicate higher levels of splicing for genes with 
more reads mapped to the intronic region. 
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Figure 3.3: Visualization of the NOD-Mapped Ly49 Receptor Aligned Reads. 
Representative Ly49 receptor transcript reads for Ly49D using IGV Genome Browser. For each 
row, the grey histogram indicates a summation of total mapped reads to that genomic region (for 
each organ listed on the left). Bottom: Blue horizontal line indicates the full genomic region for 
Ly49D with thick blue boxes indicating exons. 
 
 
The sequenced genomic region, idd6, contains all but one known NOD Ly49 family 
member, Ly49W, which Belanger and colleagues predicted to be in a gap between Ly49M and 
Ly49P1, outside the sequenced region (Belanger et al., 2008).  Therefore, the mapped library 
represented a near-comprehensive analysis of the transcribed repertoire of Ly49 receptors. All 20 
of the Ly49 genes contained showed some level of expression, ranging from 39 (Ly49A, spleen) 
to 6859 aligned RNA reads (Ly49P3, pancreas) (Table 3.1).  Notably, there was a range of 
expression between different Ly49 family members but predicted activating genes, in general, 
showed  higher expression compared with  inhibitory genes, which in turn showed  higher 
expression than pseudo-genes (briefly summarized in Table 3.2). 
 
Spleen
Pancreas
Lung
Ly49D47 
 
Table 3.1: Organ-Specific Transcriptional Repertoire of the Ly49 Receptors  
Left: Full list of Ly49 receptors as predicted by sequence.  The color of highlight for each gene 
indicates activating (green), inhibitory (blue) or pseudogene (grey) as predicted by the genomic 
sequence. Middle: Total counts for the normalized aligned reads for each gene in each organ. 
Right: fold-change calculations to indicate where genes changed between organs. Fold-changes 
were then highlighted using conditional formatting (from (blue) low to equal (white) to high 
(red) based on numerical percentile). 
Receptor 
Spleen 
Aligned 
Reads 
Lung 
Aligned 
Reads 
Pancreas 
Aligned 
Reads 
Pancreas 
vs. 
Spleen 
Lung 
vs. 
Spleen 
Pancreas 
vs.  
Lung 
Ly49a  39  89  101  2.58  2.28  1.13 
Ly49e  299  409  537  1.80  1.37  1.31 
Ly49p2  1580  1534  2162  1.37  0.97  1.41 
Ly49x  61  47  81  1.32  0.76  1.74 
Ly49p3  5994  6180  6859  1.14  1.03  1.11 
Ly49i1  470  742  528  1.12  1.58  0.71 
Ly49p1  4962  4925  5540  1.12  0.99  1.12 
Ly49q  77  102  84  1.09  1.32  0.83 
Ly49g2  1072  965  1171  1.09  0.90  1.21 
Ly49u  1151  1135  1256  1.09  0.99  1.11 
Ly49c  190  302  199  1.05  1.59  0.66 
Ly49d  3243  4038  3248  1.00  1.25  0.80 
Ly49g1  139  136  139  1.00  0.98  1.02 
Ly49m  2397  1840  2331  0.97  0.77  1.27 
Ly49i3  538  537  488  0.91  1.00  0.91 
Ly49i2  216  252  185  0.85  1.17  0.73 
Ly49h  2368  2347  1930  0.81  0.99  0.82 
Ly49f  142  120  106  0.74  0.85  0.88 
Ly49pd2  384  244  202  0.53  0.63  0.83 
Ly49pd1  394  232  174  0.44  0.59  0.75 
 
Table 3.2: Summary Statistics for Table 3.1 
   Pseudo  Activating  Inhibitory 
Number of Genes  8  6  6 
Minimum Counts  47  1135  39 
Maximum Counts  2162  6859  1171 
Average Counts  420.54  3430.22  409.78 
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The differences  in Ly49 receptor expression between the pancreas (disease-relevant 
organ), spleen (systemic control) and lung (irrelevant organ control) were assessed using a fold-
change calculation. Overall, there were relatively few differences between organs. Only 4 of 20 
genes (encoding  Ly49A, E, P2 and X) were >20% increased and a different set of 4 genes 
(encoding Ly49H, F, PD2 and PD1) were ~20% decreased. Of the 4 increased genes, only those 
encoding Ly49A (2.58-fold increase) and Ly49E (1.8-fold increase) produced proteins. Of the 4 
decreased genes, only that encoding Ly49H (0.81x) produced a protein. Expression of Ly49A, 
and Ly49E to a smaller extent, were similar between the pancreas and the lung – potentially 
indicating their overrepresentation as a function of their “tissue”  location.  Ly49H, to the 
contrary, was also slightly underrepresented in the pancreas compared with the lung – indicating 
that this Ly49 was distinctly down in the pancreas compared with both spleen and lung. 
  With transcriptional evidence in hand as support, the protein-level expression of Ly49 
receptors was carefully  assessed using flow cytometry (Figure 3.4A).  No change in the 
frequency of Ly49A+ cells was apparent, disagreeing with the over-representation  in  the 
RNAseq analysis. However, it was unclear if increases in Ly49 receptor transcription would be 
apparent at the level of cellular frequency rather than a change to mean fluorescence intensity 
(MFI) on a per-cell basis. Therefore, the relative MFI fold-change of pancreas compared to 
spleen was calculated for samples in which the pancreas and spleen were run on the same day in 
the same fluorescent compensation file (Figure 3.4B). Still, no clear change in MFI was apparent 
when comparing the pancreas versus the spleen for Ly49A. Ly49E, on the other hand, had a mild 
increase in frequency supporting the over-representation in the RNAseq analysis.  However, no 
difference was apparent for Ly49E when comparing MFI between pancreas vs. spleen. A slight 
(~20%) underrepresentation of NK cells expressing Ly49H was apparent between pancreas and 49 
 
spleen, as predicted by the RNASeq analysis. However, similar to Ly49E and A, no change in 
the MFI was clear (and if anything, trended in the direction of pancreas-enrichment). 
Collectively, the protein-level expression pattern matched the predictions by RNAseq for 
an over-representation of Ly49E and under-representation of Ly49H  (but not for Ly49A). 
However, the changes were rather subtle, including a shift in the Ly49E+ population from 4.66% 
± 0.16 (spleen) to 8.23± 0.59 (pancreas) and a shift in the Ly49H+ population from 52.07% ± 
6.43 (spleen) to 45.47% ± 5.35 (pancreas).  Whether or not these minute differences yield some 
functional change in NK cell reactivity or the pathogenicity of the NOD idd6 locus remains 
unclear. 
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Figure 3.4: Organ-Specific Expression of the Ly49A, E and H Receptors  
(A) Left: representative flow cytometry plots with negative control CD19+ B cells (red) used for 
gating,  CD3
-NKp46
+  NK cells (shown in blue:  spleen,  and green:  pancreas)  indicate  Ly49 
expression.  Right:  summary statistics for the frequency of Ly49-expressing  populations.  (B) 
Summary statistics for the fold-change of pancreatic versus splenic MFI of Ly49 receptor 
expression. Pancreas-to-spleen comparisons were only calculated for samples run on the same 
flow cytometry compensation file on the same day. Fold-change=1 is indicated with a horizontal 
black line (implies no difference in MFI between organs). Vertical arrow on the right indicates 
the potential organ-centric gradient from pancreas (green) to spleen (blue).  Mean ± S.D. of at 
least 2 independent experiments.   
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3.3.3 Profiling pancreatic NK cell heterogeneity using CyTOF 
 
  NK cells also express a range of non-Ly49 receptors that collectively differentiate their 
state of maturity, activation and functional capacity.  However, very little effort has been placed 
on characterizing NK cell diversity at the single-cell level with a high dimensionality approach, 
especially in the pancreas. To study cell changes during insulitis, we developed two antibody 
panels for use with the CyTOF (Table 3.3). One panel focused on cells, markers and receptors 
typically found on lymphoid cells (“L” panel – 2
31 possible combinations of markers) while the 
second focused on myeloid cells, granulocytes and a marker of degranulation (“MGD” panel - 
2
22 possible combinations of markers). 
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Table 3.3: List of Antibodies, Clones and Metal-Couplings for L and MGD Panels 
Lymphoid  - L - Panel   
Myeloid Granulocyte 
Degranulation - MGD - Panel 
 Target       Clone  Metal     Target       Clone  Metal 
CD44   IM7   141Pr     CRIg   17C9  143Nd  
IgM   RMM-1   142Nd     CD4  GK1.5   145Nd  
CD21   7E9  143Nd     CD11c  N418   146Nd  
CD5   53-7.3   144Nd     PDCA-1   927  148Nd  
CD4   GK1.5   145Nd     CD19   6D5  149Sm  
CD62L   MEL-14   146Nd     CD11b   MAC1  150Nd  
CD138   281-2   147Sm     Ly6C   HK1.4  151Eu  
CD127   A7R34   148Nd     CD3e   145-2C11   152Sm  
CD19   6D5   149Sm     CD335  298A1.4  153Eu  
TCRb   H57-597   150Nd     CD103  2E7  154Sm  
CD27   LG.3A10   151Eu     Ly6G  1A8  158Gd  
CD3e   145-2C11   152Sm     NKp46   A2F10  162Dy  
NKp46   298A1.4   153Eu     CD8  53-6.7  164Dy  
CD103   2E7  154Sm     CD45  30-F11  165Ho  
CD69   H1.2F3   156Gd     CD86  GL-1  166Er  
Tbet   4B10   158Gd     CD107a  1D4B  167Er  
CD23   B3B4   159Tb     FcεR1a  41334  169Tm  
Sca-1   D7   160Gd     CD80  16-10A   170Er  
Foxp3   FJK-16s   162Dy     CD49b  Dx5  171Yb  
CD8a   53-6.7   164Dy     Ag7  g7  174Yb  
CD45    30-F11   165Ho     F4/80  BM8  175Lu  
GATA3   TWAJ   166Er     CCR7  4B12  176Yb  
CD25   3C7   167Er          
c-kit   ACK2   168Er          
Thy1   G7   169Tm          
RORγT  AFKJS-9   170Er          
PD-1   29F.1A12   171Yb          
TCRgd   GL3   172Yb          
Ag7   g7  174Yb          
IgD   11-26c.2a   175Lu          
CCR7   4B12   176Yb          
 
Spanning-tree progression analysis of density-normalized events (SPADE) was utilized 
to cluster pancreatic infiltrate from 18wk prediabetic female NOD mice into 445 (L panel) and 
381  (MGD panel) populations  of similar-marker expression  (Figure 3.5).  In a SPADE tree, 53 
 
groups of cells are visualized in an inter-connected fashion based on their relative similarity to 
one another.  The overall  shape of the tree is irrelevant;  rather the connectivity of  these 
populations, also called nodes, indicates similarity between groups of cells.  NK cells (defined by 
NKp46 expression) represented 4.2% of total cells, in line with previously reported frequencies 
for NOD mice of this age.  NKp46-containing nodes included  33 out of 445 total nodes 
(representing 7.4% of total pancreatic diversity) for the L panel analysis. In the MGD panel 
analysis, NK cells were 4.6% of cells and 25/385 nodes (equating to 6.5% of diversity). The 
most over-represented NK cell phenotype accounted for only 12.6% of NK cells in the L panel 
analysis and 21% of the MGD panel analysis. 
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Figure 3.5: SPADE Analysis Reveals High-Dimensional Diversity for Pancreatic NK Cells. 
Representative SPADE trees of NKp46 expression in pancreatic infiltrate. Left: L panel. Right: 
MGD panel.  Node color represents signal intensity (NKp46 in this figure) while the size of the 
node represents frequency  (ranging from 1-229 cells  for L panel and 1-255 cells for MGD 
panel). The black bubble labeled “NKp46” identifies the group of nodes most consistently and 
highly expressing NKp46.  
  
 
  In order to assess the underlying expression patterns driving the heterogeneity between 
nodes, the signal intensity for each antibody co-expressed  in NKp46-containing nodes was 
visualized separately (Figure 3.6A and B for the L panel and 3.6C and D for the MGD panel). 
NKp46-containing nodes in the L panel co-expressed a wide variety of markers including CD44, 
CD62L, CD127, CD27, CCR7, PD1, CD69, Tbet, CD25 and RORγT (Figure 3.6A).  Marker 
signal intensities presented in two general patterns.  Tbet, CD44 and CD27, for example, were 
widely expressed at consistent levels.  CD62L, CD127, PD1, CD69, CD25 and RORγT were 
L Panel MGD Panel55 
 
more punctuate (highly expressed in some nodes but not expressed in others).  Markers were not 
shown if they were not expressed or if the antibody failed. 
  Highlighting T cell-identifying markers such as TCRγδ and TCRαβ revealed that some of 
the  NKp46-containing  nodes  also  contained T cell  populations  due  either  to phenotypic 
similarity (and limitations in the clustering methodology) or to expression of NKp46 on T cells 
(Figure 3.6B) that was previously reported on rare populations of T cells (Narni-Mancinelli et 
al., 2011).   γδT cells, which are known to be phenotypically (and functionally) similar to NK 
cells, were the most prevalent in the NKp46-expressing collection of nodes (in terms of γδTCR 
signal).  T cell marker-containing nodes tended to have lower NKp46 signal, supporting a mix of 
NK cells with contaminating non-NK cells, or lower NKp46-expressing T cells in these nodes.  
Curiously, CD4 and CD8 were not expressed above background signal levels in either panel on 
NKp46+ cells (unpublished observation), supporting representation  from  γδT  cells  and/or 
rare/controversial αβT cells lacking CD4 and CD8 (D'Acquisto and Crompton, 2011) in these 
nodes.  Importantly, this overlap would skew the diversity representation, as those nodes might 
contain receptors expressed either partially or fully from T cells rather than NK cells.  Therefore, 
this SPADE clustering analysis may have produced an overestimate for the diversity of markers 
expressed by NK cells, or cannot differentiate rare NKp46-expressing T cells from bona fide NK 
cells. 
NKp46-containing nodes in the MGD panel contained 3 types of expression patterns 
(Figure 3.6C).  CD11b, for example, was widespread at low levels in all nodes.  CD49b was 
expressed highly in a large fraction of NKp46-containing nodes. Ly6C, CD103 and CD107α had 
a more punctate expression pattern. As was the case for the L panel, highlighting the T cell 56 
 
receptor molecule CD3 revealed a contaminating T cell population in the NKp46-expressing 
nodes – also indicating a potential overestimation on NK cell diversity (Figure 3.6D). 
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Figure 3.6: Individual Receptor Diversity for Pancreatic NK Cells.  Representative NKp46- 
containing groups of nodes from the L panel (A and B) and MGD panel (C and D). Node color 
represents signal intensity (for each indicated marker above the group of nodes) while the size of 
the node represents relative  population  frequency.  The images, including the black bubble 
surrounding the NKp46-expressing population, is the same as presented in Figure 3.5. 
   
CD44 CD62L
CD127 CD27
CD69 TBET
CD45 CD25 RORγT
PD1
CCR7
NKp46
A
TCRγδ TCRαβ B
NKp46 CD11b
CD49b CD107α
CD3
CD103
Ly6C
C
D58 
 
3.4 Discussion 
 
  Despite early claims to the contrary, NK cells are no longer considered a homogenous 
lineage (Lanier, 2014; Sojka et al., 2014b).  Rather, subsets of NK cells are found in a wide 
variety of organs, depend on a wide variety of cytokines and transcription factors and express a 
wide variety of functional molecules.  Here, we explored the heterogeneity of NK cells in NOD 
mice, specifically in the  pre-diabetic pancreas. We uncovered an array  of Ly49 receptors 
expressed by splenic and pancreatic NK cells in these mice.  We also showed that pancreatic NK 
cells have a subtle difference in surface phenotype compared with NK cells from the spleen.  
Finally, we discovered a greater resolution of heterogeneity in pancreatic NK cells than had ever 
been previously described. 
  Most of the monoclonal antibodies used to identify Ly49 receptors in other strains also 
identified Ly49 receptors in the NOD strain. These positive signals came from antibodies 
specific for Ly49A/D, AP, A, D, C/F/H/I, H, G2W and EF but not Ly49I in a binary expression 
analysis. By combining some of these antibodies into a single panel, the combinatorial 
expression pattern of Ly49 receptors was confirmed for NOD mice, especially in the pancreas 
where all 8 combinations of Ly49D, H and G2W were confirmed, to varying degrees. 
Interestingly, the largest fraction of NK cells was a triple negative population for all 3 Ly49 
receptors, but it was unclear if this specific subset expressed any other Ly49 receptor. Given that 
Ly49A often stained up to 80% of NK cells, much of this ~50% triple-negative population 
logically had to have expressed at least some Ly49A.  However, Ly49A was never included in 
the same antibody panel as Ly49H and Ly49D, the other predominantly expressed Ly49 
receptors. Future high dimensionality analysis of these receptors will make it more feasible to 59 
 
test the full combinatorial expression of Ly49 receptors on NK cells and whether or not a Ly49 
receptor negative NK cell subset exists in NOD mice as it does in B6 mice. 
The diverse array of Ly49 receptors on NK cells mediates NK cell responsiveness and 
tolerance.  However, Ly49 receptor transcription had never been profiled comprehensively in a 
comparison between organs of disease relevance. Here, we report the transcriptional repertoire of 
Ly49 receptors in BDC2.5/NOD mice  for pancreas, lung and spleen. Intriguingly,  all Ly49 
receptors were expressed, to some degree, in all organs, with no major exon-level differences 
between organs.  This expression pattern represented a dramatic increase in the number of Ly49 
receptors  previously known to be expressed in NOD mice (especially in the pancreas).  We 
confirmed a subtle difference in surface phenotype on pancreatic NK cells, compared with NK 
cells from the spleen, for Ly49E and Ly49H. However, the degree of change between organs was 
quantitatively small or on a very small fraction of NK cells. It remains unclear whether or not 
these minute differences could explain a functional role for idd6 in the pathogenesis of T1D. 
Previous work indicated that Ly49Q was uniquely expressed by DCs (especially pDCs), 
macrophages and neutrophils rather than by NK cells in diverse strains, including NOD mice 
(Belanger et al., 2008; Rahim et al., 2014).  Here we report quantitatively  low levels of 
transcripts mapping to the Ly49Q gene in all three organs.  These transcripts could indicate that 
the expression of Ly49Q is controlled post-transcriptionaly or that true protein-level expression 
exists below the detection level of existing monoclonal antibodies. 
A confounding factor for the interpretation of our data is the population-level strategy 
employed,  given the documented stochastic expression of certain Ly49 receptors (Held and 
Kunz, 1998). Shalek and colleagues recently demonstrated vast differences in the heterogeneity 
of certain immune cells when analyzed at a population level compared with single-cell resolution 60 
 
(Shalek et al., 2013).  In their study, LPS-stimulated,  bone-marrow-derived DCs (BMDCs) 
showed heterogenous expression of functional genes such as cxcl10, cxcl1 and il6 when analyzed 
at the single-cell level compared with no identifiable heterogeneity when the same set of cells 
was analyzed in a pool of 10,000 cells.  In many ways, their single-cell data for the 10,000-cell 
pooled condition genes are reminiscent of our population-level expression repertoire. In both 
cases, the shape of the histograms surrounding exons showed some small variations, but no 
major exon-level differences were apparent.  Given their findings, and the well-documented 
variegated expression pattern of the Ly49 receptors, single-cell RNAseq analysis of NK cells in 
different tissues might be a particularly useful strategy, for two reasons.  The first benefit would 
be to define true single-cell transcriptional identity.  The second benefit would be to correlate 
specific Ly49 receptors (representative of specific NK cell “arming” or “licensing”) to other 
genes and transcriptional programs indicative of NK cell function (such as IFN-γ or markers of 
maturity). This type of analysis could create a vastly different picture as to how certain Ly49s 
regulate NK cell functions in a given tissue. 
The underrepresentation of activating Ly49H was notable because the B6 form of Ly49H 
does not bind to MHC class I.  Rather, Ly49H was shown to play a role in the recognition and 
clearance of viral proteins, specifically m157, and virally infected cells (Brown et al., 2001). 
Despite possessing a Ly49H gene, NOD mice were susceptible to MCMV infection unlike their 
B6 counterparts, presumably because the Ly49H
NOD allele was incapable of binding viral protein 
m157 (Orr et al., 2010). Whether or not Ly49H engaged a ligand in the pancreas, and why that 
potential interaction decreased Ly49H expression, or limited the frequency of Ly49H+ NK cells 
remains unclear. Engagement of Ly49H normally causes NK cell activation and degranulation, 
so the decreased representation of Ly49H may be a tolerogenic mechanism. If decreased Ly49H 61 
 
causes hyporesponsiveness, it might potentially help explain some of the hyporesponsiveness 
that was previously described for pancreatic NK cells by Brauner and colleagues (Brauner et al., 
2010). 
Ly49E is a notable inhibitory receptor due to its unique expression on fetal NK cells, 
earlier than other Ly49 receptors (Fraser et al., 2002), as well as its expression on epithelial T 
cells, and NKT cells, but supposedly not on resting adult NK cells (Aust et al., 2011). An 
exception to this observation is the cytokine-induced expression of Ly49E on mature NK cells 
(including cytokines such as IL-2 and Il-15) (Gays et al., 2005). Because of these seemingly 
contradictory findings, the  reported increase of  Ly49E  might indicate  either an increased 
representation of immature NK cells (from the fetal stage) or cytokine-activated mature NK 
cells. Both scenarios could have functional implications for pancreatic NK cells, but the latter 
scenario  seems  more likely given the inflammatory environment in the pancreas and the 
activated transcriptional phenotype of pancreatic NK cells compared with spleen (unpublished 
observations). 
Two alternative,  but non-obvious,  hypotheses can be generated regarding the 
pathogenicity of the NOD idd6 region, both of which may not involve NK cells.  The first 
possibility is  the expression of the  Ly49  receptors in non-NK cells,  which tends to be an 
overlooked feature of this family. Second, the idd6 region also contains the Nkrp1 family of 
genes as well as cd69, cd94, Rmp1, Chok  and a set of resistance genes against the 
cytomegalovirus family collectively denoted cmv (Carnaud et al., 2001). 
In regards to non-NK and non-conventional NK cells expressing Ly49 receptors: uterine 
NK cells, NKT cells, γδT cells, neutrophils, DCs, and macrophages have all been described as 
expressing some of the Ly49 receptors under certain conditions – each with some functional 62 
 
consequences.  These functions have included pathogen recognition, toll-like receptor (TLR)-
signaling, IFN-production, tissue invasion, cell survival and proliferation, as described by Rahim 
and colleagues  (Rahim et al., 2014).  Many of these cell types have potential roles in the 
diabetogenic process. However, nearly all of this work was done in B6 animals and it remains to 
be seen how much is similarly true for NOD mice.  The notable exception to this knowledge-gap 
is Ly49Q, which has confirmed expression on pDCs in NOD mice, as previously discussed. 
High dimensionality analysis by the CyTOF platform was recently used to uncover 
significantly more heterogeneity in human NK cells than had ever previously been described. 
Here, we utilized the same technology to assess the heterogeneity of pancreatic NK cells with 
lymphoid-  and myeloid-“flavored” panels  of antibodies. Metal-coupled antibodies readily 
detected NKp46-expressing  cells in the pancreas and high-dimensional clustering analysis 
segregated those NKp46-expressing cells into 33 and 25 unique nodes from the L and MGD 
panel analyses, respectively. To our knowledge, these figures represent the largest degree of 
phenotypic  heterogeneity ever described for murine NK cells  (excluding studies assessing 
variegated Ly49 expression). Many of these nodes represented a mature and activated phenotype 
for NK cells, including expression of CD44, CD69, CD27, CCR7, CD25 and CD11b.  Some of 
these receptors were previously reported on pancreatic NK cells by Brauner and colleagues 
(Brauner et al., 2010), but not in a high-dimensional analysis. Agreeing with our findings, they 
also reported pancreatic NK cells that expressed low levels of CD127, CD62L and PD1.  
The clustering analysis reported here (listing  NK cells as between 6.5-7.4% of total 
pancreatic node diversity) must be an over-representation given the co-clustering of T cell 
markers, specifically γδT cells. While limiting the accurate analysis of NK cell diversity, our 
data support γδT cells, another innate-like lymphocyte, as the most phenotypically similar cell 63 
 
type to NK cells, given the markers assessed.  It is also possible that some γδT cells express 
NKp46, but the relatively low resolution of any individual marker stained with metal-coupled 
antibodies does not make it particularly suitable to make this determination as compared to 
conventional flow cytometry (unpublished observations). 
Notably, some rare NKp46-containing nodes also had RORγT expression, consistent with 
an innate lymphoid type 3 (ILC3) cell.  However, many of those nodes also expressed γδTCR, 
implicating γδT cells as a potential source for RORγT, as has been previously described (Martin 
et al., 2009). 
Although we discovered less diversity in murine NK cells than was recently reported for 
humans – we can explain the differences from a number of perspectives.  First, the human study 
utilized a much larger pool of cells. Second, their cells came from the spleen and were purified 
from other immune cells as opposed to the “whole-organ” approach that we employed. Third, the 
human study incorporated a larger number of test subjects.  Fourth, most of their subjects were 
genetically diverse, but  even the identical twin  analysis  would imply unique  environmental 
influences differentiating genetically identical subjects. In our study, we analyzed a genetically 
identical and environmentally similar set of mice. Finally, their panels were solely dedicated to 
NK cell markers whereas ours contained markers dedicated to identifying the entire immune 
system. Therefore, the studies were too different to make any strong claims about the relative 
diversity between murine and human NK cells. 
  Ultimately, our data support the new model for NK cell heterogeneity.  NK cells express 
a wide variety of Ly49 and non-Ly49 receptors and activation markers. In the future, it will be 
crucial to develop a more thorough understanding of murine NK cell diversity and the biological 
cues that inform it, as well as to determine if this phenotypic diversity is also diverse in function.   64 
 
Chapter 4: Perspectives on the Biology and Future Research of Treg and NK cells 
 
 
4.1 Perspectives on emerging NK cell biology 
 
  Our understanding of the immune system has gone through a revolution over the last few 
decades-  especially in our understanding of the biology of  NK cells. In 1989, a review 
summarized that NK cells lysed other cells but lacked any form of MHC-restriction, adaptive 
function or clonal expansion.  The authors also concluded that NK cells were not assigned to a 
formal lineage and had no documented anatomical residency outside of the blood (Trinchieri, 
1989). After 25 years of research,  we now appreciate that most of those statements  were 
incorrect or incomplete.  For example, NK cells recognize MHC class I molecules, have 
functional memory, can  expand clonally, are of  lymphocyte lineage and reside in many 
anatomical locations outside of the blood.  Furthermore, emerging research  has  implicated 
functional roles for NK cells during pregnancy, hematopoietic/organ  transplant  rejection, 
parasitic infection, autoimmunity, HIV infection and asthmatic diseases (Vivier et al., 2008).  
Finally, we now also appreciate that NK cells are a part of a set of innate lymphoid-like cells, 
many of which impact immune and non-immune physiology in diverse fashions.  
In this dissertation, we provided evidence to support many of these emerging concepts in 
NK cell biology.  First, we  discovered  how NK cells cross-talk with the adaptive immune 
compartment and uncovered the conditions permissive to drive NK cell-amplified autoimmunity. 
From this finding we conclude that IL-2 acts as a bridge between innate and adaptive immunity. 
Our model implies a more complex network of immune cell cross-talk, responsible for T1D 65 
 
prevention, than had previously been appreciated.  These data add to the developing idea that 
adaptive immunity instructs innate immunity  during autoimmune disease settings  (Ji et al., 
2002).  
Second, we comprehensively profiled the Ly49 receptor family in multiple organs and 
demonstrated  new Ly49 receptors expressed in  NOD mice.  This study  revealed a subtle 
difference in the expression of Ly49 receptors on pancreatic NK cells compared to spleen. 
Finally, we demonstrated significant heterogeneity for organ-infiltrating NK cells using high 
dimensional cytometry profiling. Our second set of studies supported the notion that NK cell 
phenotypes are dependent upon their local environment and that tissue-infiltrating murine NK 
cells are more diverse than was previously understood. 
 
 
4.2 Adaptive features of NK cells and the parallels shared between infection and autoimmunity 
 
  The assignment of NK cells to the innate immune system, many decades ago, recently 
came under fire  following multiple lines of evidence that NK cells actually share many 
“adaptive” features of their B and T lymphocyte counterparts. The “innateness” of NK cells is as 
true today as it was decades ago when they were first coined “natural” killer cells given their 
propensity to spontaneously kill target cells without preconditioning. However, it is now clear 
that NK cells can be long-lived and generate a robust recall response to cytokines (Cooper et al., 
2009), haptens (O'Leary et al., 2006) or viruses (Sun et al., 2009; Paust et al., 2010).  We add to 
this growing list of adaptive features of NK cells with supporting data that NK cells participate in 66 
 
autoimmunity and cross-talk with classical adaptive immune cells. Furthermore, our data implies 
a greater diversity in NK populations, previously underappreciated for “innate-like” cells. 
Given their function and unique phenotype, it is possible that pancreatic NK cells possess 
disease-relevant adaptive memory, but experimental evidence is lacking in this area.  Pancreatic 
NK cells experience local  inflammatory cytokine signaling (which Cooper  and colleagues 
indicated was sufficient to prime a recall response), but also might simultaneously engage β cells 
through  activating receptors  such as NKp46, as previously discussed by Gur et. al.. These 
conditions, especially together, seem ripe for NK cell-driven memory formation. In support of 
this concept, in chapter 2, we  uncovered surprising similarities between the  NK cell 
transcriptional response to Treg cell ablation and the NK cell transcriptional response to viral 
infection.  About 50% of induced and repressed genes were shared between these conditions.  
Thus, although the transcriptional machinery behind NK cell memory is not well understood, 
given the overlapping transcriptional networks, it is possible that the memory machinery is active 
in the case of the loss of Treg cells.  This overlap also implies that NK cells experience the 
inflamed pancreas in a manner similar  to how they experience viral infections, providing 
parallels between autoimmunity and infection. One major difference, however, is that most viral 
infections tend to come in bursts followed by a resolution phase.  Progressive autoimmune 
inflammatory diseases such as T1D present with a long-standing inflammation  (different, 
however, for relapse-remitting diseases such as multiple sclerosis or chronic viral infections). 
Also hinting towards a “memory-like” NK cell phenotype in the pancreas during T1D is the 
observation that CXCR6, reported to be required for memory NK cell persistence in Paust et. al., 
is uniquely expressed in pancreatic NK cells compared with  lung and especially spleen 
(unpublished observations).  Whether or not memory NK cells are formed in the pancreas during 67 
 
T1D and whether or not that (potential) memory is antigen-driven or disease-relevant will need 
to be explored further. 
 
 
4.3 Innate and adaptive immune system crosstalk 
   
A simple model for innate and adaptive immune crosstalk offers that innate immunity 
instructs the adaptive immune response  by providing inflammatory signals following  early 
pattern recognition receptor engagement.  In this commonly  cited  scenario, the cytokines 
produced by innate immunity (acting on antigen presentation machinery) are the bridge between 
innate and adaptive immune responses. In chapter 2, we provide evidence supporting the notion 
that Tconv  and  Treg cells instruct and regulate NK cells functions through the expression and 
sequestration of IL-2, respectively, representing an adaptive control over innate immunity.  In 
turn, NK cells produce diabetogenic IFN-γ,  amplifying  T cell activation  (innate immunity 
impacting adaptive immunity).  This scenario represents a dynamic adaptive-innate inter-
dependence in the pancreas via complex cytokine cross-talk.  As outlined by Kerdiles and 
colleagues, NK cell receptor education (intrinsic) and APC-provided cytokine production 
(extrinsic) were previously characterized as the two primary forms of NK functional control thus 
far (Kerdiles et al., 2013). Our data, in addition to that of Gasteiger and colleagues, supports a 
third arm of NK cell functional control: the antigen-driven local adaptive response producing and 
regulating available IL-2 levels to permit or prevent NK cell responsiveness (Kerdiles et al., 
2013). 68 
 
A number of previous reports  experimentally support this complex inter-dependent 
regulation of innate and adaptive immunity, mediated by IL-2, which  we discovered in the 
pancreas. These reports all described a dependence on Treg cells or Tconv cells for the activation or 
suppression of NK cell functions, as previously discussed throughout this manuscript (including 
NK cell functions in tumors, during bone marrow rejection and during viral infection).  
However, from the other side, innate cell-derived cytokines, such as IL-12 and IL-18 enhanced 
NK cell activation and increased NK cell competitive fitness for IL-2 by increasing NK cell 
expression of CD25 ((Lee et al., 2012), unpublished observations). Therefore, adding to the 
complex regulatory feedback loop discussed in chapter 2, NK and Treg cells also differentially 
impact APCs, and, in turn, the APC-derived IL-12 or IL-18 impacts the NK cell’s ability to 
compete for IL-2. Collectively, Treg cells suppress NK cells, Tconv cells, and APCs; Tconv cells 
activate Treg cells and NK cells; NK cells activate APCs and Tconv cells; and APCs activate Treg 
cells, NK cells, and Tconv cells. 
Surprisingly little is known about the dynamic adaptive-innate inter-dependence 
discussed here and significantly more research will be needed to determine exactly where and 
when this cross-talk is relevant. A less reductionist approach will be necessary in order achieve 
this result, as the common “cell X” impacts “cell Y” by “molecule Z” strategy often utilized in 
immunology research would miss these multi-cell  interdependencies.  New approaches that 
attempt to characterize the changes in the entire immune system under different sets of 
conditions, such as the CyTOF approach discussed in chapter 3, will be important moving 
forward to achieve these goals.  
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4.4 Perspectives on emerging Treg cell biology: context-dependent Treg cell mechanisms  
 
  A decade of research has supported the idea that Treg  cells are critical mediators of 
systemic and organ-specific peripheral immunological tolerance.  The next stage of Treg cell 
research will likely focus on how specific populations of Treg cells mediate tolerance (and other 
immune and non-immune functions) and what mechanisms they use to do so.  The efforts to 
understand how Treg cells protect from T1D, as we explored in chapter 2, serve as an instructive 
example. We showed that  one specific mechanism (IL-2 control via CD25 expression) was 
relevant to disease compared to another (TGF-β). The emerging picture from our study, and 
others, is that Treg  cells, like many other immune cells, are highly context-dependent.  The 
transcriptional programs co-opted by Treg cells are one mechanism to direct specific functions to 
specific environmental cues. However, context-dependency is also an emerging feature of Treg 
cells in non-classical immune contexts such as the adipose tissue (Feuerer et al., 2009a; 
Cipolletta et al., 2011) and muscle (Burzyn et al., 2013).   In the former case, the PPAR-γ 
transcription factor enables Treg  cell control of immune cells in the adipose tissue and the 
regulation of metabolic indices (Cipolletta et al., 2012).  In the latter case, Treg cells distinctly 
expressed amphiregulin that enhanced muscle regeneration.  Efforts like these, and our study of 
T1D, are unraveling the specific context-dependent mechanisms used by Treg cells in various 
organs and disease settings.  However, more effort will be needed to uncover, specifically and 
mechanistically, where and how Treg cells function and why they fail in certain settings. Further 
efforts will also be needed to uncover how else and where else Treg cells might influence NK cell 
functions. 
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4.5 Targeting NK cells for immunotherapy 
 
In chapter 2, we presented a model for CD25-expressing Treg cells as buffers to keep 
tissue IL-2 levels in check. In brief, adding IL-2 to a tissue will preferentially activate Treg cells, 
due to their expression of the high affinity IL-2R. Excess IL-2 will then be dampened due to the 
suppressive functions of Treg cells. However, an extreme excess of IL-2, perhaps at the point of 
CD25 saturation on Treg cells, will be free to impact lower affinity IL-2R-expressing cells such as 
NK and/or T cells, and cause disease (Tang et al., 2008; Sitrin et al., 2013). This scenario might 
be the source of the recent failed clinical trial in new onset T1D patients (Long et al., 2012) and 
why new efforts are being put into place to find the appropriate dosing window for Treg cell-
specific activation (Waldron-Lynch et al., 2014).  The bright side is that failures to treat diseases 
due to over-activation of the immune system might be beneficial for a cancer immunotherapy.  
IL-2 might be especially beneficial given that IL-2 increases both  proliferation and IFN-γ 
production by NK cells, as we show in chapter 2, but also supports the recognition of weaker 
target cells for killing, as explored by Gasteiger and colleagues  (Gasteiger et al., 2013a; 
Gasteiger et al., 2013b).  Notably, chemotherapies induce NK cell ligands (Fine et al., 2010), 
further increasing the chance of a successful immunotherapeutic effect  with a four-pronged 
attack (more NK cells by proliferation, higher inflammation by IFN-γ production, more stress 
ligands for NK cells to target and a better chance of killing relatively weaker targets).  Clinical 
and pre-clinical research efforts are being explored for combination therapies in this area 
(Gutbrodt et al., 2014).  Given these findings, next-generation cancer immunotherapies may 
consider using specific targeted therapies in combination with chemotherapy to enhance tumor 
clearance. The “super-2” reagent, discussed in chapter 2, or similar derivatives that target NK 71 
 
cells preferentially compared  with  Treg  cells, could be the key to future successful 
immunotherapies that avoid off-target effects. While this agent has yet to make it to the clinic, 
structurally optimized antagonists to the IL-1R have been explored for ophthalmic use (Hou et 
al., 2013), offering proof of principle support for “designed”  immune system 
agonists/antagonists. 
 
 
4.6 Diversity of the innate lymphoid cells (ILCs) 
 
  NK cells were recently reclassified into the ILC family. ILCs are defined by three major 
features: the absence of recombination activating gene (RAG)-dependent rearranged antigen 
receptors, a lack of myeloid and dendritic cell phenotypic markers, and a lymphoid origin and 
morphology (Spits et al., 2013). A large of body of work identified numerous novel ILC subsets 
with a range of immune and non-immune functions, many of which were  developmentally 
related as indicated by IL-2R-γ-  and Id2-dependency. ILCs can be subdivided into 3 major 
subfamilies.  NK cells (defined by NKp46-expression, production of IFN-γ and dependency on 
IL-15 and Tbet) are the prototypical  member of the ILC1 subset;  however, a rare and 
controversial  non-NKp46-expressing cell exists  with significant functional and phenotypic 
overlap with classical NK cells (Vonarbourg et al., 2010). The ILC2 family requires IL-7 for 
development (Moro et al., 2010), secretes TH2-associated cytokines such as IL-5, IL-13 and IL-9 
(Wilhelm et al., 2011), and expresses TH2-associated transcription factors (Hoyler et al., 2012).  
Meanwhile, the ILC3 subset expresses TH17-associated cytokines (IL-17A and IL-22) and the 
RORγT transcription factor. One subclass of the ILC3s expresses NKp46 and produces IL-22 at 72 
 
mucoscal surfaces. As reviewed by Spits and colleagues, the collective ILC family expands 
often, with each new subset expressing a new combination of surface receptors.  Altogether, 
ILCs are known to express CD4, CD25, Thy1, cKit, IL-7Rα, Sca1, ICOS, NKp46, IL-1R, IL-
23R, IL-12R, ST2 and IL-17Rβ in highly diverse and combinatorial fashions. The emerging 
picture for innate lymphocytes is that they contain a heterogeneity previously only thought to 
exist in the adaptive immune system.  In chapter 3,  we explored CD3
-CD19
-NKp46
+  cell 
diversity and reported impressive combinatorial expression of surface receptors typically found 
on both innate and adaptive immune cells. These receptors included many of the receptors listed 
for other ILCs.  Notably, this gating scheme allowed for the inclusion of other ILC members, 
including the NKp46-expressing ILC3 population. We also reported the expression of RORγT in 
some of the nodes co-expressing NKp46. The possibility that an ILC3 population resides in the 
pancreas, albeit a rare one, should be explored further. Arguing against the inclusion of non-
conventional NK cell ILCs in this population, these CD3
-CD19
-NKp46
+ pancreatic-origin cells 
expressed no TH2 or TH17 cytokines as measured during transcriptional profiling (unpublished 
observations).  Due to their similarity with conventional NK cells, including expression of other 
NKCRs, it would be interesting to determine whether or not non-NK cell ILCs express any of the 
Ly49 family receptors and, if so, whether or not those ILCs undergo any form of education as 
conventional NK cells do. 
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4.7 The future of “deep profiling” the immune system 
 
  Recent technological advances, including the CyTOF technology discussed and utilized 
in chapter 3, have opened the possibility for extensive profiling of immune system heterogeneity. 
Already, this technology has uncovered extensive  and unexpected  diversity in numerous 
immunological contexts, including drug responses during hematopoeisis (Bendall et al., 2011), 
CD8+ T cell anti-viral responses (Newell et al., 2012), leukemia (Amir et al., 2013), human 
peripheral blood NK cells (Horowitz et al., 2013)  and,  most recently, B cell differentiation 
(Bendall et al., 2014). The emerging picture from these studies is that the immune system is 
incredibly diverse and that diversity between and within cellular populations has dramatic effects 
on how immune cells respond to perturbations (Bendall et al., 2011).  No study yet has explored 
the diversity of the immune system during an autoimmune disease setting. This is perhaps 
surprising given that autoimmune diseases, especially T1D, are highly complex, with many cell 
types and mechanisms involved.  To that end, in chapter 3, we presented data illustrating the 
diversity of the NK cell compartment found in the pancreas of prediabetic NOD mice. NK cells, 
comprising less than 5% of the  pancreatic infiltrate, contained over 25 different phenotypic 
patterns. The pancreas-infiltrating immune system, on the whole, contained at least 385 total 
nodes depending on the antibody panel used in the assessment. Considering that only roughly 30 
parameter panels are utilized in these studies, compared with the thousands or tens of thousands 
of genes actually expressed by immune cells, the true single-cell diversity will likely be many 
logs higher than what we reported here.  In full, our data illustrates both the impressive diversity 
of total cellular infiltrate in the pancreas as well as that of the NK cell populations included. How 74 
 
this diversity develops, is maintained, and whether or not it is functionally consequential will 
need to be explored further. 
  These high-dimensional approaches are more than just an exercise in finding as many 
surface markers as possible.  Rather, they may be the key to finding specific rare subsets of cells 
and phenotypes responsible for complex diseases such as autoimmunity or cancer.  The data 
presented in chapter 3 are just the beginning of a larger effort to comprehensively identify total 
immune system infiltration in the pancreas, how that immune compartment evolves over the 
course of disease and to determine what populations or activation patterns are most correlated 
with disease parameters. By combining this strategy with disease-predictive technologies such as 
non-invasive magnetic resonance imaging of the pancreas (Denis et al., 2004), we will stratify 
predicted  disease-progressing and non-progressing animals to determine how the insulitis 
maturation  differs between these two conditions and  to  discover further predictive disease-
relevant biomarkers. 
 
 
4.8 Conclusions 
 
  The terms “innate” and “adaptive” immunity  were initially helpful descriptors to 
differentiate what seemed like, at the time, two entirely different physiological systems.  Today, 
the separation of innate and adaptive immunity might be hindering our appreciation for how 
intertwined and diverse these systems actually are. In this thesis, evidence was presented to 
support a highly context-dependent cross-talk of Treg cells and NK cells, responsible for control 
of T1D, with IL-2 at the heart of this cross-talk. We further showed a high-dimensional diversity 75 
 
in NK cells, not-too-long-ago considered a relatively homogenous lineage but with a growing 
body of evidence to the contrary. In the future, experimental efforts should further focus on the 
individual and counteracting context-dependent roles of Treg cells and NK cells, especially in the 
context of cancer and autoimmunity. Also, it will be important to increase our understanding of 
cellular cross-talk within and between innate and adaptive immunity.  Finally, significantly more 
work will be needed to assess the true diversity of immune cells and the contribution of specific 
cellular subsets to normal immune function and disease states. 
   76 
 
References 
 
Alba,A., Planas,R., Clemente,X., Carrillo,J., Ampudia,R., Puertas,M.C., Pastor,X., Tolosa,E., 
Pujol-Borrell,R., Verdaguer,J.et al. (2008). Natural killer cells are required for accelerated type 1 
diabetes driven by interferon-beta. Clin Exp Immunol. 
Amado,I.F., Berges,J., Luther,R.J., Mailhe,M.P., Garcia,S., Bandeira,A., Weaver,C., Liston,A., 
and Freitas,A.A. (2013). IL-2 coordinates IL-2-producing and regulatory T cell interplay. J Exp 
Med. 210, 2707-2720. 
Amir,E., Davis,K.L., Tadmor,M.D., Simonds,E.F., Levine,J.H., Bendall,S.C., Shenfeld,D.K., 
Krishnaswamy,S., Nolan,G.P., and Pe'er,D. (2013). viSNE enables visualization of high 
dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol. 
31, 545-552. 
Angstetra,E., Graham,K.L., Zhao,Y., Irvin,A.E., Elkerbout,L., Santamaria,P., Slattery,R.M., 
Kay,T.W., and Thomas,H.E. (2012). An indirect role for NK cells in a CD4(+) T-cell-dependent 
mouse model of type I diabetes. Immunol Cell Biol. 90, 243-247. 
Arase,H., Mocarski,E.S., Campbell,A.E., Hill,A.B., and Lanier,L.L. (2002). Direct recognition of 
cytomegalovirus by activating and inhibitory NK cell receptors. Science. 296, 1323-1326. 
Aust,J.G., Gays,F., Hussain,F., Butcher,G.W., Kist,R., Peters,H., and Brooks,C.G. (2011). Mice 
lacking Ly49E show normal NK cell development and provide evidence for probabilistic 
expression of Ly49E in NK cells and T cells. J Immunol. 186, 2013-2023. 
Barao,I., Hanash,A.M., Hallett,W., Welniak,L.A., Sun,K., Redelman,D., Blazar,B.R., Levy,R.B., 
and Murphy,W.J. (2006). Suppression of natural killer cell-mediated bone marrow cell rejection 
by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A. 103, 5460-5465. 
Barnett,A.H., Eff,C., Leslie,R.D., and Pyke,D.A. (1981). Diabetes in identical twins. A study of 
200 pairs. Diabetologia. 20, 87-93. 
Barthlott,T., Moncrieffe,H., Veldhoen,M., Atkins,C.J., Christensen,J., O'Garra,A., and 
Stockinger,B. (2005). CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and 
exploit it for the induction of IL-10 production. Int. Immunol. 17, 279-288. 
Beaulieu,A.M., Zawislak,C.L., Nakayama,T., and Sun,J.C. (2014). The transcription factor 
Zbtb32 controls the proliferative burst of virus-specific natural killer cells responding to 
infection. Nat Immunol. 15, 546-553. 
Beilke,J.N., Meagher,C.T., Hosiawa,K., Champsaur,M., Bluestone,J.A., and Lanier,L.L. (2012). 
NK cells are not required for spontaneous autoimmune diabetes in NOD mice. PLoS. ONE. 7, 
e36011. 77 
 
Belanger,S., Tai,L.H., Anderson,S.K., and Makrigiannis,A.P. (2008). Ly49 cluster sequence 
analysis in a mouse model of diabetes: an expanded repertoire of activating receptors in the NOD 
genome. Genes. Immun. 9, 509-521. 
Bendall,S.C., Davis,K.L., Amir,e., Tadmor,M.D., Simonds,E.F., Chen,T.J., Shenfeld,D.K., 
Nolan,G.P., and Pe'er,D. (2014). Single-cell trajectory detection uncovers progression and 
regulatory coordination in human B cell development. Cell. 157, 714-725. 
Bendall,S.C., Simonds,E.F., Qiu,P., Amir,e., Krutzik,P.O., Finck,R., Bruggner,R.V., 
Melamed,R., Trejo,A., Ornatsky,O.I.et al. (2011). Single-cell mass cytometry of differential 
immune and drug responses across a human hematopoietic continuum. Science. 332, 687-696. 
Bennett,C.L., Christie,J., Ramsdell,F., Brunkow,M.E., Ferguson,P.J., Whitesell,L., Kelly,T.E., 
Saulsbury,F.T., Chance,P.F., and Ochs,H.D. (2001). The immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. 
Nat. Genet. 27, 20-21. 
Bihl,F., Pecheur,J., Breart,B., Poupon,G., Cazareth,J., Julia,V., Glaichenhaus,N., and 
Braud,V.M. (2010). Primed antigen-specific CD4+ T cells are required for NK cell activation in 
vivo upon Leishmania major infection. J Immunol. 185, 2174-2181. 
Bingley,P.J. (2010). Clinical applications of diabetes antibody testing. J Clin Endocrinol. Metab. 
95, 25-33. 
Bix,M., Liao,N.S., Zijlstra,M., Loring,J., Jaenisch,R., and Raulet,D. (1991). Rejection of class I 
MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature. 349, 329-331. 
Brauner,H., Elemans,M., Lemos,S., Broberger,C., Holmberg,D., Flodstrom-Tullberg,M., 
Karre,K., and Hoglund,P. (2010). Distinct phenotype and function of NK cells in the pancreas of 
nonobese diabetic mice. J Immunol. 184, 2272-2280. 
Brown,M.G., Dokun,A.O., Heusel,J.W., Smith,H.R., Beckman,D.L., Blattenberger,E.A., 
Dubbelde,C.E., Stone,L.R., Scalzo,A.A., and Yokoyama,W.M. (2001). Vital involvement of a 
natural killer cell activation receptor in resistance to viral infection. Science. 292, 934-937. 
Brunkow,M.E., Jeffery,E.W., Hjerrild,K.A., Paeper,B., Clark,L.B., Yasayko,S.A., 
Wilkinson,J.E., Galas,D., Ziegler,S.F., and Ramsdell,F. (2001). Disruption of a new 
forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the 
scurfy mouse. Nat. Genet. 27, 68-73. 
Buckner,J.H. (2010). Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) 
regulatory T cells in human autoimmune diseases. Nat Rev. Immunol. 10, 849-859. 
Burzyn,D., Kuswanto,W., Kolodin,D., Shadrach,J.L., Cerletti,M., Jang,Y., Sefik,E., Tan,T.G., 
Wagers,A.J., Benoist,C.et al. (2013). A special population of regulatory T cells potentiates 
muscle repair. Cell. 155, 1282-1295. 78 
 
Carnaud,C., Gombert,J., Donnars,O., Garchon,H., and Herbelin,A. (2001). Protection against 
diabetes and improved NK/NKT cell performance in NOD.NK1.1 mice congenic at the NK 
complex. J. Immunol. 166, 2404-2411. 
Cerwenka,A., Baron,J.L., and Lanier,L.L. (2001). Ectopic expression of retinoic acid early 
inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing 
tumor in vivo. Proc Natl Acad Sci U S A. 98, 11521-11526. 
Chatila,T.A., Blaeser,F., Ho,N., Lederman,H.M., Voulgaropoulos,C., Helms,C., and 
Bowcock,A.M. (2000). JM2, encoding a fork head-related protein, is mutated in X-linked 
autoimmunity-allergic disregulation syndrome. J Clin Invest. 106, R75-R81. 
Chaudhry,A., Rudra,D., Treuting,P., Samstein,R.M., Liang,Y., Kas,A., and Rudensky,A.Y. 
(2009). CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science. 
326, 986-991. 
Chen,Z., Benoist,C., and Mathis,D. (2005a). How defects in central tolerance impinge on a 
deficiency in regulatory T cells. Proc Natl. Acad Sci U S. A. 102, 14735-14740. 
Chen,Z., Herman,A.E., Matos,M., Mathis,D., and Benoist,C. (2005b). Where CD4+CD25+ T reg 
cells impinge on autoimmune diabetes. J Exp Med. 202, 1387-1397. 
Christianson,S.W., Shultz,L.D., and Leiter,E.H. (1993). Adoptive transfer of diabetes into 
immunodeficient NOD-scid/scid mice. Diabetes. 42, 44-55. 
Cipolletta,D., Feuerer,M., Li,A., Kamei,N., Lee,J., Shoelson,S.E., Benoist,C., and Mathis,D. 
(2012). PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue 
Treg cells. Nature. 486, 549-553. 
Cipolletta,D., Kolodin,D., Benoist,C., and Mathis,D. (2011). Tissular T(regs): a unique 
population of adipose-tissue-resident Foxp3+CD4+ T cells that impacts organismal metabolism. 
Semin. Immunol. 23, 431-437. 
Cooper,M.A., Elliott,J.M., Keyel,P.A., Yang,L., Carrero,J.A., and Yokoyama,W.M. (2009). 
Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A. 106, 1915-1919. 
D'Acquisto,F. and Crompton,T. (2011). CD3+CD4-CD8- (double negative) T cells: saviours or 
villains of the immune response? Biochem Pharmacol. 82, 333-340. 
de la Rosa,M., Rutz,S., Dorninger,H., and Scheffold,A. (2004). Interleukin-2 is essential for 
CD4+CD25+ regulatory T cell function. Eur. J Immunol. 34, 2480-2488. 
Della Chiesa,M., Vitale,M., Carlomagno,S., Ferlazzo,G., Moretta,L., and Moretta,A. (2003). The 
natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset 
expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur. J Immunol. 33, 
1657-1666. 79 
 
Denis,M.C., Mahmood,U., Benoist,C., Mathis,D., and Weissleder,R. (2004). Imaging 
inflammation of the pancreatic islets in type 1 diabetes. Proc Natl. Acad Sci U S. A. 101, 12634-
12639. 
Diana,J., Simoni,Y., Furio,L., Beaudoin,L., Agerberth,B., Barrat,F., and Lehuen,A. (2013). 
Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune 
diabetes. Nat Med. 19, 65-73. 
Diefenbach,A., Jensen,E.R., Jamieson,A.M., and Raulet,D.H. (2001). Rae1 and H60 ligands of 
the NKG2D receptor stimulate tumour immunity. Nature. 413, 165-171. 
Ellerman,K., Wrobleski,M., Rabinovitch,A., and Like,A. (1993). Natural killer cell depletion and 
diabetes mellitus in the BB/Wor rat (revisited). Diabetologia. 36, 596-601. 
Fernandez,N.C., Treiner,E., Vance,R.E., Jamieson,A.M., Lemieux,S., and Raulet,D.H. (2005). A 
subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors 
specific for self-MHC molecules. Blood. 105, 4416-4423. 
Feuerer,M., Herrero,L., Cipolletta,D., Naaz,A., Wong,J., Nayer,A., Lee,J., Goldfine,A.B., 
Benoist,C., Shoelson,S.et al. (2009a). Lean, but not obese, fat is enriched for a unique population 
of regulatory T cells that affect metabolic parameters. Nat Med. 15, 930-939. 
Feuerer,M., Hill,J.A., Mathis,D., and Benoist,C. (2009b). Foxp3+ regulatory T cells: 
differentiation, specification, subphenotypes. Nat. Immunol. 10, 689-695. 
Feuerer,M., Shen,Y., Littman,D.R., Benoist,C., and Mathis,D. (2009c). How punctual ablation of 
regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity. 31, 
654-664. 
Fine,J.H., Chen,P., Mesci,A., Allan,D.S., Gasser,S., Raulet,D.H., and Carlyle,J.R. (2010). 
Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by 
enabling missing-self recognition. Cancer Res. 70, 7102-7113. 
Fontenot,J.D., Gavin,M.A., and Rudensky,A.Y. (2003). Foxp3 programs the development and 
function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4, 330-336. 
Fontenot,J.D., Rasmussen,J.P., Gavin,M.A., and Rudensky,A.Y. (2005). A function for 
interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142-1151. 
Fraser,K.P., Gays,F., Robinson,J.H., van,B.K., Leclercq,G., Vance,R.E., Raulet,D.H., and 
Brooks,C.G. (2002). NK cells developing in vitro from fetal mouse progenitors express at least 
one member of the Ly49 family that is acquired in a time-dependent and stochastic manner 
independently of CD94 and NKG2. Eur. J Immunol. 32, 868-878. 
Fu,W.,  Wojtkiewicz,G., Weissleder,R., Benoist,C., and Mathis,D. (2012). Early window of 
diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by 
noninvasive imaging. Nat Immunol. 13, 361-368. 80 
 
Gasteiger,G., Hemmers,S., Bos,P.D., Sun,J.C., and Rudensky,A.Y. (2013a). IL-2-dependent 
adaptive control of NK cell homeostasis. J Exp Med. 210, 1179-1187. 
Gasteiger,G., Hemmers,S., Firth,M.A., Le,F.A., Huse,M., Sun,J.C., and Rudensky,A.Y. (2013b). 
IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J 
Exp Med. 210, 1167-1178. 
Gays,F., Martin,K., Kenefeck,R., Aust,J.G., and Brooks,C.G. (2005). Multiple cytokines regulate 
the NK gene complex-encoded receptor repertoire of mature NK cells and T cells. J Immunol. 
175, 2938-2947. 
Ghiringhelli,F., Menard,C., Martin,F., and Zitvogel,L. (2006). The role of regulatory T cells in 
the control of natural killer cells: relevance during tumor progression. Immunol. Rev. 214, 229-
238. 
Ghiringhelli,F., Menard,C., Terme,M., Flament,C., Taieb,J., Chaput,N., Puig,P.E., Novault,S., 
Escudier,B., Vivier,E.et al. (2005). CD4+CD25+ regulatory T cells inhibit natural killer cell 
functions in a transforming growth factor-beta-dependent manner. J Exp Med. 202, 1075-1085. 
Gonzalez,A., Katz,J.D., Mattei,M.G., Kikutani,H., Benoist,C., and Mathis,D. (1997a). Genetic 
control of diabetes progression. Immunity. 7, 873-883. 
Gonzalez,A., Lühder,F., Benoist,C., and Mathis,D. (1997b). MHC and non-MHC genetic 
influences on the BDC2.5 TCR transgenic model of insulin-dependent diabetes. In HLA and 
disease - the molecular basis, Alfred Benzon Symposium 40. A. Svejgaard, L. Fugger, S. Buus, 
Munksgaard Eds. Copenhagen. 349-358. 
Gottlieb,P.A., Delong,T., Baker,R.L., Fitzgerald-Miller,L., Wagner,R., Cook,G., Rewers,M.R., 
Michels,A., and Haskins,K. (2014). Chromogranin A is a T cell antigen in human type 1 
diabetes. J Autoimmun. 50, 38-41. 
Grinberg-Bleyer,Y., Baeyens,A., You,S., Elhage,R., Fourcade,G., Gregoire,S., Cagnard,N., 
Carpentier,W., Tang,Q., Bluestone,J.et al. (2010). IL-2 reverses established type 1 diabetes in 
NOD mice by a local effect on pancreatic regulatory T cells. J Exp. Med. 207, 1871-1878. 
Guerra,N., Pestal,K., Juarez,T., Beck,J., Tkach,K., Wang,L., and Raulet,D.H. (2013). A selective 
role of NKG2D in inflammatory and autoimmune diseases. Clin Immunol. 149, 432-439. 
Gur,C., Enk,J., Kassem,S.A., Suissa,Y., Magenheim,J., Stolovich-Rain,M., Nir,T., Achdout,H., 
Glaser,B., Shapiro,J.et al. (2011). Recognition and killing of human and murine pancreatic beta 
cells by the NK receptor NKp46. J Immunol. 187, 3096-3103. 
Gur,C.,  Porgador,A., Elboim,M., Gazit,R., Mizrahi,S., Stern-Ginossar,N., Achdout,H., 
Ghadially,H., Dor,Y., Nir,T.et al. (2010). The activating receptor NKp46 is essential for the 
development of type 1 diabetes. Nat Immunol. 11, 121-128. 
Gutbrodt,K.L., Casi,G., and  Neri,D. (2014). Antibody-based delivery of interleukin-2 and 
cytotoxics eradicates tumors in immunocompetent mice. Mol. Cancer Ther. 81 
 
Hammond,K.J., Poulton,L.D., Palmisano,L.J., Silveira,P.A., Godfrey,D.I., and Baxter,A.G. 
(1998). alpha/beta-T cell receptor (TCR)+CD4-CD8-  (NKT) thymocytes prevent insulin-
dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin 
(IL)-4 and/or IL-10. J. Exp. Med. 187, 1047-1056. 
Hansson,M., Kiessling,R., and Andersson,B. (1981). Human fetal thymus and bone marrow 
contain target cells for natural killer cells. Eur. J Immunol. 11, 8-12. 
Haskins,K., Portas,M., Bradley,B., Wegmann,D., and Lafferty,K.J. (1988). T-lymphocyte clone 
specific for pancreatic islet antigen. Diabetes. 37, 1444-1448. 
Held,W. and Kunz,B. (1998). An allele-specific, stochastic gene expression process controls the 
expression of multiple Ly49 family genes  and generates a diverse, MHC-specific NK cell 
receptor repertoire. Eur. J Immunol. 28, 2407-2416. 
Herman,A.E., Freeman,G.J., Mathis,D., and Benoist,C. (2004). CD4+CD25+ T regulatory cells 
dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med. 
199, 1479-1489. 
Hodgkin,P.D., Heath,W.R., and Baxter,A.G. (2007). The clonal selection theory: 50 years since 
the revolution. Nat Immunol. 8, 1019-1026. 
Hoglund,P., Mintern,J., Waltzinger,C., Heath,W., Benoist,C., and Mathis,D. (1999). Initiation of 
autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the 
pancreatic lymph nodes. J. Exp. Med. 189, 331-339. 
Hori,S., Nomura,T., and Sakaguchi,S. (2003). Control of regulatory T cell development by the 
transcription factor Foxp3. Science. 299, 1057-1061. 
Horowitz,A., Strauss-Albee,D.M., Leipold,M., Kubo,J., Nemat-Gorgani,N., Dogan,O.C., 
Dekker,C.L., Mackey,S., Maecker,H., Swan,G.E.et al. (2013). Genetic and environmental 
determinants of human NK cell diversity revealed by mass cytometry. Sci Transl. Med. 5, 
208ra145. 
Hou,J., Townson,S.A., Kovalchin,J.T., Masci,A., Kiner,O., Shu,Y., King,B.M., Schirmer,E., 
Golden,K., Thomas,C.et al. (2013). Design of a superior cytokine antagonist for topical 
ophthalmic use. Proc Natl Acad Sci U S A. 110, 3913-3918. 
Hoyler,T., Klose,C.S., Souabni,A., Turqueti-Neves,A., Pfeifer,D., Rawlins,E.L., Voehringer,D., 
Busslinger,M., and Diefenbach,A. (2012). The transcription factor GATA-3 controls cell fate 
and maintenance of type 2 innate lymphoid cells. Immunity. 37, 634-648. 
Hsieh,C.S., Zheng,Y., Liang,Y., Fontenot,J.D., and Rudensky,A.Y. (2006). An intersection 
between the self-reactive regulatory and nonregulatory T cell receptor repertoires. Nat. Immunol. 
7, 401-410. 82 
 
Hutchings,P., Rosen,H., O'Reilly,L., Simpson,E., Gordon,S., and Cooke,A. (1990). Transfer of 
diabetes in mice prevented by blockade of adhesion-promoting receptor on macrophages. Nature. 
348, 639-641. 
Jaeger,B.N. and Vivier,E. (2012). Natural killer cell tolerance: control by self or self-control? 
Cold Spring Harb. Perspect. Biol. 4. 
Jerne,N.K. (1955). THE NATURAL-SELECTION THEORY OF ANTIBODY FORMATION. 
Proc Natl Acad Sci U S A. 41, 849-857. 
Ji,H., Ohmura,K., Mahmood,U., Lee,D.M., Hofhuis,F.M.A., Boackle,S.A., Holers,V.M., 
Walport,M., Gerard,C., Ezekowitz,A.et al. (2002). Arthritis critically dependent on innate 
immune system players. Immunity. 16, 157-168. 
Jobim,M., Jobim,L.F., Salim,P.H., Cestari,T.F., Toresan,R., Gil,B.C., Jobim,M.R., Wilson,T.J., 
Kruger,M., Schlottfeldt,J.et al. (2008). A study of the killer cell immunoglobulin-like receptor 
gene KIR2DS1 in a Caucasoid Brazilian population with psoriasis vulgaris. Tissue Antigens. 72, 
392-396. 
Johansson,S., Berg,L., Hall,H., and Hoglund,P. (2005). NK cells: elusive players in 
autoimmunity. Trends Immunol. 26, 613-618. 
Johnson,M.C., Garland,A.L., Nicolson,S.C., Li,C., Samulski,R.J., Wang,B., and Tisch,R. (2013). 
beta-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in 
NOD mice. Diabetes. 62, 3775-3784. 
Joncker,N.T., Shifrin,N., Delebecque,F., and Raulet,D.H. (2010). Mature natural killer cells reset 
their responsiveness when exposed to an altered MHC environment. J Exp Med. 207, 2065-2072. 
Kanagawa,O., Militech,A., and Vaupel,B.A. (2002). Regulation of diabetes development by 
regulatory T cells in pancreatic islet antigen-specific TCR transgenic nonobese diabetic mice. J 
Immunol. 168, 6159-6164. 
Katz,J.D., Wang,B., Haskins,K., Benoist,C., and Mathis,D. (1993). Following a diabetogenic T 
cell from genesis through pathogenesis. Cell. 74, 1089-1100. 
Kerdiles,Y., Ugolini,S., and Vivier,E. (2013). T cell regulation of natural killer cells. J Exp Med. 
210, 1065-1068. 
Khattri,R., Cox,T., Yasayko,S.A., and Ramsdell,F. (2003). An essential role for Scurfin in 
CD4+CD25+ T regulatory cells. Nat. Immunol. 4, 337-342. 
Kim,J.M., Rasmussen,J.P., and Rudensky,A.Y. (2007). Regulatory T cells prevent catastrophic 
autoimmunity throughout the lifespan of mice. Nat. Immunol. 8, 191-197. 
King,A. (2000). Uterine leukocytes and decidualization. Hum. Reprod. Update. 6, 28-36. 83 
 
Knip,M., Korhonen,S., Kulmala,P., Veijola,R., Reunanen,A., Raitakari,O.T., Viikari,J., and 
Akerblom,H.K. (2010). Prediction of type 1 diabetes in the general population. Diabetes Care. 
33, 1206-1212. 
Koch,M.A., Tucker-Heard,G., Perdue,N.R., Killebrew,J.R., Urdahl,K.B., and Campbell,D.J. 
(2009). The transcription factor T-bet controls regulatory T cell homeostasis and function during 
type 1 inflammation. Nat. Immunol. 10, 595-602. 
Kotecha,N., Krutzik,P.O., and Irish,J.M. (2010). Web-based analysis and publication of flow 
cytometry experiments. Curr. Protoc. Cytom. Chapter 10, Unit10. 
Kusnierczyk,P. (2013). Killer cell immunoglobulin-like receptor gene associations with 
autoimmune and allergic diseases, recurrent spontaneous abortion, and neoplasms. Front 
Immunol. 4, 8. 
Lahl,K., Loddenkemper,C., Drouin,C., Freyer,J., Arnason,J., Eberl,G., Hamann,A., Wagner,H., 
Huehn,J., and Sparwasser,T. (2007). Selective depletion of Foxp3+ regulatory T cells induces a 
scurfy-like disease. J Exp Med. 204, 57-63. 
Lanier,L.L. (2005). NK cell recognition. Annu Rev. Immunol. 23, 225-274. 
Lanier,L.L.  (2008). Up on the tightrope: natural killer cell activation and inhibition. Nat 
Immunol. 9, 495-502. 
Lanier,L.L. (2014). Of snowflakes and natural killer cell subsets. Nat Biotechnol. 32, 140-142. 
Lee,I.F., Qin,H., Trudeau,J., Dutz,J., and Tan,R. (2004). Regulation of autoimmune diabetes by 
complete Freund's adjuvant is mediated by NK cells. J Immunol. 172, 937-942. 
Lee,S.H., Fragoso,M.F., and Biron,C.A. (2012). Cutting Edge: A Novel Mechanism Bridging 
Innate and Adaptive Immunity: IL-12 Induction of CD25 To Form High-Affinity IL-2 Receptors 
on NK Cells. J Immunol. 189, 2712-2716. 
Lehuen,A., Diana,J., Zaccone,P., and Cooke,A. (2010). Immune cell crosstalk in type 1 diabetes. 
Nat Rev. Immunol. 10, 501-513. 
Lehuen,A., Lantz,O., Beaudoin,L., Laloux,V., Carnaud,C., Bendelac,A., Bach,J.F., and 
Monteiro,R.C. (1998). Overexpression of natural killer T cells protects Valpha14-Jalpha281 
transgenic nonobese diabetic mice against diabetes. J. Exp. Med. 188, 1831-1839. 
Long,S.A., Rieck,M., Sanda,S., Bollyky,J.B., Samuels,P.L., Goland,R., Ahmann,A., 
Rabinovitch,A., Aggarwal,S., Phippard,D.et al. (2012). Rapamycin/IL-2 Combination Therapy in 
Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs beta-Cell Function. 
Diabetes. 61, 2340-2348. 
Lorini,R., Moretta,A., Valtorta,A., d'Annunzio,G., Cortona,L., Vitali,L., Bozzola,M., and 
Severi,F. (1994). Cytotoxic activity in children with insulin-dependent diabetes mellitus. 
Diabetes Res. Clin Pract. 23, 37-42. 84 
 
Luhder,F., Höglund,P., Allison,J.P., Benoist,C., and Mathis,D. (1998). Cytotoxic T lymphocyte-
associated antigen 4 regulates the unfolding of autoimmune diabetes. J. Exp. Med. 187, 427-432. 
MacKay,P., Jacobson,J., and Rabinovitch,A. (1986). Spontaneous diabetes mellitus in the Bio-
Breeding/Worcester rat. Evidence in vitro for natural killer cell lysis of islet cells. J Clin Invest. 
77, 916-924. 
Martin,B., Hirota,K., Cua,D.J., Stockinger,B., and Veldhoen,M. (2009). Interleukin-17-
producing gammadelta T cells selectively expand in response to pathogen products and 
environmental signals. Immunity. 31, 321-330. 
Maruyama,T., Watanabe,K., Takei,I., Kasuga,A., Shimada,A., Yanagawa,T., Kasatani,T., 
Suzuki,Y., Kataoka,K., Sarutaet al. (1991a). Anti-asialo GM1 antibody suppression of 
cyclophosphamide-induced diabetes in NOD mice. Diabetes Res. 17, 37-41. 
Maruyama,T., Watanabe,K., Yanagawa,T., Kasatani,T., Kasuga,A., Shimada,A., Takei,I., 
Suzuki,Y., Kataoka,K., and Saruta,T. (1991b). The suppressive effect of anti-asialo GM1 
antibody on low-dose streptozotocin-induced diabetes in CD-1 mice. Diabetes Res. 16, 171-175. 
Mathis,D. and Benoist,C. (2010). Levees of immunological tolerance. Nat. Immunol. 11, 3-6. 
Mathis,D. and Benoist,C. (2012). The influence of the microbiota on type-1 diabetes: on the 
threshold of a leap forward in our understanding. Immunol. Rev. 245, 239-249. 
McInerney,M.F., Pek,S.B., and Thomas,D.W. (1991). Prevention of insulitis and diabetes onset 
by treatment with complete Freund's adjuvant in NOD mice. Diabetes. 40, 715-725. 
Middleton,D., Halfpenny,I., Meenagh,A., Williams,F., Sivula,J., and Tuomilehto-Wolf,E. 
(2006). Investigation of KIR gene frequencies in type 1 diabetes mellitus. Hum. Immunol. 67, 
986-990. 
Moraes-Vasconcelos,D., Costa-Carvalho,B.T., Torgerson,T.R., and Ochs,H.D. (2008). Primary 
immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED. J Clin 
Immunol. 28 Suppl 1, S11-S19. 
Moro,K., Yamada,T., Tanabe,M., Takeuchi,T., Ikawa,T., Kawamoto,H., Furusawa,J., Ohtani,M., 
Fujii,H., and Koyasu,S. (2010). Innate production of T(H)2 cytokines by adipose tissue-
associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. 463, 540-544. 
Mueller,D.L. (2010). Mechanisms maintaining peripheral tolerance. Nat Immunol. 11, 21-27. 
Narni-Mancinelli,E., Chaix,J., Fenis,A., Kerdiles,Y.M., Yessaad,N., Reynders,A., Gregoire,C., 
Luche,H., Ugolini,S., Tomasello,E.et al. (2011). Fate mapping analysis of lymphoid cells 
expressing the NKp46 cell surface receptor. Proc Natl Acad Sci U S A. 108, 18324-18329. 
Nash,W.T., Teoh,J., Wei,H., Gamache,A., and Brown,M.G. (2014). Know Thyself: NK-Cell 
Inhibitory Receptors Prompt Self-Tolerance, Education, and Viral Control. Front Immunol. 5, 
175. 85 
 
Newell,E.W., Sigal,N., Bendall,S.C., Nolan,G.P., and Davis,M.M. (2012). Cytometry by time-
of-flight shows combinatorial cytokine expression and virus-specific cell niches within a 
continuum of CD8+ T cell phenotypes. Immunity. 36, 142-152. 
Nikitina-Zake,L., Rajalingham,R., Rumba,I., and Sanjeevi,C.B. (2004). Killer cell 
immunoglobulin-like receptor genes in Latvian patients with type 1 diabetes mellitus and healthy 
controls. Ann. N Y Acad Sci. 1037, 161-169. 
Noorchashm,H., Noorchashm,N., Kern,J., Rostami,S.Y., Barker,C.F., and Naji,A. (1997). B-cells 
are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes. 46, 
941-946. 
O'Leary,J.G., Goodarzi,M., Drayton,D.L., and von Andrian,U.H. (2006). T cell-  and B cell-
independent adaptive immunity mediated by natural killer cells. Nat Immunol. 7, 507-516. 
Ogasawara,K., Hamerman,J.A., Ehrlich,L.R., Bour-Jordan,H., Santamaria,P., Bluestone,J.A., 
and Lanier,L.L. (2004). NKG2D blockade prevents autoimmune diabetes in NOD mice. 
Immunity. 20, 757-767. 
Orr,M.T., Beilke,J.N., Proekt,I., and Lanier,L.L. (2010). Natural killer cells in NOD.NK1.1 mice 
acquire cytolytic function during viral infection and provide protection against cytomegalovirus. 
Proc Natl Acad Sci U S A. 107, 15844-15849. 
Pandiyan,P., Zheng,L., Ishihara,S., Reed,J., and Lenardo,M.J. (2007). CD4+CD25+Foxp3+ 
regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat 
Immunol. 8, 1353-1362. 
Papiernik,M., do Carmo Leite-de-MoraesM, Pontoux,C., Joret,A.M., Rocha,B., Penit,C., and 
Dy,M. (1997). T cell deletion induced by chronic infection with mouse mammary tumor virus 
spares a CD25-positive, IL-10-producing T cell population with infectious capacity. J Immunol. 
158, 4642-4653. 
Park,Y., Choi,H., Park,H., Park,S., Yoo,E.K., Kim,D., and Sanjeevi,C.B. (2006). Predominance 
of the group A killer Ig-like receptor haplotypes in Korean patients with T1D. Ann. N. Y. Acad 
Sci. 1079, 240-250. 
Paust,S., Gill,H.S.,  Wang,B.Z., Flynn,M.P., Moseman,E.A., Senman,B., Szczepanik,M., 
Telenti,A., Askenase,P.W., Compans,R.W.et al. (2010). Critical role for the chemokine receptor 
CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol. 11, 
1127-1135. 
Paust,S. and von Andrian,U.H. (2011). Natural killer cell memory. Nat Immunol. 12, 500-508. 
Peng,Y., Laouar,Y., Li,M.O., Green,E.A., and Flavell,R.A. (2004). TGF-beta regulates in vivo 
expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection 
against diabetes. Proc Natl. Acad Sci U S. A. 101, 4572-4577. 86 
 
Poirot,L., Benoist,C., and Mathis,D. (2004). Natural killer cells distinguish innocuous and 
destructive forms of pancreatic islet autoimmunity. Proc Natl. Acad Sci U S. A. 101, 8102-8107. 
Qiu,P., Simonds,E.F., Bendall,S.C., Gibbs,K.D., Jr., Bruggner,R.V., Linderman,M.D., Sachs,K., 
Nolan,G.P., and Plevritis,S.K. (2011). Extracting a cellular hierarchy from high-dimensional 
cytometry data with SPADE. Nat Biotechnol. 29, 886-891. 
Rabinovitch,A., Suarez-Pinzon,W.L., Shapiro,A.M., Rajotte,R.V., and Power,R. (2002). 
Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent 
autoimmune diabetes in NOD mice. Diabetes. 51, 638-645. 
Rahim,M.M., Tu,M.M., Mahmoud,A.B., Wight,A., Abou-Samra,E., Lima,P.D., and 
Makrigiannis,A.P. (2014). Ly49 Receptors: Innate and Adaptive Immune Paradigms. Front 
Immunol. 5, 145. 
Ramos-Lopez,E., Scholten,F., Aminkeng,F., Wild,C., Kalhes,H., Seidl,C., Tonn,T., Van der 
Auwera,B., and Badenhoop,K. (2009). Association of KIR2DL2 polymorphism rs2756923 with 
type 1 diabetes and preliminary evidence for lack of inhibition through HLA-C1 ligand binding. 
Tissue Antigens. 73, 599-603. 
Rodacki,M., Svoren,B., Butty,V., Besse,W., Laffel,L., Benoist,C., and Mathis,D. (2007). Altered 
natural killer cells in type 1 diabetic patients. Diabetes. 56, 177-185. 
Rogner,U.C., Boitard,C., Morin,J., Melanitou,E., and Avner,P. (2001). Three loci on mouse 
chromosome 6 influence onset and final incidence of type I diabetes in NOD.C3H congenic 
strains. Genomics. 74, 163-171. 
Ronnblom,L. and Eloranta,M.L. (2013). The interferon signature in autoimmune diseases. Curr. 
Opin. Rheumatol. 25, 248-253. 
Rosenberg,S.A. (2014). IL-2: The First Effective Immunotherapy for Human Cancer. J Immunol. 
192, 5451-5458. 
Rudensky,A.Y. (2011). Regulatory T cells and Foxp3. Immunol. Rev. 241, 260-268. 
Sakaguchi,S. (2000). Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 
101, 455-458. 
Sakaguchi,S., Sakaguchi,N., Asano,M., Itoh,M., and Toda,M. (1995). Immunologic self-
tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). 
Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J 
Immunol. 155, 1151-1164. 
Salomon,B., Lenschow,D.J., Rhee,L., Ashourian,N., Singh,B., Sharpe,A., and Bluestone,J.A. 
(2000). B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ 
immunoregulatory T cells that control autoimmune diabetes. Immunity. 12, 431-440. 87 
 
Santin,I., de Nanclares,G.P., Calvo,B., Gaafar,A., Castano,L., and Bilbao,J.R. (2006). Killer cell 
immunoglobulin-like receptor (KIR) genes in the Basque population: association study of KIR 
gene contents with type 1 diabetes mellitus. Hum. Immunol. 67, 118-124. 
Scheffold,A., Huhn,J., and Hofer,T. (2005). Regulation of CD4+CD25+ regulatory T cell 
activity: it takes (IL-)two to tango. Eur. J Immunol. 35, 1336-1341. 
Schenkel,A.R., Kingry,L.C., and Slayden,R.A. (2013). The ly49 gene family. A brief guide to 
the nomenclature, genetics, and role in intracellular infection. Front Immunol. 4, 90. 
Shalek,A.K., Satija,R., Adiconis,X., Gertner,R.S., Gaublomme,J.T., Raychowdhury,R., 
Schwartz,S., Yosef,N., Malboeuf,C., Lu,D.et al. (2013). Single-cell transcriptomics reveals 
bimodality in expression and splicing in immune cells. Nature. 498, 236-240. 
Shimizu,J., Yamazaki,S., and Sakaguchi,S. (1999). Induction of tumor immunity by removing 
CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 
163, 5211-5218. 
Sitrin,J., Ring,A., Garcia,K.C., Benoist,C., and Mathis,D. (2013). Regulatory T cells control NK 
cells in an insulitic lesion by depriving them of IL-2. J Exp. Med. 210, 1153-1165. 
Smith,H.R., Heusel,J.W., Mehta,I.K., Kim,S., Dorner,B.G., Naidenko,O.V., Iizuka,K., 
Furukawa,H., Beckman,D.L., Pingel,J.T.et al. (2002). Recognition of a virus-encoded ligand by 
a natural killer cell activation receptor. Proc Natl Acad Sci U S A. 99, 8826-8831. 
Smyth,M.J., Teng,M.W., Swann,J., Kyparissoudis,K., Godfrey,D.I., and Hayakawa,Y. (2006). 
CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J 
Immunol. 176, 1582-1587. 
Sojka,D.K., Plougastel-Douglas,B., Yang,L., Pak-Wittel,M.A., Artyomov,M.N., Ivanova,Y., 
Zhong,C., Chase,J.M., Rothman,P.B., Yu,J.et al. (2014a). Tissue-resident natural killer (NK) 
cells are cell lineages distinct from thymic and conventional splenic NK cells. Elife. 3, e01659. 
Sojka,D.K., Tian,Z., and Yokoyama,W.M. (2014b). Tissue-resident natural killer cells and their 
potential diversity. Semin. Immunol. 26, 127-131. 
Spits,H., Artis,D., Colonna,M., Diefenbach,A., Di Santo,J.P., Eberl,G., Koyasu,S., 
Locksley,R.M., McKenzie,A.N., Mebius,R.E.et al. (2013). Innate lymphoid cells--a proposal for 
uniform nomenclature. Nat Rev. Immunol. 13, 145-149. 
Stadinski,B.D., Delong,T., Reisdorph,N., Reisdorph,R., Powell,R.L., Armstrong,M., 
Piganelli,J.D., Barbour,G., Bradley,B., Crawford,F.et al. (2010). Chromogranin A is an 
autoantigen in type 1 diabetes. Nat. Immunol. 11, 225-231. 
Sun,J.C. (2010). Re-educating natural killer cells. J Exp Med. 207, 2049-2052. 
Sun,J.C., Beilke,J.N., and Lanier,L.L. (2009). Adaptive immune features of natural killer cells. 
Nature. 457, 557-561. 88 
 
Sun,J.C. and Lanier,L.L. (2008). Tolerance of NK cells encountering their viral ligand during 
development. J Exp Med. 205, 1819-1828. 
Sun,J.C., Ugolini,S., and Vivier,E. (2014). Immunological memory within the innate immune 
system. EMBO J. 
Suri-Payer,E., Amar,A.Z., Thornton,A.M., and Shevach,E.M. (1998). CD4
+CD25
+ T cells inhibit 
both the induction and effector function of autoreactive T cells and represent a unique lineage of 
immunoregulatory cells. J. Immunol. 160, 1212-1218. 
Tang,Q., Adams,J.Y., Penaranda,C., Melli,K., Piaggio,E., Sgouroudis,E., Piccirillo,C.A., 
Salomon,B.L., and Bluestone,J.A. (2008). Central role of defective interleukin-2 production in 
the triggering of islet autoimmune destruction. Immunity. 28, 687-697. 
Tang,Q., Henriksen,K.J., Bi,M., Finger,E.B., Szot,G., Ye,J., Masteller,E.L., McDevitt,H., 
Bonyhadi,M., and Bluestone,J.A. (2004). In Vitro-expanded Antigen-specific Regulatory T Cells 
Suppress Autoimmune Diabetes. J Exp Med. 199, 1455-1465. 
Tarbell,K.V., Yamazaki,S., Olson,K., Toy,P., and Steinman,R.M. (2004). CD25+ CD4+ T Cells, 
Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide, Suppress 
Autoimmune Diabetes. J Exp Med. 199, 1467-1477. 
Terme,M., Chaput,N., Combadiere,B., Ma,A., Ohteki,T., and Zitvogel,L. (2008). Regulatory T 
cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting 
CD4+ self-reactive T cells. J Immunol. 180, 4679-4686. 
Tisch,R. and McDevitt,H. (1996). Insulin-dependent diabetes mellitus. Cell. 85, 291-297. 
Torgerson,T.R. and Ochs,H.D. (2007). Immune dysregulation, polyendocrinopathy, enteropathy, 
X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin 
Immunol. 120, 744-750. 
Trapnell,C., Pachter,L., and Salzberg,S.L. (2009). TopHat: discovering splice junctions with 
RNA-Seq. Bioinformatics. 25, 1105-1111. 
Trinchieri,G. (1989). Biology of natural killer cells. Adv. Immunol. 47, 187-376. 
Trzonkowski,P., Zaucha,J.M., Mysliwska,J., Balon,J., Szmit,E., Halaburda,K., 
Bieniaszewska,M., Mlotkowska,M., Hellmann,A., and Mysliwski,A. (2004). Differences in 
kinetics of donor lymphoid cells in response to G-CSF administration may affect the incidence 
and severity of acute GvHD in respective HLA-identical sibling recipients. Med Oncol. 21, 81-
94. 
Tu,M.M., Mahmoud,A.B., Wight,A., Mottashed,A., Belanger,S., Rahim,M.M., Abou-Samra,E., 
and Makrigiannis,A.P. (2014). Ly49 family receptors are required for cancer 
immunosurveillance mediated by natural killer cells. Cancer Res. 89 
 
Turley,S., Poirot,L., Hattori,M., Benoist,C., and Mathis,D. (2003). Physiological {beta} Cell 
Death Triggers Priming of Self-reactive T Cells by Dendritic Cells in a Type-1 Diabetes Model. 
J Exp Med. 198, 1527-1537. 
van der Slik,A.R., Koeleman,B.P., Verduijn,W., Bruining,G.J., Roep,B.O., and Giphart,M.J. 
(2003). KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer 
cell receptors in patients versus HLA-matched control subjects. Diabetes. 52, 2639-2642. 
Vehik,K. and Dabelea,D. (2011). The changing epidemiology of type 1 diabetes: why is it going 
through the roof? Diabetes Metab Res. Rev. 27, 3-13. 
Verdaguer,J., Schmidt,D., Amrani,A., Anderson,B., Averill,N., and Santamaria,P. (1997). 
Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. J Exp Med. 
186, 1663-1676. 
Vignali,D.A., Collison,L.W., and Workman,C.J. (2008). How regulatory T cells work. Nat. Rev. 
Immunol. 8, 523-532. 
Vijayakrishnan,L., Slavik,J.M., Illes,Z., Greenwald,R.J., Rainbow,D., Greve,B., Peterson,L.B., 
Hafler,D.A., Freeman,G.J., Sharpe,A.H.et al. (2004). An autoimmune disease-associated CTLA-
4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity. 20, 563-
575. 
Vivier,E., Tomasello,E., Baratin,M., Walzer,T., and Ugolini,S. (2008). Functions of natural killer 
cells. Nat Immunol. 9, 503-510. 
Vonarbourg,C., Mortha,A., Bui,V.L., Hernandez,P.P., Kiss,E.A., Hoyler,T., Flach,M., 
Bengsch,B., Thimme,R., Holscher,C.et al. (2010). Regulated expression of nuclear receptor 
RORgammat confers distinct functional fates to NK cell receptor-expressing RORgammat(+) 
innate lymphocytes. Immunity. 33, 736-751. 
Vosshenrich,C.A., Garcia-Ojeda,M.E., Samson-Villeger,S.I., Pasqualetto,V., Enault,L., Richard-
Le Goff,O., Corcuff,E., Guy-Grand,D., Rocha,B., Cumano,A.et al. (2006). A thymic pathway of 
mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat. 
Immunol. 7, 1217-1224. 
Waldron-Lynch,F., Kareclas,P., Irons,K., Walker,N.M., Mander,A., Wicker,L.S., Todd,J.A., and 
Bond,S. (2014). Rationale and study design of the Adaptive study of IL-2 dose on regulatory T 
cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. 
BMJ Open. 4, e005559. 
Wildin,R.S., Ramsdell,F., Peake,J., Faravelli,F., Casanova,J.L., Buist,N., Levy-Lahad,E., 
Mazzella,M., Goulet,O., Perroni,L.et al. (2001). X-linked neonatal diabetes mellitus, enteropathy 
and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27, 18-20. 
Wildin,R.S., Smyk-Pearson,S., and Filipovich,A.H. (2002). Clinical and molecular features of 
the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med 
Genet. 39, 537-545. 90 
 
Wilhelm,C., Hirota,K., Stieglitz,B., Van,S.J., Tolaini,M., Lahl,K., Sparwasser,T., Helmby,H., 
and Stockinger,B. (2011). An IL-9 fate reporter demonstrates the induction of an innate IL-9 
response in lung inflammation. Nat Immunol. 12, 1071-1077. 
Willerford,D.M., Chen,J., Ferry,J.A., Davidson,L., Ma,A., and Alt,F.W. (1995). Interleukin-2 
receptor  α  chain regulates the size and content of the peripheral lymphoid compartment. 
Immunity. 3, 521-530. 
Wing,J.B. and Sakaguchi,S. (2012). Multiple treg suppressive modules and their adaptability. 
Front Immunol. 3, 178. 
Xie,Z., Chang,C., and Zhou,Z. (2014). Molecular Mechanisms in Autoimmune Type 1 Diabetes: 
a Critical Review. Clin Rev. Allergy Immunol. 
Yang,M., Charlton,B., and Gautam,A.M. (1997). Development of insulitis and diabetes in B cell-
deficient NOD mice. J. Autoimmun. 10, 257-260. 
Zheng,Y., Chaudhry,A., Kas,A., Deroos,P., Kim,J.M., Chu,T.T., Corcoran,L., Treuting,P., 
Klein,U., and Rudensky,A.Y. (2009). Regulatory T-cell suppressor program co-opts transcription 
factor IRF4 to control T(H)2 responses. Nature. 458, 351-356. 
 
 
 
   91 
 
Appendix 
 
A.  Publication: 
 
Jonathan Sitrin,  Aaron Ring, K. Christopher Garcia, Christophe Benoist
  and Diane 
Mathis (2013). Tregs Control NK Cells in an Insulitic Lesion by Depriving them of IL-2. 
The Journal of Experimental Medicine 93:2260. doi:10.1084/jem.20122248 
 
 
 
 Article
The Rockefeller University Press  $30.00
J. Exp. Med. 2013 Vol. 210 No. 6  1153-1165
www.jem.org/cgi/doi/10.1084/jem.20122248
1153
Regulatory T (T reg) cells , in particular those 
expressing the forkhead box transcription fac-
tor Foxp3, are primary controllers of immune 
responsiveness  and  peripheral  immunological 
tolerance (Rudensky, 2011). These critical im-
munoregulatory cells have been implicated in 
the control of an assortment of immunological 
processes, ranging from autoimmunity to infec-
tion. In humans, loss-of-function mutations of 
Foxp3 lead to a severe multi-organ autoimmune 
and inflammatory disorder called IPEX (immune 
dysfunction, polyendocrinopathy, enteropathy, 
X-linked inheritance). Scurfy mice, carrying a 
frameshift mutation in Foxp3, show a similar 
fatal systemic disease. Moreover, conditional 
ablation of the T reg cell lineage demonstrated 
a  lifelong  requirement  for  Foxp3-expressing 
cells to contain highly aggressive, multi-organ 
autoimmunity, even after normal development 
of the immune system.
T reg cells also regulate several organ-specific 
autoimmune diseases, notably type-1 diabetes 
(T1D), characterized by autoimmune attack spe-
cifically on  cells in the pancreatic islets of 
Langerhans (Bluestone et al., 2008). Supplemen-
tation with T reg cells or enhancement of their 
function protected from T1D, whereas genetic 
deficiencies in or experimental reductions of   
T reg cells exacerbated disease in the nonobese 
diabetic (NOD) mouse model or its T cell re-
ceptor (TCR) transgenic derivatives.
Exactly how T reg cells exert their impact 
on immune responsiveness has been the subject 
of extensive exploration. To date, numerous 
protective mechanisms have been ascribed to 
them, reflecting their expression of several reg-
ulatory molecules, either displayed at the cell sur-
face or secreted (Vignali et al., 2008; Josefowicz 
et al., 2012). It has become clear that the con-
text in which T reg cells perform their regulatory 
function can shape the mechanisms of immune 
suppression they use, i.e., the tissular location or 
inflammatory “flavor” of the response they are 
participating in (Sojka et al., 2008; Josefowicz   
et al., 2012).
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Regulatory T cells control NK cells in an 
insulitic lesion by depriving them of IL-2
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Regulatory T (T reg) cells control progression to autoimmune diabetes in the BDC2.5/NOD 
mouse model by reining in natural killer (NK) cells that infiltrate the pancreatic islets, 
inhibiting both their proliferation and production of diabetogenic interferon-. In this 
study, we have explored the molecular mechanisms underlying this NK–T reg cell axis, 
following leads from a kinetic exploration of gene expression changes early after punctual 
perturbation of T reg cells in BDC2.5/NOD mice. Results from gene signature analyses, 
quantification of STAT5 phosphorylation levels, cytokine neutralization experiments, cyto-
kine supplementation studies, and evaluations of intracellular cytokine levels collectively 
argue for a scenario in which T reg cells regulate NK cell functions by controlling the 
bioavailability of limiting amounts of IL-2 in the islets, generated mainly by infiltrating 
CD4+ T cells. This scenario represents a previously unappreciated intertwining of the innate 
and adaptive immune systems: CD4+ T cells priming NK cells to provoke a destructive T effector 
cell response. Our findings highlight the need to consider potential effects on NK cells 
when designing therapeutic strategies based on manipulation of IL-2 levels or targets.
© 2013 Sitrin et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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This feature permitted us to perform an accurate, detailed in-
ventory of molecular changes over time, and to test mecha-
nistic hypotheses with short courses of inhibitory or enhancing 
treatments. Our findings need to be considered in future 
strategies to prevent or dampen T1D.
RESULTS
Acute T reg cell perturbation in BDC2.5/NOD mice rapidly 
induced signs of activation in pancreas-infiltrating NK cells
To identify molecular pathways underlying the response of 
pancreatic NK cells to a loss of T reg control, we performed   
microarray-based gene-expression profiling, as a comprehensive 
and unbiased approach. NK cells from pancreata of insulitic 
BDC2.5/NOD.Foxp3DTR mice and control DTR-negative 
littermates were analyzed 24 h after DT treatment (Fig. 1 A). 
Even at this relatively early time point, there were clear tran-
scriptional changes in the T reg cell–depleted mice: induction 
of 89 genes >2-fold (highlighted in red) and repression of 
123 genes >2-fold (in blue) compared with 1 and 0 loci, re-
spectively, in an analogous comparison of randomized datasets. 
The transcripts up-regulated in the absence of T reg cells in-
cluded indicators of the three canonical activities of NK cells: 
proliferation (zbtb32, 5.9-fold [J.C. Sun, personal communi-
cation]), cytokine production (ifng, 2.5-fold), and cytotoxic-
ity (gzmb, 2.6-fold). Such changes fit well with our previous 
demonstration that ablation of T reg cells in this model induced 
cytotoxic activity from, proliferation of, and IFN- produc-
tion by islet-infiltrating NK cells (Feuerer et al., 2009).
The full list of genes whose expression was at least dou-
bled or halved in response to T reg cell removal is presented 
in Table S1. A quick glance at the induced loci revealed many 
of them to be characteristic of activated NK cells. More pre-
cisely, we compared the response of pancreatic NK cells to 
T reg depletion with that of splenic NK cells challenged by 
general (cytokine) or more specific [murine cytomegalovirus 
(MCMV)] stimuli. The diagonal nature of the red cloud in the 
fold-change/fold-change (FC/FC) plot of Fig. 1 B denotes 
substantial overlap between the genes induced in pancreatic 
NK cells by removal of T reg cells and in splenic NK cells stim-
ulated in culture with IL-12 + IL-18. The tilt toward the hori-
zontal axis signifies that the cytokine stimulus was more potent 
under these particular experimental conditions. An analogous 
result was found for the blue-colored repressed transcripts, with 
an even more pronounced skewing. Overall, 79% of the tran-
scripts that increased or decreased by >2-fold after T reg cell 
removal were similarly augmented or diminished, respectively, 
subsequent to cytokine stimulation in culture. Similar, although 
less striking, observations came from the comparison of pancre-
atic NK cells responding to a loss of T reg cells and splenic NK 
cells mobilized by MCMV infection (Fig. 1 C). In this case, 
51% of the transcripts induced or repressed >2-fold by T reg 
cell ablation were enhanced or dampened, respectively. Nota-
bly, ifng, zbtb32, and gzmb were induced in both the cytokine-
stimulated and MCMV-induced responses.
We also addressed how rapid and localized the transcrip-
tome alterations were after punctual T reg cell ablation. Fig. 1 D 
(Katz et al., 1993) serves as an instructive example. This line 
carries the rearranged TCR genes of a diabetogenic T cell 
clone isolated from a NOD mouse and has been instrumental 
in the identification of a spectrum of immunoregulatory genes, 
molecules, and cells that control the frequency and aggressivity 
of diabetogenic T cells (André et al., 1996). When the BDC2.5 
TCR transgenes are propagated on the NOD genetic back-
ground, T cells stereotypically invade the islets at 15–18 d of 
age and seed a massive infiltration therein; however, progression 
to diabetes occurs rarely (10–20%) and only months later, re-
flecting strong immunoregulation (Gonzalez et al., 1997). When 
a transgene expressing the diphtheria toxin receptor (DTR) 
under the dictates of the Foxp3 promoter/enhancer elements 
was crossed into this system (BDC2.5/NOD.Foxp3DTR mice), 
conditional T reg lineage ablation provoked nearly 100% pene-
trance of diabetes within days (Feuerer et al., 2009), highlight-
ing the requirement for T reg cells to guard against T1D. 
Analysis of the insulitic lesion revealed, surprisingly, that the 
earliest detectable responders to the loss of T reg cells were NK 
cells, which accumulated to a higher fraction of the infiltrating 
cells and began to produce IFN- within hours. Subsequently, 
there was increased activation of diabetogenic CD4+ T cells, 
including their production of IFN-. Neutralizing IFN- or 
depleting NK cells dampened pancreatic CD4+ T cell activa-
tion and substantially delayed the onset of diabetes. Thus, there 
seemed to be a direct and continual requirement for T reg cells 
to keep NK cells, and ultimately diabetes, in check.
Much of the T reg cell–centered research over the last 
decade has focused on their control of populations typically 
considered to be participants in adaptive immune responses, 
especially other T cells and antigen-presenting cells. Less em-
phasis has been placed on their impact on cells involved in 
innate immune responses, notably NK cells. This neglect is a 
bit surprising given that NK cells were long ago found to be 
hyperproliferative and functionally enhanced in scurfy mice 
(Ghiringhelli et al., 2005). Furthermore, the original report de-
scribing T reg ablation also documented a large increase in NK 
cell numbers (Kim et al., 2007). An exception is the growing   
body of work on mouse cancer models and human cancer pa-
tients that demonstrates a negative correlation between NK 
and T  reg  cells,  as  concerns  both  presence  and  function   
(Shimizu et al., 1999; Ghiringhelli et al., 2005, 2006, 2007; 
Smyth et al., 2006). The mechanism most commonly high-
lighted in these studies was T reg mobilization of TGF-, often 
in surface-bound form, to directly inhibit NK cell function. 
In support of this scenario, blockade of TGF- signaling in 
NK cells in a mutant TGF- receptor transgenic model caused 
a dramatic increase in cell numbers and enhanced secretion of 
IFN- (Laouar et al., 2005).
Given that this axis is still relatively unexplored, partic-
ularly in the context of autoimmune disease, we sought to 
identify the molecular underpinnings of T reg cell/NK cell 
cross-talk in control of diabetes in the BDC2.5/NOD model. 
Our explorations were greatly facilitated by the rapidity and 
synchrony of the diabetogenic changes unleashed by punctual 
ablation of T reg cells in BDC2.5/NOD.Foxp3DTR mice. 
93JEM Vol. 210, No. 6 
Article
1155
at 15 h. At 24 h, slight tilts of both the induced and repressed 
transcript values away from the horizontal axis, toward the di-
agonal, suggest that the same set of genes was modulated in 
the spleen, but with delayed kinetics.
T reg control of pancreas-infiltrating NK cells  
did not operate acutely through TGF-
Considering that TGF- has repeatedly been implicated in the 
control of NK cell functions in other contexts (Uhl et al., 2004; 
Friese et al., 2004; Lee et al., 2004; Ghiringhelli et al., 2005, 
shows FC/FC plots comparing transcriptional changes in the 
pancreas and spleen with or without T reg cell perturbation 
at 8-, 15-, and 24-h time points. The bull’s eye nature of the 
black cloud of expression values at 8 h indicates that the bulk 
of transcripts were only minimally changed in the two organs. 
Yet, values for transcripts destined to be up-regulated (red) or 
down-regulated (blue) in pancreas-infiltrating NK cells had 
already diverged in the pancreas, which is impressive given 
that there was no evident loss of T reg cells at this early time 
point (unpublished data). This divergence was further amplified 
Figure 1.  Gene expression changes in pancreatic NK cells soon after T reg cell perturbation. NK cells were sorted from the pancreatic infiltrate 
24 h after DT injection into BDC2.5/NOD mice with or without DTR expressed in T reg cells, and were profiled by microarray. (A) Transcript changes. 
Differential gene-expression (FC) values for DTR+ (n = 3) and DTR mice (n = 6) (y axis) versus their two-class mean (x axis). Induced (>2-fold) genes are 
highlighted in red and repressed (>2-fold) genes are highlighted in blue. (B and C) Activation features. FC/FC plots of the same NK cell data as in A versus 
NK cells responding to different activation stimuli. Y axis, FC values for DTR+ versus DTR mice; x axis, FC values for splenic NK cells cultured with (n = 3)  
or without (n = 2) IL-12 + IL-18 (see Materials and methods for details; B) or splenic NK cells from C57/BL6 mice 24 h after being infected with 
MCMV or not (n = 3; C). (D) Time course of transcript changes. Carried out as in A, except additional time points at 8 and 15 h were examined. FC/FC  
plots comparing gene expression differentials for pancreatic NK cells from DTR+ and DTR BDC2.5/NOD mice (y axis) versus splenic NK cells from the 
same animals (x axis). Multiple replicates of cellular populations were collected (usually n = 3–6) and averaged. Highlighting in A–D represents the  
same set of genes.
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system. Indeed, splenic NK cells stimulated in culture with 
IL-12+IL-18 produced less IFN- in the presence of TGF- 
(Fig. 2 A; mean fluorescence intensity [MFI] reduced 77 ± 
11%). Moreover, microarray analysis revealed a clear negative 
correlation between transcript changes provoked by addition 
of TGF- to cultures of activated splenic NK cells and by in-
terference with in vivo T reg control of pancreatic NK cells; 
i.e., the majority of genes up-regulated in the absence of T reg 
2006; Laouar et al., 2005; Smyth et al., 2006), we wondered 
whether this cytokine is involved in the ability of T reg cells 
in the pancreas of BDC2.5/NOD mice to keep the insulitic 
lesion in check. The slight underrepresentation of TGF-–
dependent genes in the pancreatic CD4+ T cell transcriptome 
after T reg ablation fit this hypothesis (Feuerer et al., 2009). 
First, we confirmed that TGF- could regulate IFN- pro-
duction by NOD-genotype NK cells in an in vitro culture 
Figure 2.  The role of TGF- signaling. (A, left) Representative flow cytometry profiles of IFN- expression in NOD-derived splenic NK cells cultured with  
(red) or without (gray) IL-12 + IL-18 in the absence of TGF-, or with both cytokines and TGF- (blue). (right) Summary data from three independent experiments. 
Mean ± SD. The p-value was calculated using the two-tailed unpaired Students’ t test. (B) Reciprocal transcript changes promoted by the loss of TGF- and T reg 
cells. FC/FC plot comparing cytokine-activated, cultured, splenic NK cells ± TGF- (x axis, n = 3) versus pancreatic NK cells from BDC2.5/NOD mice ± T reg ablation 
(y axis, same data as in Fig. 1 A). Dashed red line, linear regression. (C) FC/FC plot comparing transcriptional profiles of cytokine-activated, cultured, 
splenic NK cells ± TGF- (y axis, as in Fig. 2 B) versus NK cells ± cytokine-activation (x axis, as in Fig. 1 B). Activation-independent TGF-–induced genes were 
highlighted in pink and were superimposed (D in pink) on a volcano plot (p-value vs. fold change) of NK cell transcripts from BDC2.5/NOD mice depleted or not  
of T reg cells (same data as in Fig. 1). The number of signature genes up-regulated (right) or down-regulated (left) 24 h after T reg cell perturbation are indicated. 
P-value from the 2 test. (E and F) Summary flow cytometry data for BDC2.5/NOD mice treated for 24 h with anti–TGF- versus either an isotype-control mAb or 
PBS (combined). Percentage of NK cells of lymphocytes (E) and percentage of IFN-+ NK cells (F) for two or three independent experiments. Mean ± SD. 
Dotted line (mean) and gray shading (SD) represents values achieved after T reg cell ablation (a composite of multiple independent experiments).
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cells were down-regulated by TGF-, and vice versa (Fig. 2 B). 
Lastly, we generated a signature for TGF-’s impact on NK 
cells independent of general activation by comparing transcrip-
tional profiles of NK cells that were cytokine-activated or not 
and stimulated with TGF- or not (Fig. 2 C; genes listed in 
Table S2), and followed its distribution in pancreas-infiltrating 
NK cells unleashed in the absence of T reg cells (Fig. 2 D). 
The TGF-–induced genes were repressed upon removal of 
T reg cells (i.e., they fall to the left of unity in the FC versus 
p-value volcano plot of Fig. 2 D). These data were all consis-
tent with the notion that T reg cells might operate through 
TGF- signaling to control NK cells in the insulitic lesion.
To directly test this hypothesis, we attempted to mimic 
punctual T reg cell ablation by injecting a mAb recognizing   
TGF- into BDC2.5/NOD mice. This intervention was unable 
to recapitulate the effects of T reg depletion as neither the frac-
tion/number of pancreatic NK cells (Fig. 2 E) nor their pro-
duction of IFN- (Fig. 2 F) was induced anywhere near the 
levels observed with T reg ablation (shaded gray). The mAb 
was bioactive, however, as it substantially reduced the fraction 
of CD103+ T reg cells, in particular in the mesenteric lymph 
nodes (not shown), a population known to be TGF- depen-
dent (Feuerer et al., 2010; Reynolds and Maizels, 2012). Thus, 
TGF- may not play an important role in T reg control of 
NK cell activation in this context, at least not acutely. It is also 
possible that the insulitic lesion provides an environment that 
is unusually resistant to neutralization of TGF-.
Punctual ablation of T reg cells elicited an IL-2 response 
signature in pancreas-infiltrating NK cells
For several reasons, we wondered whether IL-2 might be a 
driver of the pancreatic NK cell transcriptome changes pro-
voked by loss of T reg cells in BDC2.5/NOD mice: first, a 
rapid loss of cells, like T reg cells, that express the high-affinity 
IL-2R component IL-2R (CD25) stands to substantially 
increase IL-2 bioavailability; second, sequestration of IL-2 by 
T reg cells is known to be one of their mechanisms of con-
trolling T cells (Barthlott et al., 2005; Scheffold et al., 2005; 
Pandiyan et al., 2007); third, IL-2 can prime NK cells, both 
in vitro and in vivo, for proliferation and IFN- production 
(Fehniger et al., 2003; Granucci et al., 2004; Lee et al., 2012); 
and, finally, previous studies on the NOD mouse model of T1D 
suggested a limited IL-2 availability in the islet infiltrate (Tang 
et al., 2008b). To address this possibility, we overlaid an IL-2–
responsive gene signature derived from a human CD4+ T cell 
lymphoma (Marzec et al., 2008) onto a volcano plot depict-
ing the transcriptional response of pancreatic NK cells to punc-
tual T reg ablation (Fig. 3 A). As early as 8 h and continuing 
through 24 h after DT treatment, there was a significant skew-
ing of IL-2–induced genes within the set of loci up-regulated 
in pancreatic NK cells and an analogous enrichment of signa-
ture IL-2–repressed genes among the down-regulated loci, 
Figure 3.  An IL-2 footprint is induced by T reg ablation. (A) IL-2–
induced (orange) and –repressed (blue) gene transcripts (Marzec et al., 2008) 
are superimposed on volcano plots (p-value versus FC) of pancreatic NK cell 
transcripts up-regulated (to the right) or down-regulated (to the left) by per-
turbation of T reg cells (data from Fig. 1) at 8 h (top) and 24 h (bottom).  
P-values calculated using the 2 test. (B) Representative flow cytometry plots 
for NK cells isolated from the pancreas of BDC2.5/NOD mice 24 h after T reg 
ablation or not. (C) Summary data for three to four independent experi-
ments with mean ± SD. (D, left) Representative flow cytometry plots for pan-
creas-infiltrating NK cells after T reg cell ablation; (right) summary for the 
percentage of CD25-expressing versus CD25-negative NK cells simultane-
ously expressing IFN- from at least three independent experiments.
 
961158 T reg cells control pancreatic NK cells by limiting IL-2 | Sitrin et al.
extremely rapid induction of T1D (Feuerer et al., 2009). Thus, 
IL-2 appears to be a crucial element in the unleashing of 
pancreatic NK cells when relieved of T reg cell control.
A potential caveat to the use of a mAb that forms IL-2 com-
plexes preferentially capable of engaging CD25 is that NK 
cells often increase CD25 expression in response to activating 
stimuli. Therefore, we examined to what extent T reg cell ab-
lation induced expression of this receptor and if mAb block-
ade altered that effect. Levels of CD25 did not increase on 
NK cells in the absence of T reg cells; however, T reg ablation 
combined with mAb treatment did enhance expression of 
CD25 (Fig. 4 D).
IL-2 supplementation overcame T reg cell control  
of pancreas-infiltrating NK cells, inducing their activation
We explored to what extent the addition of IL-2 to BDC2.5/
NOD mice could surmount T reg cell control of NK cell ac-
tivities within the insulitic lesion. Given the relatively short 
in vivo half-life of IL-2 (Donohue and Rosenberg, 1983), we 
chose to administer IL-2–anti–IL-2 mAb complexes, which 
stabilize the cytokine and target it preferentially to one or the 
other of the IL-2 receptors. In this case, S4B6 was the most ap-
propriate mAb, as IL-2–S4B6 complexes bind well to IL-2R–
expressing cells, notably NK cells, and poorly to cells displaying 
IL-2R, such as T reg cells (Létourneau et al., 2010). Although 
treatment of BDC2.5/NOD mice with IL-2–S4B6 complexes 
did not result in the anticipated expansion of the pancreatic 
NK cell population (Fig. 5 A), it did elicit IFN- synthesis 
(Fig. 5 B; also true for splenic NK cells; not depicted). The induc-
tion of IFN-, measured as an increase in IFN-+ cells, was 
similar to what was seen after ablation of T reg cells (Fig. 2 E 
and Fig. 4 C). However, we realized that this experiment had 
an unexpected complication that might explain the lack of 
NK cell proliferation: although previous studies claimed no   
effect on T reg cells after treatment of mice with IL-2–S4B6 
complexes, we observed an approximate doubling of T reg 
cells in terms of both fraction of T cells and total cell numbers 
(unpublished data).
To circumvent this issue, we treated BDC2.5/NOD mice 
with a mutant form of IL-2 (Super 2), which structurally re-
lieves the dependence of IL-2 on engaging the IL-2R chain, 
thereby shifting the competitive advantage for binding of 
IL-2 from T reg cells to IL-2R chain–expressing NK cells 
(Levin et al., 2012). This intervention also induced IFN- 
synthesis by pancreatic NK cells in the absence of population 
expansion (Fig. 5, A and B), with a less pronounced influence 
on T reg cells than found in IL-2–S4B6 complex treatment 
(not depicted).
Although disjunctions between readouts of NK cell prolif-
eration and production of IFN- have been described (Cooper 
et al., 2009), we were surprised to find a divergence in this 
context because past studies have documented both activities 
after treatment of mice with IL-2–S4B6 complexes (Jin et al., 
2008). However, we noticed that this study and others (Boyman 
et al., 2006; Mostböck et al., 2008; Létourneau et al., 2010), 
focused on expansion of NK cells quantified at later time 
suggesting an increased signaling by the cytokine. Such en-
richment was also seen with two other IL-2 responsive gene 
signatures: one derived from murine CD8+ T cells (Verdeil   
et al., 2006) and the other from human NK cells (Dybkaer   
et al., 2007; not depicted).
In addition, flow cytometric analysis revealed a substantial 
increase in the phosphorylation of STAT5, an event down-
stream of IL-2R engagement and required for signal transduc-
tion, in pancreatic NK cells from T reg cell–depleted versus 
control mice. STAT1, not a member of the signaling cascade 
downstream of IL-2R, showed minimal additional phosphor-
ylation, which was not statistically significant (Fig. 3, B and C). 
When we gated on IFN-+ NK cells, the MFI of pSTAT5 
was 2.2-fold (±0.7) higher. Furthermore, a higher fraction of 
CD25-expressing, as opposed to CD25-nonexpressing, NK 
cells in the pancreatic infiltrate made IFN- (Fig. 3 D), sug-
gesting that the former might have a competitive advantage. 
However, the fact that a clear CD25 IFN-+ population 
was detectable indicated that expression of CD25 was not 
required for IFN- production. Collectively, these data indicate 
that, upon removal of T reg cells, pancreatic NK cells experi-
enced heightened signaling through the IL-2R, which could 
potentially be responsible for their activation.
IL-2 was required for the activation of pancreas-infiltrating 
NK cells provoked by loss of T reg cells
To evaluate the importance of IL-2 in the pancreatic NK cell 
response to acute T reg depletion in BDC2.5/NOD mice, we 
tested the effect of neutralizing this cytokine with a mAb. Com-
plicating such an experiment was the fact that the mAb could 
potentially stabilize IL-2 and direct its binding to the high- and/or   
low-affinity receptor (Boyman et al., 2006). Therefore, we 
used the mAb JES6-1, as the complexes it forms with IL-2 bind 
highly preferentially to the  chain of the high-affinity IL-2R 
(expressed mostly on T reg cells) rather than to the low-affinity 
IL-2R chain (expressed on NK cells; Boyman et al., 2006). 
In the context of T reg cell ablation, then, any such in vivo–
generated IL-2–JES6-1 complexes should be fairly innocuous.
Treatment of BDC2.5/NOD mice with JES6-1 in con-
junction with T reg cell ablation blocked NK cell accumula-
tion, whereas analogous administration of an isotype-control 
mAb had no detectable effect (Fig. 4 A). Importantly, no sig-
nificant drop in NK cell number or fraction occurred when 
JES6-1 was administered to DTR-negative littermate con-
trols, indicating that simple IL-2 starvation did not provoke a 
wave of NK cell death. T reg cells remained at low levels after 
DT plus anti–IL-2 injection, demonstrating that IL-2–JES6-1 
complexes did not trigger “bounce-back” of the T reg cell 
population in the pancreas (Fig. 4 B).
IL-2 neutralization also blocked the NK cell production 
of IFN- elicited by punctual T reg depletion, as measured by 
the percentage of IFN-–expressing NK cells (Fig. 4 C) and 
a reduction in the MFI of IFN- in NK cells (55 ± 19%). 
This is a critical point because we have previously docu-
mented that experimental blockade of IFN- signaling in 
this model sufficed in and of itself to halt the characteristic 
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was also evident, but was delayed in comaparison with the   
T reg ablation model, perhaps reflecting a requirement to 
surpass a higher signaling threshold or the need for an addi-
tional cofactor.
To determine whether clinical diabetes could be rescued 
by supplementing BDC2.5/NOD mice with IL-2, we injected 
them for 3 d with IL-2–S4B6 complexes. Most complex-
injected mice rapidly succumbed to diabetes, starting 6 d after 
the beginning of treatment. In contrast, none of the control 
mice developed diabetes during this time frame (Fig. 5 C).
points. Indeed, when we administered IL-2–S4B6 complexes 
to BDC2.5/NOD mice and assayed at day 4 (rather than the 
usual 24 h), there was a clear induction of both proliferation 
of and IFN- synthesis by pancreatic NK cells (Fig. 5 A and B). 
Thus, supplementation with IL-2 was able to overcome the 
restraint on NK cells imposed by T reg cells in the insulitic 
lesion of BDC2.5/NOD mice. Most important was the aug-
mentation of IFN- synthesis 24 h after IL-2 administration, 
as this cytokine is an important and required element in the 
rapid induction of T1D after T reg ablation. NK cell proliferation 
Figure 4.  Neutralization of IL-2 prevents the activation of pancreatic NK cells in response to T reg cell ablation. (A–D) The pancreatic infiltrate 
from BDC2.5/NOD mice (DTR+ or DTR control littermates) was analyzed 24 h after DT injection ± anti–IL-2 mAb JES6-1 (or isotype control) co-injection. 
(left) Representative flow cytometry plots. (right) Summary data for fraction and numbers with mean ± SD from three to four independent experiments. 
(A) NK cells (NKp46+CD3CD19) and (B) Foxp3+ T reg cells (Foxp3+CD4+CD3+CD19) in the pancreatic infiltrate (FSC/SSC lymphocyte gated). (C) IFN-–
producing NK cells among total NK cells in the pancreatic infiltrate. (D) CD25 expression on pancreatic NK cells.
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No difference was found in the fraction or number of IL-2–
expressing cells, or in the MFI of IL-2–expressing cells (Fig. 6 B). 
Although it remains possible that at later time points an expan-
sion of CD4+ T cells entails higher IL-2 levels, this scenario 
is unlikely within the first few hours, as the fraction and total 
number of IL-2–producing CD4+ T cells remained constant 
(Fig. 6 C). Thus, T reg cells seem to acutely regulate NK cells 
by sequestering local IL-2 rather than dampening its synthesis.
DISCUSSION
Foxp3+CD4+ T reg cells are known to regulate the progres-
sion of T1D in several mouse models, and are thought to exert 
an analogous influence in human T1D patients (Bluestone   
et al., 2008). Nonetheless, our understanding of the role of 
T reg cells during the human disease remains very limiting 
owing to a dearth of preclinical samples, when T reg cells likely 
exert the most important influences. Mouse models such as 
the BDC2.5/NOD line, which have facilitated the study of 
CD4+ T cells were by far the major producers of IL-2 in the 
pancreatic lesion in the presence or absence of T reg cells
These findings raised a pair of important questions: what cells 
produced IL-2 in the pancreatic infiltrate of BDC2.5/NOD 
mice? And how did IL-2 levels change with T reg ablation? 
To address the first issue, we performed intracellular staining 
of IL-2 in pancreatic cells from unmanipulated BDC2.5/NOD 
mice. CD45+ cells showed a clear IL-2 signal, easily distinguish-
able from the isotype control background staining. The vast 
majority of IL-2-expressing cells (>95%) were CD4+ T cells 
(Fig. 6 A).  The remaining signal (3%) came from CD3+CD4 
cells, which further analysis revealed to be CD8+ (unpublished 
data), and double-negative cells (<1%). Next, we compared lev-
els of IL-2–expressing cells in the BDC2.5/NOD pancreatic 
infiltrate, with or without T reg cell ablation, at 8 h after DT 
treatment (when the increased transcriptional activity of IL-2 
response genes is clearly detectable; Fig. 1 D). This analysis in-
cluded the entire CD45+ population to ensure a broad coverage. 
Figure 5.  Supplementation with IL-2 induces early IFN- production and eventual accumulation of NK cells in the pancreatic lesion, as 
well as clinical diabetes. Pancreatic infiltrate from BDC2.5/NOD mice was analyzed 24 h after treatment with control PBS, IL-2–S4B6 complexes, or 
mutant IL-2 analogue Super-2, or 4 d after injection of IL-2–S4B6 complexes. (A, left) Representative flow cytometry data. (middle) Summary data for 
fraction of NK cells in the FSC/SSC lymphocyte gate. (right) Cell number summary data. (B) Analogous data for IFN-–producing NK cells. Mean ± SD, at 
least three independent experiments for both panels. (C) Summary diabetes data for 2 cohorts after 3 consecutive treatments with IL-2–S4B6 complexes 
(n = 14 IL-2–S4B6 complex; n = 9 PBS).
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chains; (c) expressing mostly the low-affinity IL-2R com-
plex, NK cells are deprived of IL-2, dampening their acti-
vation; (d) punctual ablation of T reg cells liberates IL-2 at a 
sufficient concentration to permit NK cell (and eventual T cell) 
activation, unleashing their proliferation and production of 
IFN-; and (e) IFN-, likely in concert with the liberated 
IL-2, drives the activity of T eff cells, provoking conversion 
of an innocuous to a pathogenic insulitic lesion and the devel-
opment of T1D. This sequence of events is consistent with the 
belief that IL-2 can prime NK cells, both in vitro and in vivo, 
for proliferation and IFN- production (Fehniger et al., 2003; 
Granucci et al., 2004; Lee et al., 2012). This represents an in-
teresting intertwining of innate and adaptive immunity, wherein 
the adaptive (CD4+ T cells) primes the innate (NK cells) to 
promote the adaptive (CD4+ and, eventually, CD8+ T eff cells) 
immune response.
The primary means reported for T reg control of NK cells 
thus far is production and cell-surface display of inhibitory 
TGF- (Ghiringhelli et al., 2005), a mechanism that seems 
less critical in the present context. However, a scenario con-
ceptually similar to ours has been proposed for the impact of   
T reg cells on T cell responses in several experimental models; 
i.e., T reg and T eff cell competition for limiting IL-2 (Barthlott 
et al., 2005; Scheffold et al., 2005; Pandiyan et al., 2007). Other 
studies (see Gasteiger et al. and Gasteiger et al. in this issue) that 
were carried out on the basis of punctual T reg cell ablation 
experiments have recently found that T reg control of IL-2 
availability is an important systemic control on NK cell homeo-
stasis and activation (A. Rudensky, personal communication).
prediabetic pathogenic processes, particularly those that play 
out within the insulitic lesion, are an important resource. We 
recently reported that T reg cells control the conversion of in-
sulitis to diabetes in this model primarily by reining in the ac-
tivities of islet-infiltrating NK cells, notably their production 
of IFN- (Feuerer et al., 2009). Neutralization of this cyto-
kine during ablation of T reg cells inhibited the mobilization 
of T effector (T eff) cells within the islets and drastically re-
duced the incidence of hyper-acute T1D that typically devel-
ops in this model in the absence of T reg cells. Here, we have 
explored the molecular underpinnings of the NK cellT reg 
cell axis, exploiting the robust, rapid, and synchronous pheno-
typic changes characteristic of the model. Our studies un-
covered a previously undocumented scenario whereby T reg 
cells control NK cell activation in the islet infiltrate by limit-
ing their exposure to IL-2. This mechanism was indicated by 
the induction of an IL-2–dependent gene signature in NK 
cells upon T reg cell ablation, a parallel increase in NK cell 
pSTAT5 levels, reduction in NK cell accumulation and IFN- 
production after treatment of T reg cell–depleted BDC2.5/
NOD mice with anti–IL-2 mAb, and a corresponding en-
hancement of these parameters in BDC2.5/NOD mice sup-
plemented with IL-2.
More precisely, the scenario we propose is that in the   
insulitic lesion of prediabetic BDC2.5/NOD mice: (a) CD4+ 
T eff cells (primarily) produce limiting amounts of IL-2; (b) 
T reg cells in the vicinity efficiently consume most of this cy-
tokine, reflecting their elevated expression of the high-affinity 
IL-2R, composed of the  (CD132),  (CD122), and  (CD25) 
Figure 6.  IL-2 production in the pancreas before and after T reg ablation. (A) Representative flow cytometry plots for pancreatic infiltrate from 
BDC2.5/NOD mice stained and analyzed for IL-2 by intracellular flow cytometry. An extended FSC/SSC gate was taken to include both lymphocytes and 
leukocytes along with a live/dead stain to exclude dead cells. CD45+IL-2+ cells were analyzed for CD3 and CD4 expression. (B) Summary data for pancre-
atic infiltrate from mice depleted of T reg cells (8 h with DT, DTR+) or not (8 h with DT, DTR). Mean ± SD, at least three independent experiments. (C) Sum-
mary data, as in B, gated on CD4+ T cells.
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Given a strong rationale from studies on both mice and 
humans, there has been substantial interest in developing pro-
tocols for treating T1D patients with IL-2, likely in combina-
tion with other agents (Hulme et al., 2012; Shevach, 2012). 
The results from a phase I clinical trial wherein IL-2 and   
rapamycin were administered to 9 T1D patients within 4 yr of 
diagnosis were recently published, and proved disappointing 
(Long et al., 2012). There was, as hoped for, a transient aug-
mentation in T reg cell fraction and numbers, accompanied 
by a more persistent enhancement of their STAT5 phosphory-
lation levels. However, these changes were accompanied by an 
unanticipated transient impairment in islet -cell function, in 
concert with increases in the NK and eosinophil populations, 
ultimately resulting in trial closure. As cogently argued by 
Bonifacio (2012), the detrimental impact on  cells could re-
flect rapamycin effects and/or influences of the expanded 
populations of innate immune system cells. Certainly, rapamy-
cin has been reported to inhibit -cell regeneration and nor-
malization of blood-glucose levels in mice (Nir et al., 2007). 
However, our findings, especially the rapid induction of dia-
betes after IL-2 supplementation, highlight the potentially 
destructive effects of IL-2–mediated unleashing of NK cells. 
Activation of islet-infiltrating NK cells could be directly cyto-
toxic or, through production of IFN-, could promote the ac-
tivities of pathogenic T eff cells. This represents another example 
of the predictive value of murine models of T1D, though only 
if the available mouse data are reviewed and translation to 
humans is performed in a precise and critical manner (Shoda 
et al., 2005).
As recognized early on (Tang et al., 2008b; Grinberg-
Bleyer et al., 2010; Hulme et al., 2012; Shevach, 2012), har-
nessing the tremendous potential of IL-2–IL-2R-based therapies 
while avoiding the detrimental side-effects is a great chal-
lenge. Novel approaches, such as the engineering of designer 
IL-2 derivatives (Levin et al., 2012), are promising in this re-
gard. Even so, we need to understand much better how the 
various regulatory and effector populations in the insulitic   
lesions are orchestrated, and perspicaciously apply this knowl-
edge to the development of therapeutic protocols.
MATERIALS AND METHODS
Mice. NOD/ShiltJ (NOD), BDC2.5/NOD TCR transgenic (Katz et al., 1993), 
and BDC2.5/NOD.Foxp3DTR double-transgenic (Feuerer et al., 2009) mice 
were bred in our colony at The Jackson Laboratory, and were genotyped 
and maintained at Harvard Medical School (under specific pathogen–free 
conditions). Females between 7 and 10 wk of age were generally used. Pro-
tocols were approved by Harvard Medical School’s Institutional Animal Care 
and Use Committee.
In vivo treatments. All in vivo treatments were via intraperitoneal injec-
tion. For T reg cell ablation, BDC2.5/NOD.Foxp3DTR mice were admin-
istered 1 µg DT (Sigma-Aldrich) in sterile PBS, and samples were taken at 
the indicated time points. Control mice were littermates lacking the DTR 
transgene. For blockade of TGF-, anti–TGF- mAb (clone 1D11.11) was 
produced in the laboratory, and 1 mg was injected in sterile PBS 24 h before 
experimentation or at day 0, 3, and 5 for the long-term experiments. Con-
trol mice received an equal amount of isotype-control mAb (MOPC-21; 
Our findings should be viewed in the context of an ex-
tensive body of work weighing the role of IL-2 in human and 
mouse T1D (Hulme et al., 2012; Shevach, 2012). For example, 
Il2 and IL2RA have shown a genetic association with disease 
in NOD mice and human diabetes patients, respectively. The 
effects of IL-2–IL-2R signaling on T reg cell homeostasis and 
function were routinely cited in interpretation of these associa-
tions. Indeed, mice devoid of IL-2, IL-2R, IL-2R, or STAT5 
all succumb to lymphoproliferative disease caused by T reg cell 
reduction or dysfunction, which can be reversed by adminis-
tration of exogenous IL-2 or wild-type T reg cells. Nonetheless, 
given the data presented herein, it seems plausible that allelic 
variation in IL-2–IL-2R signaling could, instead or in addi-
tion, result in aberrant NK cell function and thereby exacerbate 
disease in a manner not currently appreciated. Consistent with 
this possibility, the mouse Klr and human killer immunoglobulin-
like receptor (KIR) families that modulate NK cell activation have 
also been associated with diabetes in numerous human studies 
(van der Slik et al., 2003; Nikitina-Zake et al., 2004; Rodacki 
et al., 2007; Ramos-Lopez et al., 2009), as well as in the NOD 
mouse (Rogner et al., 2001). More information on the effects 
of mutant alleles of elements of the IL-2–IL-2R signaling path-
way on NK cells is imperative.
In humans, modulation of the IL-2–IL-2R axis has been 
achieved through treatment with daclizumab, a mAb target-
ing IL-2R. In multiple sclerosis, where autoreactive T cells 
recognizing antigens from the central nervous system promote 
inflammation and demyelination, daclizumab induced a pop-
ulation of CD56bright NK cells that can target and kill CD4+ 
T cells. Expansion of this NK cell population was associated 
with enhanced disease outcomes (Rose, 2012). Although mul-
tiple mechanisms of action for this mAb have been proposed, 
increased bioavailability of IL-2 as a result of IL-2R blockade 
would mirror the findings and interpretation reported here.
The role of IL-2–IL-2R signaling in diabetes progression 
has been experimentally dissected in NOD mice (Hulme et al., 
2012; Shevach, 2012). Alone, or in combination with agents such 
as rapamycin, IL-2 supplementation had disease-modulating 
effects, in both preventive and curative protocols. Interest-
ingly, one set of studies reported that although low-dose IL-2 
treatment suppressed diabetes, high-dose administration ac-
tually triggered disease (Tang et al., 2008b). The diabetes-
suppressive effect of low-dose IL-2 was interpreted as correction 
of an imbalance between T reg and T eff cells downstream 
of a genetic deficiency in IL-2 signaling. The relatively low 
expression of CD25 on islet-infiltrating T reg cells was taken 
as evidence of this notion, although it later became apparent 
that dampened CD25 expression is a characteristic of T reg 
cells at inflammatory sites in general (Lazarski et al., 2008; 
Tang et al., 2008a). The diabetogenic effect of high-dose IL-2 
was explained as an enhancement of the activities of patho-
genic T eff cells (although there was also a striking systemic 
expansion of NK cells). The results presented here emphasize 
that the response of islet-infiltrating NK cells to manipula-
tion of IL-2–IL-2R signaling is not to be ignored in inter-
preting outcomes.
101JEM Vol. 210, No. 6 
Article
1163
expressed in any condition. Microarray data are available from the National 
Center for Biotechnology Information/GEO repository under accession 
no. GSE39197.
In vitro cultures. Before cell sorting, splenocytes were depleted of B and 
CD8+ T cells using biotin-labeled mAbs to CD8 (2.43; prepared in-laboratory) 
and CD19 (6D5; BioLegend), followed by depletion using the CELLection 
Biotin Binder kit (Invitrogen) according to the manufacturer’s instructions. 
NK cells (CD19CD3NKp46+) were sorted, and then cultured in sterile 
complete RPMI (10% FBS, 1X PenStrep [Invitrogen], 2 mM l-glutamine, 
55 M 2-mercaptoethanol (Sigma-Aldrich), RPMI [Invitrogen]), and were 
activated with rIL-12 (0.5 ng/ml; PeproTech) and rIL-18 (0.5 ng/ml; MBL) 
for 15–20 h with or without rTGF- (1 ng/ml; PeproTech). After culture, 
cells were either stained for intracellular IFN- or resorted to high purity for 
microarray analysis as described above.
Statistical analysis. All nonmicroarray statistical analyses for cytometry 
experiments were performed with GraphPad Prism software. For in vivo 
mouse readouts, p-values were calculated using the Mann-Whitney test. For 
diabetes incidence experiments, p-values were calculated using the Log-rank 
test. P-values were considered significant at P < 0.05 (*), P < 0.01 (**), P < 
0.001 (***). 2 p-value analysis for microarray expression data (volcano 
plots) was calculated using Microsoft Excel based on the number of genes 
dropping to the left or right side of the fold-change distribution.
Online supplemental material. Table S1 lists transcripts differentially ex-
pressed in pancreatic NK cells in the presence or absence of T reg cells as de-
scribed in Fig. 1. Table S2 shows the gene list of an activation-independent 
TGF--responsive signature used in Fig. 2. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20122248/DC1.
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  SUPPLEMENTAL MATERIAL 
  Sitrin et al., http://www.jem.org/cgi/content/full/jem.20122248/DC1 
  Table S1, available as an Excel fi  le, lists transcripts differentially expressed in pancreatic NK cells in the presence or absence 
of T reg cells, as described in Fig. 1. 
  Table S2, available as an Excel fi  le, shows the gene list of an activation-independent, TGF-    –responsive signature used in 
Fig. 2 
105TABLE S1. Transcripts differentially expressed in pancreatic NK cells in the presence or absence of T reg cells (related to Fig. 1)
Over-represented Genes Under-represented Genes
Probe Gene Symbol Panc DTR-
Panc DTR+ 24 
hr
Panc DTR + vs 
DTR- Probe Gene Symbol Panc DTR-
Panc DTR+ 24 
hr
Panc DTR + vs 
DTR-
10585778 Sema7a 131.37 972.47 7.403 10427628 Il7r 2979.32 523.06 0.176
10349603 Il10 81.56 558.78 6.851 10435907 Cd200r1 456.22 83.68 0.183
10562044 Zbtb32 165.64 983.23 5.936 10538150 Tmem176a 825.14 178.94 0.217
10531724 Plac8 197.56 1147.35 5.808 10455901 Slc27a6 421.17 107.21 0.255
10482030 Stom 165.58 934.01 5.641 10435948 Ccdc80 425.67 111.17 0.261
10570434 Ifitm1 93.63 434.24 4.638 10412298 Itga1 1153.11 326.09 0.283
10405211 Gadd45g 360.34 1630.88 4.526 10358421 Rgs18 460.01 131.63 0.286
10476314 Prnp 91.29 371.45 4.069 10480275 Nebl 584.64 174.56 0.299
10563377 Sult2b1 220.74 864.49 3.916 10544596 Tmem176b 2193.71 670.86 0.306
10558769 Ifitm1 198.99 694.95 3.492 10493812 S100a4 712.94 228.35 0.320
10516064 Mfsd2a 122.43 396.47 3.238 10434302 Klhl24 1165.05 386.54 0.332
10363498 Ppa1 501.47 1513.86 3.019 10596303 Acpp 727.89 247.3 0.340
10541307 Usp18 549.57 1635.7 2.976 10502890 St6galnac3 309.41 105.89 0.342
10543067 Asns 136.33 401.81 2.947 10394674 Socs2 952.48 326.45 0.343
10582275 Slc7a5 574.01 1665.96 2.902 10559248 Tspan32 1011 348.72 0.345
10360398 Ifi202b 29.16 83.93 2.878 10355998 Fam124b 360.77 124.59 0.345
10472916 Cdca7 393.59 1077.32 2.737 10466779 Pip5k1b 468.04 162.88 0.348
10483679 Gpr155 458.77 1241.57 2.706 10447056 Qpct 184.25 64.21 0.348
10420308 Gzmb 2786 7368.13 2.645 10454856 Psd2 313.03 111.95 0.358
10421774 Dgkh 368.24 972.44 2.641 10573082 Inpp4b 1151.63 415.95 0.361
10493474 Muc1 381.72 1006.09 2.636 10574246 Gpr114 1087.59 401.8 0.369
10498350 P2ry14 225.91 587.4 2.600 10600901 Ar 758.91 286.25 0.377
10502791 Ifi44 280.25 714.15 2.548 10365428 Btbd11 753.14 289.94 0.385
10495794 Pde5a 604.36 1538.35 2.545 10450367 Hspa1a 1972.25 761.8 0.386
10366796 Mettl1 232.32 581.47 2.503 10568392 Rgs10 899.19 353.88 0.394
10571752 Dctd 754.36 1882.73 2.496 10389190 Gm11435 717.73 283.07 0.394
10366586 Ifng 3405.62 8390.93 2.464 10416371 Lpar6 2492.42 991.43 0.398
10510391 Srm 1147.3 2804.86 2.445 10505911 Dmrta1 255.26 101.78 0.399
10586591 Car12 120.11 291.66 2.428 10512949 Abca1 539.12 216.02 0.401
10429926 Dgat1 834.91 2025.05 2.425 10523297 Ccng2 306.74 123.83 0.404
10584712 Hyou1 946.42 2268.99 2.397 10529375 Mxd4 1127.04 455.29 0.404
10453887 Cables1 176.1 407.2 2.312 10605113 L1cam 399.23 161.4 0.404
10344713 Ahcy 589.88 1361.78 2.309 10382300 Map2k6 271.76 109.95 0.405
10579142 --- 592.49 1365.99 2.306 10563706 Mrgpra9 74.76 30.42 0.407
10515943 Ctps 194.82 447.8 2.299 10377927 Rnf167 1792.21 734.11 0.410
10361760 Timm8a1 102.7 234.94 2.288 10368886 Foxo3 1290.85 530.52 0.411
10396610 Mthfd1 346.96 791.94 2.283 10430818 Tnfrsf13c 881.06 362.92 0.412
10439762 Ahcy 542.78 1237.46 2.280 10531952 Abcg3 215.85 89.14 0.413
10424349 Sqle 126.81 286.36 2.258 10363231 Smpdl3a 1714.64 713.85 0.416
10552311 --- 280.78 625.91 2.229 10431017 Ttll1 684.29 287.34 0.420
10488816 Ahcy 512.98 1140.89 2.224 10428698 Sntb1 440.34 185.34 0.421
10414522 Apex1 285.59 633.18 2.217 10427454 Card6 972.58 410.56 0.422
10589041 Impdh2 553.34 1226.73 2.217 10360040 Fcgr3 557.06 235.57 0.423
10393449 Socs3 392.48 870.09 2.217 10365344 Tcp11l2 488.5 206.64 0.423
10408762 Eef1e1 747.93 1656.96 2.215 10399897 Hbp1 1140.81 483 0.423
10407173 Il6st 498.97 1099.79 2.204 10488482 Acss1 616.08 263.3 0.427
10606689 Timm8a1 86.95 191.59 2.203 10576218 Cpne7 286.64 122.81 0.428
10384474 Pno1 316.75 696.98 2.200 10530503 Cnga1 179.55 77.52 0.432
10351095 Tnfsf4 54.34 119.4 2.197 10601867 Kir3dl1 512.37 221.38 0.432
10426098 Creld2 891.96 1953.82 2.190 10497817 Anxa5 2919.25 1264.11 0.433
10388389 Hic1 170.01 371.51 2.185 10358389 Rgs2 2027.06 880.84 0.435
10351039 Gas5 193 421.3 2.183 10394054 Cd7 6954.7 3025.97 0.435
10488785 E2f1 274.09 595.99 2.174 10443027 A930001N09Rik 801.16 350.42 0.437
10399636 Mrto4 176.3 383.01 2.172 10557481 Ypel3 1502.05 657.54 0.438
10392207 Tex2 361.74 784.25 2.168 10507040 Spata6 438.68 192.48 0.439
10527920 Cyp51 136.11 293.73 2.158 10557895 Itgax 1123.68 495.07 0.441
10409338 Nop16 842.12 1816.15 2.157 10499160 Cd1d1 233.38 103.26 0.442
10528143 Ppp1r14b 558.36 1201.92 2.153 10469457 Plxdc2 205.54 91.5 0.445
10388010 C1qbp 619.92 1330.14 2.146 10356880 St8sia4 1405.15 626.02 0.446
10473414 Ssrp1 1138.12 2441.71 2.145 10501046 Gm10673 218.51 97.52 0.446
10422493 Gpr18 1369.48 2933.74 2.142 10429114 Tmem71 1023.48 456.83 0.446
10384373 Fignl1 162.65 345.69 2.125 10360684 Ephx1 201.27 90.13 0.448
10441436 Snx9 105.87 224.81 2.123 10378549 Rtn4rl1 1388.79 622.03 0.448
10455588 Hspe1 1453.94 3084.71 2.122 10422598 Sepp1 1676.22 753.42 0.449
10564960 Furin 1413.12 2997.97 2.122 10575052 Cdh1 379.28 170.94 0.451
10394770 Odc1 298.75 632.68 2.118 10428376 Angpt1 141.48 63.96 0.452
10461022 Ppp1r14b 554.84 1170.74 2.110 10606058 Cxcr3 2921.74 1322.36 0.453
10445767 Treml2 339.47 715.65 2.108 10528102 Crot 2060.68 934.54 0.454
10526120 Tpst1 153.32 321.18 2.095 10443690 Glp1r 253.58 115.59 0.456
10375880 Nhp2 214.43 448.9 2.093 10554094 Igf1r 348.26 158.77 0.456
10580382 Neto2 97.54 203.59 2.087 10371220 Gna15 651.54 297.42 0.456
10610592201 Chek1 325.38 678.28 2.085 10517287 Man1c1 800.8 365.72 0.457
10443836 Rrp1b 360.86 751.55 2.083 10439744 Cd96 3308.18 1512.27 0.457
10445894 Erh 790.23 1644.59 2.081 10459620 Rab27b 351.68 160.99 0.458
10346303 Hspe1 1057.04 2198.22 2.080 10350247 Kif21b 1291.15 592.63 0.459
10378088 Mybbp1a 585.51 1201.4 2.052 10355214 Idh1 189.59 88.08 0.465
10434668 Tmem97 387.29 792.81 2.047 10350742 Rnasel 1049.22 487.54 0.465
10361110 Dtl 367.67 752.63 2.047 10555235 Arrb1 901.46 419.47 0.465
10473432 Tnks1bp1 611.25 1249.9 2.045 10351689 Gm10521 503.23 234.37 0.466
10394735 Pdia6 599.15 1225.09 2.045 10454286 Mapre2 2008.74 936.08 0.466
10583732 Ldlr 219.21 447.7 2.042 10458581 Gm10008 313.33 146.44 0.467
10576034 Irf8 2459.63 5006.46 2.035 10503259 Trp53inp1 1726.21 807.12 0.468
10346634 Nop58 526.39 1068.95 2.031 10598750 Gpr34 125.34 58.67 0.468
10347193 Atic 633.66 1283.95 2.026 10439239 Dirc2 277.35 130.17 0.469
10546163 Mcm2 814 1649.1 2.026 10436304 Abi3bp 165.91 77.94 0.470
10517706 Mrto4 188.68 381.17 2.020 10479852 Camk1d 798.19 375.79 0.471
10574427 Impdh2 111.52 223.68 2.006 10598101 Maml2 781.17 368.6 0.472
10462973 Hells 316.47 634.59 2.005 10524310 Ttc28 639.5 301.83 0.472
10582295 Odc1 581.58 1165.06 2.003 10538802 A930038C07Rik 260.7 123.19 0.473
10541114 Rasgef1a 476.27 225.07 0.473
10548729 Mansc1 332.34 157.07 0.473
10390103 Pdk2 457.33 216.7 0.474
10563170 Dkkl1 365.69 173.35 0.474
10492815 Tmem154 404.5 191.8 0.474
10435930 Cd200r2 583.99 277.08 0.474
10485622 Qser1 302.2 143.64 0.475
10433057 Calcoco1 952.94 455.41 0.478
10404496 Nqo2 1065.12 510.23 0.479
10596148 Trf 370.16 177.59 0.480
10397346 Fos 872.32 418.69 0.480
10476819 Plk1s1 316.68 152.27 0.481
10484856 Olfr1259 64.51 31.08 0.482
10439634 Gtpbp8 175.26 84.49 0.482
10401244 Actn1 333.25 161.22 0.484
10549102 Kcnj8 793.57 385.31 0.486
10453049 Cdc42ep3 676.57 328.83 0.486
10441195 Dscam 338.58 164.95 0.487
10475532 Sqrdl 223.55 109.14 0.488
10371356 Appl2 646.59 316.37 0.489
10415021 Abhd4 657.54 323.22 0.492
10387909 Chrne 451.65 222.14 0.492
10573319 Podnl1 488.85 240.5 0.492
10360315 Fcrl6 763.17 375.93 0.493
10595402 Fam46a 452.32 223.1 0.493
10602009 Rnf128 190.1 93.98 0.494
10502052 Alpk1 223.12 110.33 0.494
10576639 Nrp1 186.13 92.12 0.495
10479726 Pcmtd2 738.64 365.6 0.495
10579744 Large 505.69 251.54 0.497
10479159 Zfp831 807.46 402.61 0.499
10594774 Ccnb2 763.58 380.93 0.499
10390691 Nr1d1 298.37 148.92 0.499
10457168 Cd226 2455.26 1225.64 0.499
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Scn3b Rnf149 2900026A02Rik Zfp1
Gpr34 Arrdc4 Fam134b Tiam1
H2-Aa Epb4.1l2 St8sia1 Ddc8
Tnfsf10 Scn1b Ccdc80 Arnt2
Adssl1 Osgin1 Anp32-ps Acsbg1
Mapkapk3 Tmem2 H2-Eb1 B4galnt4
3110043O21Rik Nrarp Ece1 Gch1
Spsb1 Anp32a Nox1 Mobkl2b
Inpp4b Cd72 H2-Ab1 Fam124b
Cd81 Adam19 1700049G17Rik Dkkl1
Vipr2 Cpeb4 Ttc39b Bmf
Gpr68 Dusp2 Ttc39b Nsun4
Gne Osbpl1a Plau 2810408A11Rik
Kcnn4 Ninj1 Klf10 Suox
Cish Cx3cr1 Skil Prnd
Pacsin1 Accn3 Myadm Gpr56
Gpr68 Dusp4
List of genes derived in Fig. 2 C.
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